(54) Title: METHODS AND COMPOSITIONS FOR MODULATING INTERLEUKIN-21 RECEPTOR ACTIVITY

(57) Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ("IL-21R" or "MU-1"), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

METHODS AND COMPOSITIONS FOR MODULATING INTERLEUKIN-21 RECEPTOR ACTIVITY

FIELD OF THE INVENTION

The present invention relates to methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using IL-21 receptor agonists and antagonists. The methods and compositions disclosed herein are useful as immunotherapeutical agents.

BACKGROUND OF THE INVENTION

Human IL-21 is cytokine about a 131-amino acids in length that shows sequence homology to IL-2, IL-4 and IL-15 (Parrish-Novak et al. (2000) Nature 408:57-63). Despite low sequence homology among interleukin cytokines, cytokines share a common fold into a "four-helix-bundle" structure that is representative of the family. Most cytokines bind either the class I or the class II cytokine receptors. Class II cytokine receptors include the receptors for IL-10 and the interferons, whereas class I cytokine receptors include the receptors for IL2-IL7, IL-9, IL-11-13, and IL-15, as well as hematopoietic growth factors, leptin and growth hormone (Cosman, D. (1993) Cytokine 5:95-106).

Human IL-21R is a class I cytokine receptor that is expressed in lymphoid tissues, in particular by NK, B and T cells (Parrish-Novak et al. (2000) supra). The nucleotide and amino acid sequences encoding human interleukin-21 (IL-21) and its receptor (IL-21R) are described in WO 00/53761; WO 01/85792; Parrish-Novak et al. (2000) supra; Ozaki et al. (2000) Proc. Natl. Acad. Sci. USA 97:11439-114444. IL-21R has the highest sequence homology to IL-2 receptor β chain and IL-4 receptor α chain (Ozaki et al. (2000) supra). Upon ligand binding, IL-21R associates with the common gamma cytokine receptor chain (γc) that is shared by receptors for IL-2, IL-3, IL-4, IL-7, IL-9, IL-13 and IL-15 (Ozaki et al. (2000) supra; Asao et al. (2001) J. Immunol. 167:1-5). The widespread lymphoid distribution of IL-21R suggests that IL-21 may play a role in immune regulation. Indeed, in vitro studies have shown that IL-21 significantly modulates the function of B cells, CD4+ and CD8+ T cells, and NK cells (Parrish-Novak

et al. (2000) *supra*; Kasaian, M.T. *et al.* (2002) *Immunity.* 16:559-569). Nevertheless,
' evidence supporting a regulatory effect of IL-21 *in vivo* is limited.

SUMMARY OF THE INVENTION

Methods and compositions for modulating the activity of, and/or an interaction
5   between, an interleukin-21 (IL-21) and an IL-21 receptor (also referred to herein as "IL-
21R" or "MU-1") using agonists or antagonists of IL-21 or IL-21R are disclosed (also
referred to herein as an "IL-21/IL-21R agonist" or "agonist," and "IL-21/IL-21R
antagonist" or "antagonist," respectively).

In one embodiment, Applicants have shown that reducing IL-21R activity by
10   using an IL-21 antagonist, e.g., a fusion protein that includes the extracellular domain of
the IL-21R fused to an Fc immunoglobulin region, ameliorates inflammatory symptoms
in collagen-induced arthritis (CIA) animal models (Example 7). Expression of IL-21R
mRNA is upregulated in the paws of CIA mice (Example 8). Accordingly, antagonists of
IL-21/IL-21R activity can be used to induce immune suppression *in vivo*, e.g., for treating
15   or preventing immune cell-associated pathologies (e.g., pathologies associated with
aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells),
mature NK cells, B cells, macrophages and megakaryocytes, including transplant
rejection and autoimmune disorders, e.g., arthritis (including rheumatoid arthritis).

Accordingly, in one aspect, the invention features a method of treating (e.g.,
20   curing, suppressing, ameliorating, delaying or preventing the onset of, or preventing
recurrence or relapse of) or preventing an immune cell-associated disease, e.g.,
rheumatoid arthritis, in a subject, the method includes: administering to the subject an IL-
21/IL-21R antagonist, in an amount sufficient to inhibit or reduce immune cell activity
and/or cell number, thereby treating or preventing the immune cell-associated disease,
25   e.g., rheumatoid arthritis,.

The IL-21/IL-21R antagonist can be administered to the subject, alone or in
combination, with other therapeutic modalities as described herein. Preferably, the
subject is a mammal, e.g., a human suffering from an immune cell-associated pathology
(e.g., pathology associated with aberrant activity of one or more of mature T cells
30   (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and
megakaryocytes, including transplant rejection and autoimmune disorders. For example,
the method can be used to treat or prevent, in a subject, an immune cell-associated

disorders, e.g., a disorder chosen from one or more of: transplant rejection or an autoimmune disorder (e.g., including, for example, diabetes mellitus (type I), arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and ankylosing spondylitis), multiple sclerosis, myasthenia gravis, vasculitis, systemic lupus erythematosis, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, scleroderma, asthma, allergy, IBD or Crohn's disease). Treatment of an arthritic disorder, e.g., a disorder chosen from one or more of rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or ankylosing spondylitis (preferably, rheumatoid arthritis) using the IL-21- or IL-21R antagonists of the present invention is preferred.

In one embodiment, the IL-21/IL-21R antagonist interacts with, e.g., binds to, IL-21 or IL-21R, preferably, mammalian, e.g., human IL-21 or IL-21R (referred to herein as an "IL-21 antagonist" and "IL-21R antagonist," respectively), and reduces or inhibits one or more IL-21 and/or IL-21R activities. Preferred antagonists bind to IL-21 or IL-21R with high affinity, e.g., with an affinity constant of at least about 10^7 M^{-1}, preferably about 10^8 M^{-1}, and more preferably, about 10^9 M^{-1} to 10^{10} M^{-1} or stronger.

For example, an IL-21/IL-21R antagonist can reduce and/or inhibit IL-21R activity by neutralizing IL-21. In one embodiment, the antagonist can be a fusion protein that includes a fragment of an IL-21R fused to a non-IL21R fragment, e.g., an immunoglobulin Fc region. In other embodiments, the antagonist is an anti-IL21R or anti-IL21 antibody or an antigen-binding fragment thereof, a soluble form of the IL-21 receptor, a peptide or a small molecule inhibitor.

In one embodiment, the IL-21/IL-21R antagonist is an anti-IL21R or anti-IL21 antibody, or an antigen-binding fragment thereof. E.g., the antibody is a monoclonal or single specificity antibody, that binds to IL-21, e.g., human IL-21, or an IL-21 receptor, e.g., human IL-21 receptor polypeptide, or an antigen-binding fragment thereof (e.g., an Fab, F(ab')2, Fv or a single chain Fv fragment). Preferably, the antibody is a human, humanized, chimeric, or *in vitro* generated antibody to human IL-21 or human IL-21 receptor polypeptide. Preferably, the antibody is a neutralizing antibody.

In other embodiments, the IL-21/IL-21R antagonist includes full length, or a fragment of an IL-21 polypeptide, e.g., an IL-21 receptor-binding domain of an IL-21 polypeptide, e.g., a human IL-21 polypeptide (e.g., a human IL-21 polypeptide as

described herein having an amino acid sequence shown as SEQ ID NO:19) or a sequence at least 85%, 90%, 95%, 98% or more identical thereto; or encoded by a corresponding nucleotide sequence shown as SEQ ID NO:18 or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. Alternatively, the antagonist includes full length (e.g.,

5 from about amino acids 1-538 or 20-538 of SEQ ID NO:2; or from about amino acids 1-529 or 20-529 of SEQ ID NO:10), or a fragment of an IL-21 receptor polypeptide, e.g., an IL-21-binding domain of an IL-21 receptor polypeptide, e.g., a soluble fragment of an IL-21R (e.g., a fragment of an IL-21R comprising the extracellular domain of murine or human IL-21R; e.g., from about amino acids 1-235, 1-236, 20-235, 20-236 of SEQ ID

10 NO:2 (human), or from about amino acids 1-236, 20-236 of SEQ ID NO:10 (murine), or encoded by the corresponding nucleotides of SEQ ID NO:1 or 9, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto.

In one embodiment, the antagonist is a fusion protein comprising the aforesaid IL-21 or Il-21 receptor polypeptides or fragments thereof and, e.g., fused to, a second

15 moiety, e.g., a polypeptide (e.g., an immunoglobulin chain, a GST, Lex-A or MBP polypeptide sequence). In a preferred embodiment, the fusion protein includes at least a fragment of an IL-21R polypeptide, which is capable of binding IL-21, e.g., a soluble fragment of an IL-21R (e.g., a fragment of an IL-21R comprising the extracellular domain of murine or human IL-21R; e.g., from about amino acids acids 1-235, 1-236, 20-

20 235, 20-236 of SEQ ID NO:2 (human), or from about amino acids 1-236, 20-236 of SEQ ID NO:10 (murine), or encoded by the corresponding nucleotides of SEQ ID NO:1 or 9, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto) and, e.g., fused to, a second moiety, e.g., a polypeptide (e.g., an immunoglobulin chain, an Fc fragment, a heavy chain constant regions of the various isotypes, including: IgG1, IgG2, IgG3, IgG4,

25 IgM, IgA1, IgA2, IgD, and IgE). For example, the fusion protein can include the extracellular domain of human IL-21R, e.g., from about amino acids 1-235, 1-236, 20-235, 20-236 of SEQ ID NO:2, and, e.g., fused to, a human immunoglobulin Fc chain (e.g., human IgG, e.g., human IgG1 or a mutated form of human IgG1). In one embodiment, the human Fc sequence has been mutated at one or more amino acids, e.g.,

30 mutated at residues 254 and 257 of SEQ ID NO:28, from the wild type sequence to reduce Fc receptor binding. In other embodiments, the fusion protein can include the extracellular domain of murine IL-21R, e.g., from about amino acids 1-236, 20-235 of

SEQ ID NO:10 (murine), and, e.g., fused to, a murine immunoglobulin Fc chain (e.g.,
murine IgG, e.g., murine IgG2a or a mutated form of murine IgG2a).

The fusion proteins may additionally include a linker sequence joining the first
moiety, e.g., an IL-21R fragment, to the second moiety, e.g., the immunoglobulin
fragment. In other embodiments, additional amino acid sequences can be added to the N-
or C-terminus of the fusion protein to facilitate expression, steric flexibility, detection
and/or isolation or purification.

Examples of antagonistic fusion proteins that can be used in the methods of the
invention are shown in Figures 7-15. In one embodiment, the fusion protein includes an
amino acid sequence chosen from, e.g., SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27,
SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, or
SEQ ID NO:39, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto.
In other embodiments, the fusion protein includes an amino acid sequence encoded by a
nucleotide sequence chosen from, e.g., SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26,
SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, or
SEQ ID NO:38, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto.
Preferred fusion proteins have the amino acid sequence shown as SEQ ID NO:25 or SEQ
ID NO:29 (Figures 8A-8C and 10A-10C, respectively), or a sequence at least 85%, 90%,
95%, 98% or more identical thereto. In other embodiments, the fusion protein includes
an amino acid sequence encoded by a nucleotide sequence chosen from, e.g., SEQ ID
NO:24 or SEQ ID NO:28 (Figures 8A-8C and 10A-10C, respectively), or a sequence at
least 85%, 90%, 95%, 98% or more identical thereto. Most preferably, the fusion protein
has the amino acid sequence shown as SEQ ID NO:29, or has an amino acid sequence
encoded by a nucleotide sequence shown as SEQ ID NO:28 (Figure 10A-10C).

The IL-21/IL-21R antagonists described herein, e.g., the fusion protein described
herein, can be derivatized or linked to another functional molecule, e.g., another peptide
or protein (e.g., an Fab' fragment). For example, the fusion protein or an antibody, or
antigen-binding portion, can be functionally linked (e.g., by chemical coupling, genetic
fusion, non-covalent association or otherwise) to one or more other molecular entities,
such as an antibody (e.g., a bispecific or a multispecific antibody), toxins, radioisotopes,
cytotoxic or cytostatic agents, among others.

6

In one embodiment, the IL-21/IL-21R antagonists described herein, e.g., the

pharmaceutical compositions thereof, are administered in combination therapy, i.e.,

combined with other agents, e.g., therapeutic agents, which are useful for treating

immune cell-associated pathological disorders, e.g., a disorder chosen from one or more

5   of: arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis,

psoriatic arthritis, or ankylosing spondylitis), or scleroderma, systemic lupus

erythematosis, or vasculitis; preferably, rheumatoid arthritis). For example, the

combination therapy can include one or more IL-21/IL-21R antagonists, e.g., an anti-IL-

21- or anti-IL-21R antibody or an antigen-binding fragment thereof; an IL-21R fusion

10   protein; a soluble IL-21R receptor; a peptide inhibitor or a small molecule inhibitor) co-

formulated with, and/or co-administered with, one or more additional therapeutic agents,

e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-

inflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or

cytostatic agents, as described in more herein.

15   Examples of preferred additional therapeutic agents that can be co-administered

and/or co-formulated with one or more IL-21/IL-21R antagonists, include, but are not

limited to, one or more of: TNF antagonists (e.g., chimeric, humanized, human or *in*

vitro generated antibodies, or antigen-binding fragments thereof, that bind to TNF;

soluble fragments of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives

20   thereof, e.g., 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, Enbrel$^{TM)}$, p55

kD TNF receptor-IgG fusion protein; TNF enzyme antagonists, e.g., TNFα converting

enzyme (TACE) inhibitors); antagonists of IL-12, IL-15, IL-17, IL-18, IL-22; T cell and

B cell depleting agents (e.g., anti-CD4 or anti-CD22 antibodies); small molecule

inhibitors, e.g., methotrexate and leflunomide; sirolimus (rapamycin) and analogs

25   thereof, e.g., CCI-779; Cox-2 and cPLA2 inhibitors; NSAIDs; p38 inhibitors, TPL-2,

Mk-2 and NFkb inhibitors; RAGE or soluble RAGE; P-selectin or PSGL-1 inhibitors

(e.g., small molecule inhibitors, antibodies thereto, e.g., antibodies to P-selectin);

estrogen receptor beta (ERB) agonists or ERB-NFkb antagonists. Most preferred

additional therapeutic agents that can be co-administered and/or co-formulated with one

30   or more IL-21/IL-21R antagonists include one or more of: a soluble fragment of a TNF

receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kdTNFR-

IgG (75 kD TNF receptor-IgG fusion protein, Enbrel™); methotrexate, leflunomide, or a sirolimus (rapamycin) or an analog thereof, e.g., CCI-779.

Applicants have further shown that an IL-21/IL-21R agonist, e.g., an IL-21 polypeptide, stimulates immunity *in vivo* against immunogenic and non-immunogenic

5   tumor cells (Example 9). The increased immunity is due in part by the IL-21-mediated potentiation of mature CD8+ T cell effector function. IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response *in vivo*, e.g., for example, for use in treating cancer or an infectious disorder in a subject.

10   Accordingly, the invention provides a method of treating (e.g., curing, suppressing, ameliorating, delaying or preventing the onset of, or preventing recurrence or relapse of) or preventing a cancer or an infectious disorder, in a subject, the method includes: administering to the subject an IL-21/IL-21R agonist, e.g., an agent that increases or potentiates IL-21/IL-21R activity, in an amount sufficient to increase

15   immune cell (e.g., CD8+ cell) activity (e.g., effector cell activity) and/or cell number, thereby treating or preventing said disorder. Exemplary cancer disorders include, but are not limited to, a solid tumor, a soft tissue tumor (e.g., a lymphoma or a leukemia), and a metastatic lesion. Examples of infections disorders that can be treated or prevented include bacterial, viral and parasitic infections.

20   In one embodiment, a method for increasing the ability of a vaccine composition containing an antigen, e.g., an antigen from a pathogen, e.g., a bacterial, viral and parasitic pathogen, or a tumor cell, to elicit a protective immune response in a subject against the antigen by administering to the subject, either simultaneously with or sequentially, to the vaccine composition, an effective adjuvanting amount of an IL-21/IL-

25   21R agonist (e.g., a IL-21 polypeptide or a biologically active fragment thereof, or a nucleic acid encoding the same). In one embodiment, the pathogen against which the vaccine is directed is an intracellular pathogen, e.g., a virus, bacterium, or protozoan. The pathogen may also be an extracellular parasite, e.g., a helminth or bacterium. The antigen may be a whole cell, a protein, a protein subunit or fragment.

30   Preferred IL-21/IL-21R agonists bind to IL-21 or IL-21R with high affinity, e.g., with an affinity constant of at least about 10^7 M^{-1}, preferably about 10^8 M^{-1}, and more preferably, about 10^9 M^{-1} to 10^{10} M^{-1} or stronger.

In one embodiment, the IL-21/IL-21R agonist is an IL-21 polypeptide, e.g., a human IL-21 polypeptide, or an active fragment thereof (e.g., a human IL-21 polypeptide comprising the amino acid sequence shown as SEQ ID NO:19, or encoded by a nucleotide sequence shown as SEQ ID NO:18, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto). In other embodiments, the IL-21/IL-21R agonist is a fusion protein comprising an IL-21 polypeptide, e.g., human IL-21 polypeptide, or a fragment thereof and, e.g., fused to, a second moiety, e.g., a polypeptide (e.g., an immunoglobulin chain, an Fc fragment, a heavy chain constant regions of the various isotypes, including: IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE); an agonist antibody or antigen-binding fragment thereof, to the IL-21 receptor; or a small molecule or peptide agonist. In other embodiments, the IL-21/IL-21R agonist is an agent that increases the activity or levels of IL-21 by, e.g., increasing expression, processing and/or secretion of functional IL-21. Nucleic acids encoding the aforesaid IL-21/IL-21R agonists and/or antigen can also be administered to the subject.

The IL-21/IL-21R agonists described herein can be used, alone or in combination, with other therapeutic modalities. If desired, the IL-21/IL-21R agonist can be administered in conjunction with one or more additional agents that increase an immune response, e.g., an agent that enhances an immune response to a cancer or infectious disease, in the subject (e.g., an antigen, an antigenic peptide, alone or in combination with an antigen-presenting cell, e.g., a dendritic cell). For example, the IL-21/IL-21R agonist(s) can be administered by themselves, or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant) and/or in combination with other cytokines (e.g., IL-2, GM-CSF and/or IL-15). The combination therapy can be carried out in any order, e.g., IL-15 and antigen can be co-administered to a subject, followed by boosting the immune response by administering IL-21 and the antigen.

Preferably, the subject is a mammal, e.g., a human suffering a cancer or an infectious disorder. The IL-21/IL-21R agonist is preferably designed to increase the immune response to a cancer or infectious disease. The infectious disease can be caused by, e.g., bacterial, parasitic or viral agents.

In another aspect, the invention features a method for modulating, e.g., increasing or decreasing, immune cell activity and/or number (e.g., the activity and/or number of one or more of: a mature T cell (mature, CD8+, CD4+ T cell), mature NK cell, B cell,

macrophage or megakaryocyte; preferably, a mature CD8+ T cell or a macrophage) or a population of immune cells, e.g., a mixed or a substantially purified immune cell population. The method includes contacting an immune cell, e.g., an immune cell as described herein, with an IL-21/IL-21R agonist or antagonist, e.g., an agonist or

5   antagonist as described herein, in an amount sufficient to modulate, e.g., increase or decrease, immune cell activity and/or number.

The subject method can be used on cells in culture, e.g. *in vitro* or *ex vivo*. For example, immune cells, e.g., T cells as described herein, can be cultured *in vitro* in culture medium and the contacting step can be effected by adding one or more IL-21/IL-

10   21R agonist(s) or antagonist(s), e.g., an agonist or antagonist as described herein, to the culture medium. Alternatively, the method can be performed on cells (e.g., immune cells as described herein) present in a subject, e.g., as part of an *in vivo* (e.g., therapeutic or prophylactic) protocol.

The immune cell can be chosen from, e.g., one or more of: a mature T cell

15   (mature, CD8+, CD4+, lymph node T cell, memory T cell), mature NK cell, B cell, antigen presenting cell (APC), e.g., a dendritic cell, macrophage or megakaryocyte, or a population of cells, e.g., a mixed or a substantially purified immune cell population. Preferably, the immune cell is a mature CD8+ T cell or a macrophage.

A change in immune cell activity includes any variation(s), e.g.,

20   increase/decrease, in one or more of: proliferation, cytokine secretion and/or production, survival, differentiation, cell responsiveness (e.g., desensitization), cytolytic activity, effector cell activity, gene expression, among others, of the immune cell contacted with an IL-21/IL-21R agonist or antagonist compared to a reference, e.g., an untreated immune cell. For example, contacting an immune cell with an IL-21/IL-21R agonist,

25   e.g., an IL-21 polypeptide, can induce one or more of: proliferation, cytolytic activity, effector cell function, or cytokine secretion of one or more of: antigen- or anti-CD3 antibody stimulated thymocytes; lymph node T cells, mature CD4+ T cells, mature CD8+ T cells, or macrophages.

Responsiveness of immune cells, e.g., T cells, to stimulatory signals can also be

30   modulated using an agonist or antagonist as described herein. For example, proliferation of T cells to alloantigens can be increased in the presence of an IL-21 polypeptide. IL-21 may also enhance proliferation and/or differentiation of mature CD8+ T cells. For

example, priming of CD8+ T cells in the presence of IL-21 can generate effector cells with enhanced lytic (CTL) activity and/or increased ability to secrete cytokines, e.g., IFNγ. In other embodiments, IL-21/IL-21R agonist can be used to induce the proliferation and/or cytokine secretion of macrophages.

5   In one embodiment, a method for decreasing immune cell activity (e.g., the activity of one or more of: a mature T cell (mature, CD8+, CD4+, lymph node T cell, memory T cell), mature NK cell, B cell, antigen presenting cell (APC), e.g., a dendritic cell, macrophage or megakaryocyte, or a population of cells, e.g., a mixed or a substantially purified immune cell population, is provided. The method includes

10   contacting the immune cell with an IL-21/IL-21R antagonist, e.g., an antagonist as described herein, in an amount sufficient to decrease immune cell activity.

In other embodiments, a method for increasing immune cell activity and/number (e.g., the activity and/or number of one or more of: a mature T cell (mature, CD8+, CD4+, lymph node T cell, memory T cell), mature NK cell, B cell, antigen presenting

15   cell (APC), e.g., a dendritic cell, macrophage or megakaryocyte, or a population of cells, e.g., a mixed or a substantially purified immune cell population, is provided. The method includes contacting an immune cell with an IL-21/IL-21R agonist, e.g., an agonist as described herein, in an amount sufficient to increase immune cell activity.

In another aspect, the invention features a fusion protein that includes at least a

20   fragment of an IL-21R polypeptide, which is capable of binding an IL-21 polypeptide, e.g., a soluble fragment of an IL-21R (e.g., a fragment of an IL-21R comprising the extracellular domain of murine or human IL-21R; e.g., from about amino acids 1-235, 1-236, 20-235, 20-236 of SEQ ID NO:2 (human), or from about amino acids 1-236, 20-236 of SEQ ID NO:10 (murine), or encoded by the corresponding nucleotides of SEQ ID

25   NO:1 or 9, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto) and, e.g., fused to, a second moiety, e.g., a polypeptide (e.g., an immunoglobulin chain, an Fc fragment, a heavy chain constant regions of the various isotypes, including: IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE). For example, the fusion protein can include the extracellular domain of human IL-21R, e.g., from about amino acids 1-235,

30   1-236, 20-235, 20-236 of SEQ ID NO:2, and, e.g., fused to, a human immunoglobulin Fc chain (e.g., human IgG, e.g., human IgG1 or a mutated form of human IgG1). In one embodiment, the human Fc sequence has been mutated at one or more amino acids, e.g.,

mutated at residues 254 and 257 of SEQ ID NO:28, from the wild type sequence to reduce Fc receptor binding. In other embodiments, the fusion protein can include the extracellular domain of murine IL-21R, e.g., from about amino acids 1-236, 20-236 of SEQ ID NO:10 (murine), and, e.g., fused to, a murine immunoglobulin Fc chain (e.g., murine IgG, e.g., murine IgG2a or a mutated form of murine IgG2a). The fusion proteins may additionally include a linker sequence joining the IL-21R fragment to the second moiety. In other embodiments, additional amino acid sequences can be added to the N- or C-terminus of the fusion protein to facilitate expression, detection and/or isolation or purification.

The fusion protein described herein, can be derivatized or linked to another functional molecule, e.g., another peptide or protein (e.g., an Fab' fragment). For example, the fusion protein can be functionally linked (e.g., by chemical coupling, genetic fusion, non-covalent association or otherwise) to one or more other molecular entities, such as an antibody (e.g., a bispecific or a multispecific antibody), toxins, radioisotopes, cytotoxic or cytostatic agents, among others.

Examples of antagonistic fusion proteins that can be used in the methods of the invention are shown in Figures 7-15. In one embodiment, the fusion protein includes an amino acid sequence chosen from, e.g., SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, or SEQ ID NO:39, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. In other embodiments, the fusion protein includes an amino acid sequence encoded by a nucleotide sequence chosen from, e.g., SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, or SEQ ID NO:38, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. Preferred fusion proteins have the amino acid sequence shown as SEQ ID NO:25 or SEQ ID NO:29 (Figures 8A-8C and 10A-10C, respectively), or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. In other embodiments, the fusion protein includes an amino acid sequence encoded by a nucleotide sequence chosen from, e.g., SEQ ID NO:24 or SEQ ID NO:28 (Figures 8A-8C and 10A-10C, respectively), or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. Most preferably, the fusion protein has the amino acid sequence shown as SEQ ID NO:29, or has an amino acid sequence encoded by a nucleotide sequence shown as SEQ ID NO:28 (Figure 10A-10C).

The invention also features nucleic acid sequences that encode the fusion proteins described herein.

In another aspect, the invention features host cells and vectors containing the nucleic acids of the invention. Preferably, the host cell is a eukaryotic cell, e.g., a

5   mammalian cell, an insect cell, a yeast cell, or a prokaryotic cell, e.g., *E. coli*. For example, the mammalian cell can be a cultured cell or a cell line. Exemplary mammalian cells include lymphocytic cell lines (e.g., NSO), Chinese hamster ovary cells (CHO), COS cells, oocyte cells, and cells from a transgenic animal, e.g., mammary epithelial cell. For example, nucleic acids encoding the fusion proteins described herein can be

10   expressed in a transgenic animal. In one embodiment, the nucleic acids are placed under the control of a tissue-specific promoter (e.g., a mammary specific promoter) and the antibody is produced in the transgenic animal. For example, the fusion protein is secreted into the milk of the transgenic animal, such as a transgenic cow, pig, horse, sheep, goat or rodent.

15   In another aspect, the invention provides a process for producing a fusion protein, e.g., a fusion protein as described herein. The process comprises: (a) growing a culture of the host cell of the present invention in a suitable culture medium; and (b) purifying the fusion protein from the culture. Proteins produced according to these methods are also provided.

20

In another aspect, the invention provides, compositions, e.g., pharmaceutical compositions, which include a pharmaceutically acceptable carrier and at least one of IL-21/IL-21R agonist or an antagonist as described herein (e.g., a fusion protein described herein). In one embodiment, the compositions, e.g., pharmaceutical compositions,

25   comprise a combination of two or more one of the aforesaid IL-21/IL-21R agonists or antagonists. Combinations of the IL-21/IL-21R agonists or antagonists and a drug, e.g., a therapeutic agent (e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostatic agents, as described in more herein) or an antigen, e.g., an

30   antigenic peptide and/or an antigen-presenting cell, are also within the scope of the invention.

In one embodiment, the pharmaceutical composition includes an IL-21/IL-21R antagonist agonist and at least one additional therapeutic agent, in a pharmaceutically-acceptable carrier. Examples of preferred additional therapeutic agents that can be co-formulated in a composition, e.g., a pharmaceutical composition, with one or more IL-21/IL-21R antagonists, include, but are not limited to, one or more of: TNF antagonists (e.g., chimeric, humanized, human or *in vitro* generated antibodies, or antigen-binding fragments thereof, that bind to TNF; soluble fragments of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, Enbrel™), p55 kD TNF receptor-IgG fusion protein; TNF enzyme antagonists, e.g., TNFα converting enzyme (TACE) inhibitors); antagonists of IL-12, IL-15, IL-17, IL-18, IL-22; T cell and B cell depleting agents (e.g., anti-CD4 or anti-CD22 antibodies); small molecule inhibitors, e.g., methotrexate and leflunomide; sirolimus (rapamycin) and analogs thereof, e.g., CCI-779; Cox-2 and cPLA2 inhibitors; NSAIDs; p38 inhibitors, TPL-2, Mk-2 and NFkb inhibitors; RAGE or soluble RAGE; P-selectin or PSGL-1 inhibitors (e.g., small molecule inhibitors, antibodies thereto, e.g., antibodies to P-selectin); estrogen receptor beta (ERB) agonists or ERB-NFkb antagonists. Most preferred additional therapeutic agents that can be co-administered and/or co-formulated with one or more IL-21/IL-21R antagonists include one or more of: a soluble fragment of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, Enbrel™); methotrexate, leflunomide, or a sirolimus (rapamycin) or an analog thereof, e.g., CCI-779.

In another embodiment, a pharmaceutical composition useful as a vaccine comprising an antigen from a pathogenic microorganism, e.g., a viral, bacterial or parasitic microorganism, and an effective adjuvanting amount of an IL-21/IL-21R agonist, in a pharmaceuticallt acceptable carrier, is provided. In one embodiment, the resulting composition is capable of eliciting the vaccinated subject's immunity for a protective response to the pathogen. The IL-21/IL-21R agonist and antigen used in the composition may be a polypeptide or biologically active fragment thereof, or in a composition comprising nucleic acids encoding the same. These nucleic acids, together with the appropriate promoter sequences, may be employed directly as an antigen administered with, or close in time to, the IL-21/IL-21R agonist adjuvant. Alternatively,

these nucleic acids sequences may be transduced in alternate vaccine strains of the pathogenic microorganism, and upon expression *in vivo* may provide the antigen of the vaccine.

In other embodiments, the invention provides a composition, e.g., a pharmaceutical composition, for the treatment or amelioration of a cancer, and a method for adjuvanting a cancer "vaccine," in a pharmaceutically acceptable carrier. A cancer vaccine may comprise an antigen expressed on the surface of a cancer or a tumor cell. This antigen may be naturally present on the cancer cell. Alternatively, the cancer cell may be manipulated *ex vivo* and transfected with a selected antigen, which it then expresses when introduced into the patient. An exemplary pharmaceutical composition described herein can contain a cancer- or a tumor cell-antigen (either alone as a protein, biologically active fragment thereof, or nucleic acid encoding same), or a cell, e.g., a cancer cell, transfected with the cancer or tumor cell antigen, in combination with an IL-21/IL-21R agonist (e.g., an agonist as described herein, a fragment thereof, or a nucleic acid encoding the same). In one embodiment, the co-administration of IL-21/IL-21R agonist with the tumor cell antigen enhances the CD8+ T-cell effector cell activity of the tumor cell antigen.

Methods of producing the aforesaid compositions, e.g., vaccine compositions, are also encompassed by the present invention.

The following terms are used interchangeably herein: "MU-1" and "IL-21R," and peptides, polypeptides and proteins.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A depicts the full-length cDNA sequence of murine IL-21R/MU-1. The nucleotide sequence corresponds to nucleotides 1-2628 of SEQ ID NO:9.

Figures 2A-2B depict the amino acid sequences of murine and human IL-

5   21R/MU-1. *Figure 2A* depicts the amino acid sequence of murine IL-21R/MU-1 (corresponding to the amino acids 1-529 of SEQ ID NO:10). There is a predicted leader sequence at amino acids 1-19, which was predicted by Susan with score of 10.1 (bold-face type). There is a predicted transmembrane domain at amino acids 237-253 of SEQ ID NO:10 (underlined). Predicted signaling motifs include the following regions: Box 1:

10   amino acids 265-274 and Box 2: amino acids 310-324 (bold and underlined); six tyrosine's are located at amino acid positions 281, 319, 361, 368, 397, and 510, of SEQ ID NO:10. The WSXWS motif (SEQ ID NO:8) is located at amino acid residue 214 to amino acid residue 218 (in large, bold-face type). Potential STAT docking sites include, amino acids 393-398 and amino acids 510-513 of SEQ ID NO:10.

15   *Figure 2B* depicts the amino acid sequence of human MU-1 (corresponding to SEQ ID NO:2). The location of the predicted signal sequence (about amino acids 1-19 of SEQ ID NO:2); WSXWS motif (about amino acids 213-217 of SEQ ID NO:2); and transmembrane domain (about amino acids 236-252, 236-253, 236-254, of SEQ ID NO:2 (underlined)). Potential JAK binding sites, signaling motifs and STAT docking sites are

20   also indicated. The approximate location of these sites is boxed.

Figure 3 depicts the GAP comparison of human and murine MU-1cDNA sequences (corresponding to nucleic acids 1-2665 of SEQ ID NO:1 and nucleic acids 1-2628 of SEQ ID NO:9, respectively). HuMU-1= human MU-1, murMU-1= murine MU-1. Gap Parameters: Gap Weight= 50, Average Match= 10.000, Length Weight= 3,

25   Average Mismatch= 0.000. Percent Identity= 66.116.

Figure 4 depicts a GAP comparison of the human MU-1 protein (corresponding to amino acids 538 of SEQ ID NO:2) and the murine MU-1 protein (corresponding to amino acids 1-529 of SEQ ID NO:10). BLOSUM62 amino acid substitution matrix. (Henikoff, S. and Henikoff, J. G. (1992)). Amino acid substitution matrices from protein

30   blocks (Proc. Natl. Acad. Sci. USA 89: 10915-10919). Gap parameters= Gap Weight: 8,

Average Match= 2.9 12, Length Weight= 2, Average Mismatch= -2.003. Percent
Identity= 65.267.

      Figure 5 depicts a multiple sequence alignment of the amino acids of human MU-
1 (corresponding to SEQ ID NO:2), murine MU-1 (corresponding to SEQ ID NO: 10),

5   and human IL2beta chain (GENbank Accession No. M26062). Leader and
transmembrane domains are underlined. Conserved cytokine receptor module motifs are
indicated by bold-face type. Potential signaling regions are indicated by underlining and
bold-face type.

      Figure 6 depicts signaling through MU-1. MU-1 phosphorylates STAT 5 in

10   Clone E7 EPO-MU-1 chimera. Under the conditions specified in Example 3, signaling
through MU-1 results in the phosphorylation of STAT 5 at all time-points tested.
Treatment of controls or the chimeric BAF-3 cells with IL-3 resulted in phosphorylation
of STAT 3, but not STAT 1 or 5.

      Figures 7A-7B depict an alignment of the nucleotide and amino acid sequences of

15   human IL-21R monomer (corresponding to amino acids 20-235 of SEQ ID NO:2) fused
at the amino terminal to honey bee leader sequence and His6 tags (amino acids 1-44 of
SEQ ID NO:23). The nucleotide and amino acid sequences are shown as SEQ ID NO:22
and SEQ ID NO:23, respectively.

      Figures 8A-8C depict an alignment of the nucleotide and amino acid sequences of

20   human IL-21R extracellular domain (corresponding to amino acids 1-235 of SEQ ID
NO:2) fused at the C-terminus via a linker (corresponding to amino acids 236-243 of
SEQ ID NO:25) to human immunoglobulin G1 (IgG1) Fc sequence (corresponding to
amino acids 244-467 of SEQ ID NO:25). The nucleotide and amino acid sequences are
shown as SEQ ID NO:24 and SEQ ID NO:25, respectively.

25   *Figures 9A-9C* depict an alignment of the nucleotide and amino acid sequences of
human IL-21R extracellular domain (corresponding to amino acids 1-235 of SEQ ID
NO:2) fused at the C-terminus via a linker (corresponding to amino acids 236-243 of
SEQ ID NO:27) to human immunoglobulin G1 (IgG1) Fc sequence (corresponding to
amino acids 244-467 of SEQ ID NO:27), and His6 sequence tag (corresponding to amino

30   acids 468-492 of SEQ ID NO:27). The nucleotide and amino acid sequences are shown
as SEQ ID NO:26 and SEQ ID NO:27, respectively.

Figures 10A-10C depicts an alignment of the nucleotide and amino acid
sequences of human IL-21R extracellular domain (corresponding to amino acids 1-235 of
SEQ ID NO:2) fused at the C-terminus via a linker (corresponding to amino acids 236-
243 of SEQ ID NO:29) to human immunoglobulin G1 (IgG1) Fc sequence

5   (corresponding to amino acids 244-467 of SEQ ID NO:29)to human immunoglobulin G1
(IgG1) Fc mutated sequence. The human Fc sequence has been mutated at residues 254
and 257 from the wild type sequence to reduce Fc receptor binding. The nucleotide and
amino acid sequences are shown as SEQ ID NO:28 and SEQ ID NO:29, respectively.

Figures 11A-11B depict an alignment of the nucleotide and amino acid sequences

10   of human IL-21R extracellular domain (corresponding to amino acids 1-235 of SEQ ID
NO:2) fused at the C-terminus to a rhodopsin sequence tag. The nucleotide and amino
acid sequences are shown as SEQ ID NO:30 and SEQ ID NO:31, respectively.

Figures 12A-12C depict an alignment of the nucleotide and amino acid sequences
of human IL-21R extracellular domain (corresponding to amino acids 1-235 of SEQ ID

15   NO:2) fused at the C-terminus to an EK cleavage site and mutated IgG1 Fc region
(corresponding to amino acids 236-470 of SEQ ID NO:33). The nucleotide and amino
acid sequences are shown as SEQ ID NO:32 and SEQ ID NO:33, respectively.

Figures 13A-13B depict an alignment of the nucleotide and amino acid sequences
of murine IL-21R extracellular domain fused at the C-terminus to mouse

20   immunoglobulin G2a (IgG2a). The nucleotide (genomic) and amino acid sequences are
shown as SEQ ID NO:34 and SEQ ID NO:35, respectively.

Figures 14A-14B depict an alignment of the nucleotide and amino acid sequences
of murine IL-21R extracellular domain fused at the C-terminus to Flag and His6
sequence tags. The nucleotide (genomic) and amino acid sequences are shown as SEQ

25   ID NO:36 and SEQ ID NO:37, respectively.

Figures 15A-15B depict an alignment of the nucleotide and amino acid sequences
of (honey bee leader) murine IL-21R extracellular domain fused at the C-terminus to Flag
and His6 sequence tags. The nucleotide (genomic) and amino acid sequences are shown
as SEQ ID NO:38 and SEQ ID NO:39, respectively.

30   *Figure 16* is a timetable summarizing the prophylactic, therapeutic and semi-
therapeutic treatment schedules for the experiments using collagen-induced arthritis
(CIA) mouse models.

Figure 17 is a graph depicting the effects of muIL21RFc (200 μg/mouse 3x/week) on a semi-therapeutic CIA mouse as a function of days post treatment. Mouse Ig (200 μg/mouse 3x/week) was used as a control.

Figure 18 is a graph depicting the effects of murine IL-21 on mean CIA score as a function of days post collagen boost. Mice were injected with 1 μg of murine IL21 intraperitoneally when presenting a total body score of 2-4.

Figure 19, panels A-B, are photographs showing increased expression of IL-21R mRNA in arthritic paws of mice with CIA (panel A) compared to negative controls (panel B).

Figures 20A-20C are bar graphs depicting the level and biological activity of IL-21 secreted by IL-21- transduced B16F1 and MethA cells. *Figure 20A* shows the level of IL-21 secretion by transduced tumor cells. *Figures 20(B, C)* are bar graphs depicting the biological activity of IL-21 secreted by transduced tumor cells. Naïve splenocytes from either C57BL/6 (B) or Balb/C (C) mice were stimulated for 72 hours with the indicated concentrations of irradiated syngeneic tumor cells. The cultures were supplemented with sub-optimal amount of anti-CD3 and anti-CD28 mAb in 96-well plates. ^{3}H thymidine was added during the last 6 hours of culture.

Figures 21A-21C are graphs depicting the *in vitro* growth characteristics of transduced tumor cells and evaluation of IL-21R expression. *Figures 21A* and *21B* depict the number of B16F1-IL-21 and B16F1-GFP or MethA-IL-21 and MethA-GFP tumor cells, respectively, with respect to time in culture. *Figure 21C* is a bar graph depicting expression of IL-21RmRNA in the transfected cells was normalized to cyclophilin values and expressed as relative unite (R.U.).

Figures 22A-22B are linear graphs depicting the *in vivo* growth characteristics of transduced tumor cells. IL-21 or GFP expressing tumor cells were injected in syngeneic naïve mice as indicated. Tumor size was scored by multiplying perpendicular diameters and was averaged for all mice in each group. (A) Tumor growth in C57BL/6 mice that were injected with 10^5 of B16F1-IL-21 or GFP cells. (B) Tumor growth in Balb/C mice that were injected with either 1×10^6 or 2×10^6 of MethA-IL-21or MethA-GFP cells.

Figures 23A-23B are linear graphs depicting the changes in B16F1-IL-21 tumor growth in scid and nude mice with respect to number of days after injection of B16F1-IL-

21 cells. B16F1-IL-21 and B16F1-GFP tumor cells (10^5/mouse) were injected into C57BL/6 scid (A) or C57BL/6 nude (B) mice. Tumor size was monitored twice weekly.

Figures 24A-24B are linear graphs depicting the growth of B16F1-IL-21 cells *in vivo* in CD4$^+$, CD8$^+$ T or NK cell depleted mice. A) C57BL/6 were depleted of CD4$^+$ or

5   CD8$^+$ T cells by three consecutive injections of anti-CD4 or anti-CD8 mAb on days -3, -2 and -1 before tumor cell injection and every other day post 10^5 B16F1-IL-21 and B16F1-GFP tumor cell injection. (rat IgG was used as isotype control). B) C57BL/6 were depleted of NK cells by one injection of anti-asialo GM1 Ab on day -1 before tumor cell injection and twice per week post 10^5 B16F1-IL-21 and B16F1-GFP tumor cell

10   injection. (rat IgG or rabbit IgG were used as isotype controls for T and NK cell depletion respectively). Tumor size was monitored twice per week as described in Figure 23.

Figures 25A-25C are graphs showing TRP-2 specific T cell responses in B16F1-IL-21 injected mice. (A) Equal numbers of splenocytes (2 - 4 x10^5) from mice injected

15   with either B16F1-IL-21 or B16F1-GFP were stimulated with 5µg/ml of TRP-2 peptide in the presence of 20 U of IL-2 in an ELISPOT plate pre-coated with anti-IFNγ Ab. After 24 hours, the plate was developed and spot forming units were counted. Results are expressed as number of spot forming units/million of splenocytes (SPU/million splenocytes). (B) Cytolytic activity of splenocytes from B16F1-IL-21 or (C) control

20   B16F1-GFP injected mice were tested against RMA-S cells pulsed with TRP-2 or OVA peptide (control). Cytolytic activity was measured by standard 4-hr Cr^{51} Release Assay

Figures 26A-26B are linear graphs depicting the *in vivo* growth of B16F1-IL-21 cells in IFNγ $^{-/-}$ and IL-10$^{-/-}$ mice. (A) IFNγ$^{-/-}$ mice or (B) IL-10$^{-/-}$ mice were injected with 10^5 of either B16F1-IL-21 or B16F1-GFP tumor cells and the tumor growth was

25   monitored twice weekly.

Figures 27A-27B are bar graphs depicting IL-21R and IL-21 expression by naïve CD8+ T cells. CD8+/CD62L+ T cells were sorted from LN of 2C TCR Tg mice and stimulated with anti-CD3 (2.5ug/ml plate-bound), IL-21 (12.5ng/ml) or anti-CD28 (7.5ug/ml plate-bound). At the indicated times, cells were harvested, RNA prepared and

30   RPA analysis performed. Samples were quantitated by phosphoimager analysis relative to an internal control. (A) Quantitation of RPA pixels for IL-21R bands. (B) Quantitation of RPA pixels for IL-21 bands.

Figures 28A-28D are linear graphs depicting the effects of IL-21 on proliferation of CD8+ T cells. (A) IL-21 enhances antigen stimulation of CD8+ T cells. Purified 2C CD8+ T cells were stimulated for 72hrs with irradiated Balb/c splenocytes at 5:1 APC:T ratio with the indicated amount of IL-21 or equivalent dilution of mock-transfected

5   supernatant (representative experiment, n=5). (B) Effect of IL-21 vs IL-2, IL-12, IL-15 on antigen stimulation. 2C T cells were stimulated with 3:1 T-depleted APC:T ratio and the indicated concentration of cytokine (n=3). (C) IL-21 acts directly on CD8+ T cells to specifically enhance proliferation. 2C CD8+ T cells were stimulated on anti-CD3-coated plates (2.5ug/ml) with the indicated titer of IL-21 +/- mIL-21R.Fc (20ug/ml) (n=3). (D)

10   Effect of IL-21 vs IL-2, IL-12, IL-15 on anti-CD3 mAb stimulation (5ug/ml plate-bound).

Figures 29A-29C are graphs showing the effects of IL-21 on development of CD8+ T cell effector functions. (A) IL-21 enhances CTL generation. 2C T cells were stimulated with irradiated APCs (APC:T) and IL-2 (10U/ml), IL-21 (titer) or the equivalent dilution of mock supernatant for 4 days then washed, counted and set up in a

15   4hr CTL assays using 51-Cr-labeled P815 as specific targets (representative experiment, n=3). (B) IL-21 is comparable to IL-12, IL-15 for inducing lytic activity from CD8+ T cells. 2C CD8+ T cells were stimulated and assayed for CTL activity as in (A) using IL-2 (5ng/ml), IL-15 (50ng/ml), IL-12 (5ng/ml), IL-21 (25ng/ml). (C) IL-21 during priming results in increased ability to produce IFNg. 2C T cells were stimulated as indicated in

20   (B) for 5 days then washed and restimulated for on anti-CD3-coated plates (1ug/ml). IFNg ELISAs were done on 40hr supernatants.

DETAILED DESCRIPTION OF THE INVENTION

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ("IL-21R" or

25   "MU-1"), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression *in vivo*, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R

30   agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response *in vivo*, e.g., for example, for use in treating cancer and infectious disorders.

In one embodiment, Applicants have shown that a reduction of IL-21R activity by using a neutralizing fusion protein that includes the extracellular domain of the IL-21R fused to an Fc immunoglobulin region ameliorates inflammatory symptoms in mouse collagen-induced arthritis (CIA) animal models (Example 7). Expression of IL-21R

5   mRNA is upregulated in the paws of CIA mice (Example 8). Accordingly, IL-21R binding agents that antagonize IL-21/IL-21R activity can be used to induce immune suppression *in vivo*, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of T cells (CD8+, CD4+ T cells), NK cells, B cells, macrophages and megakaryocytes, including transplant

10   rejection and autoimmune disorders).

In other embodiments, Applicants have shown that agonistic IL-21R binding agent stimulate, primarily via stimulation of CD8+T cells, innate and adaptive immunity *in vivo* against immunogenic and non-immunogenic tumor cells (Example 9). Accordingly, binding agents that stimulate the IL-21/IL-21R pathway can be used by

15   themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response *in vivo*, e.g., for example, for use in treating cancer and infectious disorders.

In order that the present invention may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

20   The term "MU-1," "MU-1 protein," "interleukin-21 receptor" or "IL-21R," as used herein, refers to a class I cytokine family receptor, also known as NILR (WO 01/85792; Parrish-Novak *et al.* (2000) *Nature* 408:57-63; Ozaki et al. (2000) *Proc. Natl. Acad. Sci.* USA 97:11439-114444). MU-1 is homologous to the shared β chain of the IL-2 and IL-15 receptors, and IL-4α (Ozaki et al. (2000) *supra*). Upon ligand binding,

25   IL-21R/MU-1 is capable of interacting with a common γ cytokine receptor chain (γc) (Asao *et al.* (2001) *J. Immunol.* 167:1-5), and inducing the phosphorylation of STAT1 and STAT3 (Asao et al. (2001) or STAT5 (Ozaki et al. (2000). MU-1 shows widespread lymphoid tissue distribution. The term "MU-1" refers to a receptor (preferably of mammalian, e.g., murine or human origin) which is capable of interacting with, e.g.,

30   binding to, IL-21 (preferably of mammalian, e.g., murine or human IL-21) and having one of the following features: (i) an amino acid sequence of a naturally occurring mammalian MU-1 polypeptide IL-21R/MU-1 or a fragment thereof, e.g., an amino acid

sequence shown as SEQ ID NO:2 (human) or SEQ ID NO:10 (murine) or a fragment
thereof; (ii) an amino acid sequence substantially homologous to, e.g., at least 85%, 90%,
95%, 98%, 99% homologous to, an amino acid sequence shown as SEQ ID NO:2
(human) or SEQ ID NO:10 (murine) or a fragment thereof; (iii) an amino acid sequence

5   which is encoded by a naturally occurring mammalian IL-21R/MU-1 nucleotide sequence
or a fragment thereof (e.g., SEQ ID NO:1 (human) or SEQ ID NO:9 (murine) or a
fragment thereof); (iv) an amino acid sequence encoded by a nucleotide sequence which
is substantially homologous to, e.g., at least 85%, 90%, 95%, 98%, 99% homologous to,
a nucleotide sequence shown as SEQ ID NO:1 (human) or SEQ ID NO:9 (murine) or a

10   fragment thereof; (v) an amino acid sequence encoded by a nucleotide sequence
degenerate to a naturally occurring IL-21R/MU-1 nucleotide sequence or a fragment
thereof, e.g., SEQ ID NO:1 (human) or SEQ ID NO:9 (murine) or a fragment thereof; or
(vi) a nucleotide sequence that hybridizes to one of the foregoing nucleotide sequence
sequences under stringent conditions, e.g., highly stringent conditions.

15   The IL-21R/MU-1 is of mammalian, preferably, human origin. The nucleotide
sequence and the predicted amino acid sequence of human IL-21R/MU-1 are shown in
SEQ ID NO:1 and SEQ ID NO:2, respectively. Analysis of the human IL-21R/MU-1
amino acid sequence (SEQ ID NO:2; Figure 2B) revealed the following structural
features: a leader sequence from about (about amino acids 1-19 of SEQ ID NO:2 (Figure

20   2B)); WSXWS motif (about amino acids 213-217 of SEQ ID NO:2); transmembrane
domain (about amino acids 236-252 of SEQ ID NO:2 (Figure 2B)); an extracellular
domain from about amino acids 1-235 of SEQ ID NO:2; and an intracellular domain
from about 253-538 of SEQ ID NO:2. The mature human IL-21R/MU-1 is believed to
have the sequence of amino acids 20-538 of SEQ ID NO:2.

25   The IL-21R/MU-1 cDNA was deposited with the American Type Culture
Collection on Mar. 10, 1998, as accession number ATCC 98687.
               Any form of IL-21R/MU-1 proteins of less than full length can be used in the
methods and compositions of the present invention, provided that it retains the ability to
bind to an IL-21 polypeptide. IL-21R/MU-1 proteins of less than full length, e.g., soluble

30   IL-21R, can be produced by expressing a corresponding fragment of the polynucleotide
encoding the full-length MU-1 protein in a host cell. These corresponding
polynucleotide fragments are also part of the present invention. Modified

polynucleotides as described above may be made by standard molecular biology
techniques, including construction of appropriate desired deletion mutants, site-directed
mutagenesis methods or by the polymerase chain reaction using appropriate
oligonucleotide primers.

5   As used herein, a "soluble IL-21R/MU-1 polypeptide" is a IL-21R/MU-1
polypeptide incapable of anchoring itself in a membrane. Such soluble polypeptides
include, for example, MU-1 or IL-21R polypeptides that lack a sufficient portion of their
membrane spanning domain to anchor the polypeptide or are modified such that the
membrane spanning domain is non-functional. E.g., a soluble fragment of an IL-21R

10   (e.g., a fragment of an IL-21R comprising the extracellular domain of murine or human
IL-21R includes an amino acid sequence from about amino acids 1-235, 1-236, 20-235,
20-236 of SEQ ID NO:2 (human), or from about amino acids 1-236, 20-236 of SEQ ID
NO:10 (murine). A soluble IL-21R/MU-1 polypeptide can additionally include, e.g., be
fused to, a second moiety, e.g., a polypeptide (e.g., an immunoglobulin chain, a GST,

15   Lex-A or MBP polypeptide sequence). For example, a fusion protein can includes at
least a fragment of an IL-21R polypeptide, which is capable of binding IL-21, e.g., a
soluble fragment of an IL-21R (e.g., a fragment of an IL-21R comprising the extracellular
domain of murine or human IL-21R; e.g., from about amino acids acids 1-235, 1-236, 20-
235, 20-236 of SEQ ID NO:2 (human), or from about amino acids 1-236, 20-236 of SEQ

20   ID NO:10 (murine), fused to a second moiety, e.g., a polypeptide (e.g., an
immunoglobulin chain, an Fc fragment, a heavy chain constant regions of the various
isotypes, including: IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE).

        The term "interleukin-21" or "IL-21" refers to a cytokine showing sequence
homology to IL-2, IL-4 and IL-15 (Parrish-Novak *et al.* (2000) *Nature* 408:57-63).

25   Despite low sequence homology among interleukin cytokines, cytokines share a common
fold into a "four-helix-bundle" structure that is representative of the family. It is
expressed primarily in activated CD4+ T cells, and has been reported to have effects on
NK, B and T cells (Parrish-Novak *et al.* (2000) *supra*; Kasaian, M.T. et al. (2002) *supra*).
Il-21 binds to IL-21R (also referred to herein as MU-1 and NILR). Upon IL-21 binding,

30   activation of IL-21R leads to stat5 or stat3 signaling (Ozaki et al. (2000) *supra*). The
term "IL-21" or "IL-21 polypeptide" refers to a protein (preferably of mammalian, e.g.,
murine or human origin) which is capable of interacting with, e.g., binding to, IL-21R

(preferably of mammalian, e.g., murine or human IL-21) and having one of the following features: (i) an amino acid sequence of a naturally occurring mammalian IL-21 or a fragment thereof, e.g., an amino acid sequence shown as SEQ ID NO:19 (human) or a fragment thereof; (ii) an amino acid sequence substantially homologous to, e.g., at least

5   85%, 90%, 95%, 98%, 99% homologous to, an amino acid sequence shown as SEQ ID NO:19 (human) or a fragment thereof; (iii) an amino acid sequence which is encoded by a naturally occurring mammalian IL-21 nucleotide sequence or a fragment thereof (e.g., SEQ ID NO:18 (human) or a fragment thereof); (iv) an amino acid sequence encoded by a nucleotide sequence which is substantially homologous to, e.g., at least 85%, 90%,

10   95%, 98%, 99% homologous to, a nucleotide sequence shown as SEQ ID NO:18 (human) or a fragment thereof; (v) an amino acid sequence encoded by a nucleotide sequence degenerate to a naturally occurring IL-21 nucleotide sequence or a fragment thereof, e.g., SEQ ID NO:19 (human) or a fragment thereof; or (vi) a nucleotide sequence that hybridizes to one of the foregoing nucleotide sequence sequences under stringent

15   conditions, e.g., highly stringent conditions.

The phrase "a biological activity of" a MU-1 or IL-21R polypeptide refers to one or more of the biological activities of the corresponding mature MU-1 protein, including, but not limited to, (1) interacting with, e.g., binding to, an IL-21 polypeptide; (2) associating with signal transduction molecules, e.g., γc, jak1; (3) stimulating

20   phosphorylation and/or activation of stat proteins, e.g., stat 5 and/or stat3; and/or (4) modulating, e.g., stimulating or decreasing, proliferation, differentiation, effector cell function, cytolytic activity, cytokine secretion, and/or survival of immune cells, e.g., T cells (CD8+, CD4+ T cells), NK cells, B cells, macrophages and megakaryocytes).

As used herein, a "IL-21/IL-21R agonist", that is useful in the method of the

25   invention, refers to an agent which potentiates, induces or otherwise enhances one or biological activities of an IL-21R/MU-1 polypeptide. Preferably, the agonist interacts with, e.g., binds to, an IL-21R/MU-1 polypeptide.

As used herein, a "IL-21/IL-21R antagonist", that is useful in the method of the invention, refers to an agent which reduces, inhibits or otherwise diminishes one or

30   biological activities of an IL-21R/MU-1 polypeptide. Preferably, the antagonist interacts with, e.g., binds to, an IL-21R/MU-1 polypeptide. Antagonism using an IL-21/IL-21R

antagonist does not necessarily indicate a total elimination of the IL-21R/MU-1 polypeptide biological activity.

As used herein, a "therapeutically effective amount" of an IL-21/IL-21R agonist or antagonist refers to an amount of an agent which is effective, upon single or multiple dose administration to a subject, e.g., a human patient, at curing, reducing the severity of, ameliorating one or more symptoms of a disorder, or in prolonging the survival of the subject beyond that expected in the absence of such treatment.

As used herein, "a prophylactically effective amount" of an IL-21/IL-21R agonist or antagonist refers to an amount of an IL-21/IL-21R agonist or antagonist which is effective, upon single- or multiple-dose administration to a subject, e.g., a human patient, in preventing or delaying the occurrence of the onset or recurrence of a disorder, e.g., a disorder as described herein.

The term "induce", "inhibit", "potentiate", "elevate", "increase", "decrease" or the like, e.g., which denote quantitative differences between two states, refer to at least statistically significant differences between the two states.

The term "in combination" in this context means that the agents are given substantially contemporaneously, either simultaneously or sequentially. If given sequentially, at the onset of administration of the second compound, the first of the two compounds is preferably still detectable at effective concentrations at the site of treatment.

As used herein, a "fusion protein" refers to a protein containing two or more operably associated, e.g., linked, moieties, e.g., protein moieties. Preferably, the moieties are covalently associated. The moieties can be directly associate, or connected via a spacer or linker.

As used herein, the term "antibody" refers to a protein comprising at least one, and preferably two, heavy (H) chain variable regions (abbreviated herein as VH), and at least one and preferably two light (L) chain variable regions (abbreviated herein as VL). The VH and VL regions can be further subdivided into regions of hypervariability, termed "complementarity determining regions" ("CDR"), interspersed with regions that are more conserved, termed "framework regions" (FR). The extent of the framework region and CDR's has been precisely defined (see, Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human

Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, which are incorporated herein by reference). Each VH and VL is composed of three CDR's and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

5   The antibody can further include a heavy and light chain constant region, to thereby form a heavy and light immunoglobulin chain, respectively. In one embodiment, the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are inter-connected by, e.g., disulfide bonds. The heavy chain constant region is comprised of 10   three domains, CH1, CH2 and CH3. The light chain constant region is comprised of one domain, CL. The variable region of the heavy and light chains contains a binding domain that interacts with an antigen. The constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical 15   complement system.

As used herein, the term "immunoglobulin" refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. The recognized human immunoglobulin genes include the kappa, lambda, alpha (IgA1 and IgA2), gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as 20   the myriad immunoglobulin variable region genes. Full-length immunoglobulin "light chains" (about 25 Kd or 214 amino acids) are encoded by a variable region gene at the NH2-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COOH--terminus. Full-length immunoglobulin "heavy chains" (about 50 Kd or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) 25   and one of the other aforementioned constant region genes, e.g., gamma (encoding about 330 amino acids).

As used herein, "isotype" refers to the antibody class (e.g., IgM or IgG1) that is encoded by heavy chain constant region genes.

The term "antigen-binding fragment" of an antibody (or simply "antibody 30   portion," or "fragment"), as used herein, refers to one or more fragments of a full-length antibody that retain the ability to specifically bind to an antigen (e.g., CD3). Examples of binding fragments encompassed within the term "antigen-binding fragment" of an

antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')$_2$ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of

5   a single arm of an antibody, (v) a dAb fragment (Ward *et al.*, (1989) *Nature* 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL

10   and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see *e.g.*, Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding fragment" of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the

15   art, and the fragments are screened for utility in the same manner as are intact antibodies.

        Sequences similar or homologous (e.g., at least about 85% sequence identity) to the sequences disclosed herein are also part of this application. In some embodiment, the sequence identity can be about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher. Alternatively, substantial identity exists when the nucleic acid segments will

20   hybridize under selective hybridization conditions (e.g., highly stringent hybridization conditions), to the complement of the strand. The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.

        Calculations of "homology" or "sequence identity" between two sequences (the terms are used interchangeably herein) are performed as follows. The sequences are

25   aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at

30   least 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first

sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the

5   number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred

10   embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) *J. Mol. Biol.* 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet

15   another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used if the practitioner is uncertain about what

20   parameters should be applied to determine if a molecule is within a sequence identity or homology limitation of the invention) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been

25   incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

As used herein, the term "hybridizes under stringent conditions" describes conditions for hybridization and washing. Stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John

30   Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Aqueous and nonaqueous methods are described in that reference and either can be used. A preferred, example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at

about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50°C. Another

example of stringent hybridization conditions are hybridization in 6X SSC at about 45°C,

followed by one or more washes in 0.2X SSC, 0.1% SDS at 55°C. A further example of

stringent hybridization conditions are hybridization in 6X SSC at about 45°C, followed

5   by one or more washes in 0.2X SSC, 0.1% SDS at 60°C. Preferably, stringent

hybridization conditions are hybridization in 6X SSC at about 45°C, followed by one or

more washes in 0.2X SSC, 0.1% SDS at 65°C. Particularly preferred highly stringent

conditions (and the conditions that should be used if the practitioner is uncertain about

what conditions should be applied to determine if a molecule is within a hybridization

10   limitation of the invention) are 0.5M sodium phosphate, 7% SDS at 65°C, followed by

one or more washes at 0.2X SSC, 1% SDS at 65°C.

It is understood that the IL-21/IL-21R agonists and antagonists of the present

invention may have additional conservative or non-essential amino acid substitutions,

which do not have a substantial effect on their functions.

15   A "conservative amino acid substitution" is one in which the amino acid residue

is replaced with an amino acid residue having a similar side chain. Families of amino

acid residues having similar side chains have been defined in the art. These families

include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side

chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine,

20   asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g.,

alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-

branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g.,

tyrosine, phenylalanine, tryptophan, histidine).

The term "recombinant host cell" (or simply "host cell"), as used herein, is

25   intended to refer to a cell into which a recombinant expression vector has been

introduced. It should be understood that such terms are intended to refer not only to the

particular subject cell, but to the progeny of such a cell. Because certain modifications

may occur in succeeding generations due to either mutation or environmental influences,

such progeny may not, in fact, be identical to the parent cell, but are still included within

30   the scope of the term "host cell" as used herein.

IL-21/IL-21R Agonists and Antagonists

In one embodiment, an IL-21R/MU-1 polypeptide or active fragments thereof may be fused to a second moiety, e.g., an immunoglobulin or a fragment thereof (e.g., an Fc binding fragment thereof). For example, soluble forms of the IL-21R/MU-1 may be fused through "linker" sequences to the Fc portion of an immunoglobulin. Other fusions proteins, such as those with GST, Lex-A or MBP, may also be used.

The fusion proteins may additionally include a linker sequence joining the IL-21 or IL-21R fragment to the second moiety. For example, the fusion protein can include a peptide linker, e.g., a peptide linker of about 4 to 20, more preferably, 5 to 10, amino acids in length; the peptide linker is 8 amino acids in length. Each of the amino acids in the peptide linker is selected from the group consisting of Gly, Ser, Asn, Thr and Ala; the peptide linker includes a Gly-Ser element. In other embodiments, the fusion protein includes a peptide linker and the peptide linker includes a sequence having the formula (Ser-Gly-Gly-Gly- Gly)y wherein y is 1, 2, 3, 4, 5, 6, 7, or 8.

In other embodiments, additional amino acid sequences can be added to the N- or C-terminus of the fusion protein to facilitate expression, detection and/or isolation or purification. For example, IL-21/IL-21R fusion protein may be linked to one or more additional moieties, e.g., GST, His6 tag, FLAG tag. For example, the fusion protein may additionally be linked to a GST fusion protein in which the fusion protein sequences are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of the MU-1 fusion protein.

In another embodiment, the fusion protein is includes a heterologous signal sequence (i.e., a polypeptide sequence that is not present in a polypeptide encoded by a Mu-1 nucleic acid) at its N-terminus. For example, the native Mu-1 signal sequence can be removed and replaced with a signal sequence from another protein. In certain host cells (e.g., mammalian host cells), expression and/or secretion of Mu-1 can be increased through use of a heterologous signal sequence.

A chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive

ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and

enzymatic ligation. In another embodiment, the fusion gene can be synthesized by

conventional techniques including automated DNA synthesizers. Alternatively, PCR

amplification of gene fragments can be carried out using anchor primers that give rise to

5   complementary overhangs between two consecutive gene fragments that can

subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for

example, Ausubel *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John

Wiley & Sons, 1992). Moreover, many expression vectors are commercially available

that encode a fusion moiety (*e.g.*, an Fc region of an immunoglobulin heavy chain). A

10   Mu-1 encoding nucleic acid can be cloned into such an expression vector such that the

fusion moiety is linked in-frame to the immunoglobulin protein.

In some embodiments, MU-1 fusion polypeptides exist as oligomers, such as

dimers or trimers.

The first polypeptide, and/or nucleic acids encoding the first polypeptide, can be

15   constructed using methods known in the art.

In some embodiments, the Mu-1 polypeptide moiety is provided as a variant Mu-

1 polypeptide having a mutation in the naturally-occurring Mu-1 sequence (wild type)

that results in higher affinity (relative to the non-mutated sequence) binding of the Mu-1

polypeptide to a IL-21.

20   In some embodiments, the Mu-1 polypeptide moiety is provided as a variant Mu-

1 polypeptide having mutations in the naturally-occurring Mu-1 sequence (wild type) that

results in a Mu-1 sequence more resistant to proteolysis (relative to the non-mutated

sequence).

In some embodiments, the first polypeptide includes full-length Mu-1

25   polypeptide. Alternatively, the first polypeptide comprise less than full-length Mu-1

polypeptide.

A signal peptide that can be included in the fusion protein is

MPLLLLLLLLPSPLHP (SEQ ID NO:21). If desired, one or more amino acids can

additionally be inserted between the first polypeptide moiety comprising the Mu-1

30   moiety and the second polypeptide moiety.

The second polypeptide is preferably soluble. In some embodiments, the second

polypeptide enhances the half-life, (*e.g.*, the serum half-life) of the linked polypeptide. In

some embodiments, the second polypeptide includes a sequence that facilitates
association of the fusion polypeptide with a second Mu-1 polypeptide. In preferred
embodiments, the second polypeptide includes at least a region of an immunoglobulin
polypeptide. Immunoglobulin fusion polypeptide are known in the art and are described

5   in e.g., US Patent Nos. 5,516,964; 5,225,538; 5,428,130; 5,514,582; 5,714,147; and
5,455,165.

        In some embodiments, the second polypeptide comprises a full-length
immunoglobulin polypeptide. Alternatively, the second polypeptide comprise less than
full-length immunoglobulin polypeptide, e.g., a heavy chain, light chain, Fab, Fab$_2$, Fv,

10   or Fc. Preferably, the second polypeptide includes the heavy chain of an
immunoglobulin polypeptide. More preferably, the second polypeptide includes the Fc
region of an immunoglobulin polypeptide.

        In another aspect of the invention the second polypeptide has less effector
function that the effector function of a Fc region of a wild-type immunoglobulin heavy

15   chain. Fc effector function includes for example, Fc receptor binding, complement
fixation and T cell depleting activity (see for example, US Patent No. 6,136,310).
Methods for assaying T cell depleting activity, Fc effector function, and antibody stability
are known in the art. In one embodiment the second polypeptide has low or no affinity
for the Fc receptor. In an alternative embodiment, the second polypeptide has low or no

20   affinity for complement protein C1q.

        A preferred second polypeptide sequence includes the amino acid sequence of
SEQ ID NO: 17. This sequence includes a Fc region. Underlined amino acids are those
that differ from the amino acid found in the corresponding position of the wild-type
immunoglobulin sequence:

25
```
HTCPPCPAPEALGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
K
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPVPIEKTISKAKGQPREPQVYTL
P
```
30   ```
SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
Q
QGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:17)
```

        Examples of antagonistic fusion proteins that can be used in the methods of the

35    invention are shown in Figures 7-15. In one embodiment, the fusion protein includes an
amino acid sequence chosen from, e.g., SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27,

SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, or

SEQ ID NO:39, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto.

In other embodiments, the fusion protein includes an amino acid sequence encoded by a

nucleotide sequence chosen from, e.g., SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26,

5      SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, or

SEQ ID NO:38, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto.

Preferred fusion proteins have the amino acid sequence shown as SEQ ID NO:25 or SEQ

ID NO:29 (Figures 8A-8C and 10A-10C, respectively), or a sequence at least 85%, 90%,

95%, 98% or more identical thereto. In other embodiments, the fusion protein includes

10     an amino acid sequence encoded by a nucleotide sequence chosen from, e.g., SEQ ID

NO:24 or SEQ ID NO:28 (Figures 8A-8C and 10A-10C, respectively), or a sequence at

least 85%, 90%, 95%, 98% or more identical thereto. Most preferably, the fusion protein

has the amino acid sequence shown as SEQ ID NO:29, or has an amino acid sequence

encoded by a nucleotide sequence shown as SEQ ID NO:28 (Figure 10A-10C).

15             In other embodiments, the IL-21/IL-21R agonists or antagonists are antibodies, or

antigen-binding fragments thereof, that bind to IL-21 or IL-21R, preferably, mammalian

(e.g., human or murine) IL-21 or IL-21R.

               MU-1 proteins of the invention may also be used to immunize animals to obtain

polyclonal and monoclonal antibodies which specifically react with the MU-1 protein

20     and which may inhibit binding of ligands to the receptor. Such antibodies may be

obtained using the entire MU-1 as an immunogen, or by using fragments of MU-1.

Smaller fragments of the MU-1 may also be used to immunize animals. The peptide

immunogens additionally may contain a cysteine residue at the carboxyl terminus, and

are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Additional peptide

25     immunogens may be generated by replacing tyrosine residues with sulfated tyrosine

residues. Methods for synthesizing such peptides are known in the art, for example, as in

R. P. Merrifield, J.Amer.Chem.Soc. 85, 2149-2154 (1963); J. L. Krstenansky, et al.,

FEBS Lett. 211, 10 (1987).

               Neutralizing or non-neutralizing antibodies (preferably monoclonal antibodies)

30     binding to MU-1 protein may also be useful in the treatment of conditions described

above. These neutralizing monoclonal antibodies may be capable of blocking ligand

binding to the MU-1 receptor chain.

The present invention further provides for compositions comprising an antibody that specifically reacts with an IL-21 or an IL-21R.

~~Human monoclonal antibodies (mAbs) directed against IL-21 or IL-21R can be~~ generated using transgenic mice carrying the human immunoglobulin genes rather than

5 the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al. International Application WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. International Application WO 92/03918; Kay et al. International Application

10 92/03917; Lonberg, N. et al. 1994 *Nature* 368:856-859; Green, L.L. et al. 1994 *Nature Genet.* 7:13-21; Morrison, S.L. et al. 1994 *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. 1993 *Year Immunol* 7:33-40; Tuaillon et al. 1993 *PNAS* 90:3720-3724; Bruggeman et al. 1991 *Eur J Immunol* 21:1323-1326).

Monoclonal antibodies can also be generated by other methods known to those skilled in

15 the art of recombinant DNA technology. An alternative method, referred to as the "combinatorial antibody display" method, has been developed to identify and isolate antibody fragments having a particular antigen specificity, and can be utilized to produce monoclonal antibodies (for descriptions of combinatorial antibody display see e.g., Sastry et al. 1989 *PNAS* 86:5728; Huse et al. 1989 *Science* 246:1275; and Orlandi et al. 1989

20 *PNAS* 86:3833). After immunizing an animal with an immunogen as described above, the antibody repertoire of the resulting B-cell pool is cloned. Methods are generally known for obtaining the DNA sequence of the variable regions of a diverse population of immunoglobulin molecules by using a mixture of oligomer primers and PCR. For instance, mixed oligonucleotide primers corresponding to the 5' leader (signal peptide)

25 sequences and/or framework 1 (FR1) sequences, as well as primer to a conserved 3' constant region primer can be used for PCR amplification of the heavy and light chain variable regions from a number of murine antibodies (Larrick et al.,1991, *Biotechniques* 11:152-156). A similar strategy can also been used to amplify human heavy and light chain variable regions from human antibodies (Larrick et al., 1991, *Methods: Companion*

30 *to Methods in Enzymology* 2:106-110).

Chimeric antibodies, including chimeric immunoglobulin chains, can be produced by recombinant DNA techniques known in the art. For example, a gene

encoding the Fc constant region of a murine (or other species) monoclonal antibody molecule is digested with restriction enzymes to remove the region encoding the murine Fc, and the equivalent portion of a gene encoding a human Fc constant region is substituted (see Robinson et al., International Patent Publication PCT/US86/02269;

5   Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., International Application WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988 *Science* 240:1041-1043); Liu et al. (1987) *PNAS* 84:3439-3443; Liu et al., 1987, *J. Immunol.*

10  139:3521-3526; Sun et al. (1987) *PNAS* 84:214-218; Nishimura et al., 1987, *Canc. Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al., 1988, *J. Natl Cancer Inst.* 80:1553-1559).

An antibody or an immunoglobulin chain can be humanized by methods known in the art. Humanized antibodies, including humanized immunoglobulin chains, can be

15  generated by replacing sequences of the Fv variable region which are not directly involved in antigen binding with equivalent sequences from human Fv variable regions. General methods for generating humanized antibodies are provided by Morrison, S. L., 1985, *Science* 229:1202-1207, by Oi et al., 1986, *BioTechniques* 4:214, and by Queen et al. US 5,585,089, US 5,693,761 and US 5,693,762, the contents of all of which are

20  hereby incorporated by reference. Those methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of immunoglobulin Fv variable regions from at least one of a heavy or light chain. Sources of such nucleic acid are well known to those skilled in the art and, for example, may be obtained from a hybridoma producing an antibody against a predetermined target. The recombinant DNA

25  encoding the humanized antibody, or fragment thereof, can then be cloned into an appropriate expression vector.

Humanized or CDR-grafted antibody molecules or immunoglobulins can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDR's of an immunoglobulin chain can be replaced. See e.g., U.S. Patent 5,225,539; Jones et al.

30  1986 *Nature* 321:552-525; Verhoeyan et al. 1988 *Science* 239:1534; Beidler et al. 1988 *J. Immunol.* 141:4053-4060; Winter US 5,225,539, the contents of all of which are hereby expressly incorporated by reference. Winter describes a CDR-grafting method

which may be used to prepare the humanized antibodies of the present invention (UK Patent Application GB 2188638A, filed on March 26, 1987; Winter US 5,225,539), the contents of which is expressly incorporated by reference. All of the CDR's of a particular human antibody may be replaced with at least a portion of a non-human CDR or only some of the CDR's may be replaced with non-human CDR's. It is only necessary to replace the number of CDR's required for binding of the humanized antibody to a predetermined antigen.

Monoclonal, chimeric and humanized antibodies, which have been modified by, e.g., deleting, adding, or substituting other portions of the antibody, e.g., the constant region, are also within the scope of the invention. For example, an antibody can be modified as follows: (i) by deleting the constant region; (ii) by replacing the constant region with another constant region, e.g., a constant region meant to increase half-life, stability or affinity of the antibody, or a constant region from another species or antibody class; or (iii) by modifying one or more amino acids in the constant region to alter, for example, the number of glycosylation sites, effector cell function, Fc receptor (FcR) binding, complement fixation, among others.

Methods for altering an antibody constant region are known in the art. Antibodies with altered function, e.g. altered affinity for an effector ligand, such as FcR on a cell, or the C1 component of complement can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see e.g., EP 388,151 A1, US 5,624,821 and US 5,648,260, the contents of all of which are hereby incorporated by reference). Similar type of alterations could be described which if applied to the murine, or other species immunoglobulin would reduce or eliminate these functions.

For example, it is possible to alter the affinity of an Fc region of an antibody (e.g., an IgG, such as a human IgG) for an FcR (e.g., Fc gamma R1), or for C1q binding by replacing the specified residue(s) with a residue(s) having an appropriate functionality on its side chain, or by introducing a charged functional group, such as glutamate or aspartate, or perhaps an aromatic non-polar residue such as phenylalanine, tyrosine, tryptophan or alanine (see e.g., US 5,624,821).

Amino acid sequences of IL-21 polypeptides are publicly known. For example, the nucleotide sequence and amino acid sequence of a human IL-21 is available at

Genbank Acc. No. X_011082. The disclosed human IL-21 nucleotide sequence is

presented below:

```
        1 gctgaagtga aaacgagacc aaggtctagc tctactgttg gtacttatga
gatccagtcc
       61 tggcaacatg gagaggattg tcatctgtct gatggtcatc ttcttgggga
cactggtcca
      121 caaatcaagc tcccaaggtc aagatcgcca catgattaga atgcgtcaac
ttatagatat
      181 tgttgatcag ctgaaaaatt atgtgaatga cttggtccct gaatttctgc
cagctccaga
      241 agatgtagag acaaactgtg agtggtcagc tttttcctgc tttcagaagg
cccaactaaa
      301 gtcagcaaat acaggaaaca atgaaaggat aatcaatgta tcaattaaaa
agctgaagag
      361 gaaaccacct tccacaaatg cagggagaag acagaaacac agactaacat
gcccttcatg
      421 tgattcttat gagaaaaaac cacccaaaga attcctagaa agattcaaat
cacttctcca
      481 aaagatgatt catcagcatc tgtcctctag aacacacgga agtgaagatt
cctgaggatc
      541 taacttgcag ttggacacta tgttacatac tctaatatag tagtgaaagt
catttctttg
      601 tattccaagt ggaggag (SEQ ID NO:18)
```

The amino acid sequence of the disclosed human IL-21 polypeptide is presented

below:

MRSSPGNMERIVICLMVIFLGTLVHKSSSQGQDRHMIRMRQLIDIVDQLKNYVNDLVPE
FLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKH
RLTCPSCDSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDS (SEQ ID NO:19)

The invention also encompasses nucleic acids that hybridize to the nucleotide

sequence set forth in SEQ ID NO:1, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26,

SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, or

SEQ ID NO:38, under highly stringent conditions (for example, 0.1X SSC at 65° C.).

Isolated polynucleotides which encode MU-1 proteins or fusion proteins, but which

differ from the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:22, SEQ ID

NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID

NO:34, SEQ ID NO:36, or SEQ ID NO:38, by virtue of the degeneracy of the genetic

code are also encompassed by the present invention. Variations in the nucleotide

sequence as set forth in SEQ ID NO:1, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26,

SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, or

SEQ ID NO:38, which are caused by point mutations or by induced modifications are

also included in the invention.

The isolated polynucleotides of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the MU-1 protein recombinantly. Many suitable expression control sequences are known in the art.

5   General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means enzymatically or chemically ligated to form a covalent bond between the isolated polynucleotide of the invention and the expression control sequence, in such a way that the MU-1 protein is expressed by a host cell which has been

10   transformed (transfected) with the ligated polynucleotide/expression control sequence.

The term "vector", as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector,

15   wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated

20   along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used

25   interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The term "regulatory sequence" is intended to includes promoters, enhancers and

30   other expression control elements (*e.g.*, polyadenylation signals) that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in*

Enzymology 185, Academic Press, San Diego, CA (1990). It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. Preferred regulatory

5 sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from FF-1a promoter and BGH poly A, cytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (*e.g.*, the adenovirus major late promoter (AdMLP)) and

10 polyoma. For further description of viral regulatory elements, and sequences thereof, see *e.g.*, U.S. Patent No. 5,168,062 by Stinski, U.S. Patent No. 4,510,245 by Bell *et al.* and U.S. Patent No. 4,968,615 by Schaffner *et al.*

The recombinant expression vectors of the invention may carry additional sequences, such as sequences that regulate replication of the vector in host cells (*e.g.*,

15 origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see e.g., U.S. Patents Nos. 4,399,216, 4,634,665 and 5,179,017, all by Axel *et al.*). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced.

20 Preferred selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr⁻ host cells with methotrexate selection/amplification) and the *neo* gene (for G418 selection).

A number of types of cells may act as suitable host cells for expression of the MU-1 protein or fusion protein thereof. Any cell type capable of expressing functional

25 MU-1 protein may be used. Suitable mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK,

30 Rat2, BaF3, 32D, FDCP-1, PC12, Mlx or C2C12 cells.

The MU-1 protein or fusion protein thereof may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one

or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif. U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas

5   Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. Soluble forms of the MU-1 protein may also be produced in insect cells using appropriate isolated polynucleotides as described above.

       Alternatively, the MU-1 protein or fusion protein thereof may be produced in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Suitable yeast strains

10   include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins.

       Expression in bacteria may result in formation of inclusion bodies incorporating

15   the recombinant protein. Thus, refolding of the recombinant protein may be required in order to produce active or more active material. Several methods for obtaining correctly folded heterologous proteins from bacterial inclusion bodies are known in the art. These methods generally involve solubilizing the protein from the inclusion bodies, then denaturing the protein completely using a chaotropic agent. When cysteine residues are

20   present in the primary amino acid sequence of the protein, it is often necessary to accomplish the refolding in an environment which allows correct formation of disulfide bonds (a redox system). General methods of refolding are disclosed in Kohno, Meth. Enzym., 185:187-195 (1990). EP 0433225 and copending application U.S. Ser. No. 08/163,877 describe other appropriate methods.

25   The MU-1 protein or fusion protein thereof may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a polynucleotide sequence encoding the MU-1 protein or fusion protein thereof.

       The MU-1 protein or fusion protein thereof may be prepared by growing a culture

30   transformed host cells under culture conditions necessary to express the desired protein. The resulting expressed protein may then be purified from the culture medium or cell extracts. Soluble forms of the MU-1 protein or fusion protein thereof can be purified

from conditioned media. Membrane-bound forms of MU-1 protein of the invention can be purified by preparing a total membrane fraction from the expressing cell and extracting the membranes with a non-ionic detergent such as Triton X-100.

5   The MU-1 protein or fusion protein can be purified using methods known to those skilled in the art. For example, the MU-1 protein of the invention can be concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a purification matrix such as a gel filtration medium. Alternatively, an anion exchange resin can be employed, for example, a matrix or

10   substrate having pendant diethylaminoethyl (DEAE) or polyetheyleneimine (PEI) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred (e.g., S-Sepharose ® columns).

15   The purification of the MU-1 protein or fusion protein from culture supernatant may also include one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; or by hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or by immunoaffinity chromatography. Finally, one or more reverse-phase high performance

20   liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the MU-1 protein. Affinity columns including antibodies to the MU-1 protein can also be used in purification in accordance with known methods. Some or all of the foregoing purification steps, in various combinations or with other known methods, can

25   also be employed to provide a substantially purified isolated recombinant protein. Preferably, the isolated MU-1 protein is purified so that it is substantially free of other mammalian proteins.

MU-1 proteins or fusion proteins of the invention may also be used to screen for agents which are capable of binding to MU-1. Binding assays using a desired binding

30   protein, immobilized or not, are well known in the art and may be used for this purpose using the MU-1 protein of the invention. Purified cell based or protein based (cell free) screening assays may be used to identify such agents. For example, MU-1 protein may

be immobilized in purified form on a carrier and binding or potential ligands to purified MU-1 protein may be measured.

Pharmaceutical Compositions

IL-21/IL-21R-agonists or antagonists may be used as a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may contain, in addition to the IL-21/IL-21R-agonists or antagonists and carrier, various diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration.

The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-14, IL-15, G-CSF, stem cell factor, and erythropoietin. The pharmaceutical composition may also include anti-cytokine antibodies as described in more detail below. The pharmaceutical composition may contain thrombolytic or anti-thrombotic factors such as plasminogen activator and Factor VIII. The pharmaceutical composition may further contain other anti-inflammatory agents as described in more detail below. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with an IL-21/IL-21R-agonists or antagonists, or to minimize side effects caused by the IL-21/IL-21R-agonists or antagonists. Conversely IL-21/IL-21R-agonists or antagonists may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

The pharmaceutical composition of the invention may be in the form of a liposome in which IL-21/IL-21R-agonists or antagonists is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers which in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin,

bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Pat. No. 4,235,871; U.S. Pat. No. 4,501,728; U.S. Pat. No. 4,837,028; and U.S. Pat. No. 4,737,323, all of which are incorporated herein by reference.

5   As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, e.g., amelioration of symptoms of, healing of, or increase in rate of healing of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone.

10   When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

          In practicing the method of treatment or use of the present invention, a therapeutically effective amount of an IL-21/IL-21R-agonist or antagonist is administered

15   to a subject, e.g., mammal (e.g., a human). An IL-21/IL-21R-agonists or antagonists may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors, or anti-inflammatory agents. When co-administered with one or more agents, an IL-21- and/or IL-21R-binding agent may be administered either

20   simultaneously with the second agent, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering an IL-21/IL-21R-agonist or antagonist in combination with other agents.

          Administration of an IL-21/IL-21R-agonist or antagonist used in the pharmaceutical composition or to practice the method of the present invention can be

25   carried out in a variety of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection. Intravenous administration to the patient is preferred.

          When a therapeutically effective amount of an IL-21/IL-21R-agonist or antagonist is administered orally, the binding agent will be in the form of a tablet, capsule, powder,

30   solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% binding agent, and

preferably from about 25 to 90% binding agent. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution,

5   dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of the binding agent, and preferably from about 1 to 50% the binding agent.

       When a therapeutically effective amount of an IL-21/IL-21R-agonist or antagonist

10   is administered by intravenous, cutaneous or subcutaneous injection, binding agent will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should

15   contain, in addition to binding agent an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additive known to those of skill in the art.

20   The amount of an IL-21/IL-21R-agonist or antagonist in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments that the patient has undergone. Ultimately, the attending physician will decide the amount of binding agent with which to treat each individual patient. Initially, the attending physician will

25   administer low doses of binding agent and observe the patient's response. Larger doses of binding agent may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not generally increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 µg to about 100 mg IL-21/IL-21R-

30   agonist or antagonist per kg body weight.

       The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the

condition and potential idiosyncratic response of each individual patient. It is
contemplated that the duration of each application of the IL-21/IL-21R-agonist or
antagonist will be in the range of 12 to 24 hours of continuous intravenous
administration. Ultimately the attending physician will decide on the appropriate

5   duration of intravenous therapy using the pharmaceutical composition of the present
invention.

        The polynucleotide and proteins of the present invention are expected to exhibit
one or more of the uses or biological activities (including those associated with assays
cited herein) identified below. Uses or activities described for proteins of the present

10   invention may be provided by administration or use of such proteins or by administration
or use of polynucleotides encoding such proteins (such as, for example, in gene therapies
or vectors suitable for introduction of DNA).

Uses of IL-21/IL-21R-Agonists to Enhance an Immune Response

        In one aspect, the present invention provides methods for increasing immune cell,

15   e.g., T-cell (e.g., CD8+ T cell) proliferation by contacting an immune cell or a population
of immune cells with an IL-21 or IL-21R binding agent which potentiates or enhances the
activity of an IL-21 polypeptide. These methods are based, at least in part, on the finding
that an agonist IL-21R binding agent stimulated, primarily via stimulation of CD8+T
cells, innate and adaptive immunity *in vivo* against immunogenic and non-immunogenic

20   tumor cells (Example 9). The methods are also based, in part, on the finding that IL-21
induces proliferation of antigen- or anti-CD3 antibody stimulated thymocytes, lymph
node T cells, CD4+ T cells, or CD8+ T cells. Applicants also show that proliferation of
T cells to alloantigens can be increased in the presence of IL-21. In addition, IL-21 may
also enhance proliferation and/or differentiation of CD8+ T cells (Example 10). For

25   example, priming of CD8+ T cells in the presence of IL-21 can generate effector cells
with enhanced lytic (CTL) activity and/or increased ability to secrete cytokines, e.g.,
IFNγ. IL-21- or an IL-21R binding agent that stimulates IL-21/IL-21R activity can be
used to induce the proliferation and/or cytokine secretion of macrophages. Il-21 also has
effects on memory T cells and antigen presenting cells (APCs). IL-21 has also been

30   found to be produced by activated CD4⁺ cells. Accordingly, binding agents that stimulate
the IL-21/IL-21R pathway can be used by themselves or in combination with an antigen,

e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response *in vivo*, e.g., for example, for use in treating cancer and infectious disorders.

In one embodiment, agonistic IL-21/IL-21R agonists may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to

5   overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of an IL-21/IL-21R agonist, alone or in combination with, a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or

10   B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of an IL-21/IL-21R agonist, in combination with a peptide having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the

15   necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class .alpha. a chain protein

20   and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with an IL-21/IL-21R agonist, and/or a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected

25   tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding an IL-21/IL-21R agonist and/or a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune

30   response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

In other embodiments, the IL-21/IL-21R agonists can be used as vaccine adjuvants. Adjuvants are immune modulating compounds that have the ability to enhance and/or steer the development and profile of immune responses against various antigens that are themselves poorly immunogenic. Cytokines and/or lymphokines can be

5 used as adjuvants. The appropriate selection of adjuvants can induce good humoral and cellular immune responses that would not develop in the absence of adjuvant. In particular, adjuvants have significant effects in enhancing the immune response to subunit and peptide antigens in vaccines. Their stimulatory activity is also beneficial to the development of antigen-specific immune responses directed against protein antigens.

10 For a variety of antigens that require strong mucosal responses, high serum titers, induction of CTL and vigorous cellular responses, adjuvant and cytokine/lymphokine combinations provide stimuli that are not provided by most antigen preparations.

As used herein, the phrase "vaccine adjuvant" or "vaccine therapy" is intended to mean the use of an IL-21/IL-21R agonist, e.g., an IL-21 polypeptide or polynucleotide

15 encoding the same, in combination with an antigen (e.g., viral, parasitic and bacterial polypeptides, proteins or peptides), or other antigens (e.g., tumor or cancer cell polypeptides, proteins or peptides) or polynucleotides encoding the antigen to enhance, suppress or otherwise modulate an immune response to the antigen. For the purpose of this definition, "combination" shall mean use in conjunction with, simultaneous with

20 (combined or uncombined) or sequentially with an antigen.

The term "vaccine adjuvant composition" refers to a vaccine adjuvant that additionally includes immunologically acceptable diluents or carriers in a conventional manner to prepare injectable liquid solutions or suspensions. The vaccine adjuvant composition may additionally include agents that further enhance an immune response

25 elicited by IL-21. For example, the vaccine adjuvant composition may additionally include 3-O-deacylated monophosphoryl lipid A (MPL™) or monophosphoryl lipid A and derivatives and analogs thereof. MPL™ can be used in a range of 1-100μg/dose.

The antigens used for vaccine therapy include proteins, peptides or polypeptides derived from immunogenic and non-immunogenic proteins, as well as any of the

30 following: saccharides, proteins, poly- or oligonucleotides, or other macromolecular components, or fragments thereof. As used in this section, a "peptide" comprises a series of at least six amino acids and contains at least one antigenic determinant, while a

"polypeptide" is a longer molecule than a peptide, but does not constitute a full-length protein. As used herein, a "fragment" comprises a portion, but less than all of a saccharide, protein, poly- or oligonucleotide, or other macromolecular components.

As used herein, the term "effective adjuvanting amount" means a dose of the

5   combination of adjuvants described herein, which is suitable to elicit an increased immune response in a vertebrate host. The particular dosage will depend in part upon the age, weight and medical condition of the host, as well as on the method of administration and the antigen.

The vaccine adjuvant composition of the invention can be administered to a

10   human or non-human vertebrate by a variety of routes, including, but not limited to, intranasal, oral, vaginal, rectal, parenteral, intradermal, transdermal (see, e.g., International application WO 98/20734 (44), which is hereby incorporated by reference), intramuscular, intraperitoneal, subcutaneous, intravenous and intraarterial. The amount of the antigen component or components of the antigenic composition will vary

15   depending in part upon the identity of the antigen, as well as upon the age, weight and medical condition of the host, as well as on the method of administration. Again, suitable doses are readily determined by persons skilled in the art. It is preferable, although not required, that the antigen and the combination of adjuvants be administered at the same time. The number of doses and the dosage regimen for the antigenic

20   composition are also readily determined by persons skilled in the art. In some instances, the adjuvant properties of the combination of adjuvants may reduce the number of doses needed or the time course of the dosage regimen.

The combinations of adjuvants of this invention are suitable for use in combination with wide variety of antigens from a wide variety of pathogenic

25   microorganisms, including but not limited to those from viruses, bacteria, fungi or parasitic microorganisms that infect humans and non-human vertebrates, or from a cancer cell or tumor cell (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma). The antigen may comprise peptides or polypeptides derived from proteins, as well as fragments of any of the following: saccharides, proteins, poly- or

30   oligonucleotides, cancer or tumor cells, allergens, amyloid peptide protein, or other macromolecular components. In some instances, more than one antigen is included in the antigenic composition.

Desirable viral vaccines containing the adjuvant combinations of this invention include those directed to the prevention and/or treatment of disease caused by, without limitation, Human immunodeficiency virus, Simian immunodeficiency virus, Respiratory syncytial virus, Parainfluenza virus types 1-3, Influenza virus, Herpes simplex virus,

5   Human cytomegalovirus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Human papillomavirus, poliovirus, rotavirus, caliciviruses, Measles virus, Mumps virus, Rubella virus, adenovirus, rabies virus, canine distemper virus, rinderpest virus, coronavirus, parvovirus, infectious rhinotracheitis viruses, feline leukemia virus, feline infectious peritonitis virus, avian infectious bursal disease virus, Newcastle disease virus, Marek's

10   disease virus, porcine respiratory and reproductive syndrome virus, equine arteritis virus and various Encephalitis viruses. In one embodiment, the IL-21/IL-21R agonists is administered in combination with a TNF antagonist, e.g., a TNF antagonist as described herein, to treat a Hepatitis C virus infection.

Desirable bacterial vaccines containing the adjuvant combinations of this

15   invention include those directed to the prevention and/or treatment of disease caused by, without limitation, *Haemophilus influenzae* (both typable and nontypable), *Haemophilus somnus, Moraxella catarrhalis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus faecalis, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae, Chlamydia trachomatis, Chlamydia pneumoniae,*

20   *Chlamydia* psittaci, *Bordetella pertussis, Salmonella typhi, Salmonella typhimurium, Salmonella choleraesuis, Escherichia coli, Shigella, Vibrio cholerae, Corynebacterium diphtheriae, Mycobacterium tuberculosis, Mycobacterium avium- Mycobacterium intracellulare* complex, *Proteus mirabilis, Proteus vulgaris, Staphylococcus aureus, Clostridium tetani, Leptospira interrogans, Borrelia burgdorferi, Pasteurella*

25   *haemolytica, Pasteurella multocida, Actinobacillus pleuropneumoniae* and *Mycoplasma gallisepticum.*

Desirable vaccines against fungal pathogens containing the adjuvant combinations of this invention include those directed to the prevention and/or treatment of disease caused by, without limitation, *Aspergillis, Blastomyces, Candida, Coccidiodes,*

30   *Cryptococcus* and *Histoplasma.*

Desirable vaccines against parasites containing the adjuvant combinations of this invention include those directed to the prevention and/or treatment of disease caused by,

without limitation, *Leishmania major*, *Ascaris*, *Trichuris*, *Giardia*, *Schistosoma*, *Cryptosporidium*, *Trichomonas*, *Toxoplasma gondii* and *Pneumocystis carinii*.

Desirable vaccines for eliciting a therapeutic or prophylactic anti-cancer effect in a vertebrate host, which contain the adjuvant combinations of this invention, include

5   those utilizing a cancer antigen or tumor-associated antigen including, without limitation, prostate specific antigen (PSA), prostate-specific membrane antigen (PSMA), carcino-embryonic antigen (CEA), MUC-1, Her2, CA-125, MAGE-3, EGFR, HELP, GCC, CD66-c, prostasin, TMPRSS3, TADG 12 and TADG 15.

Desirable vaccines for moderating responses to allergens in a vertebrate host,

10   which contain the adjuvant combinations of this invention, include those containing an allergen or fragment thereof. Examples of such allergens are described in United States Patent Number 5,830,877 (45) and published International Patent Application Number WO 99/51259 (46), which are hereby incorporated by reference, and include pollen, insect venoms, animal dander, fungal spores and drugs (such as penicillin). The vaccines

15   interfere with the production of IgE antibodies, a known cause of allergic reactions.

Desirable vaccines for preventing or treating disease characterized by amyloid deposition in a vertebrate host, which contain the adjuvant combinations of this invention, include those containing portions of amyloid peptide protein (APP). This disease is referred to variously as Alzheimer's disease, amyloidosis or amyloidogenic

20   disease. Thus, the vaccines of this invention include the adjuvant combinations of this invention plus Aβ peptide, as well as fragments of Aβ peptide and antibodies to Aβ peptide or fragments thereof.

In the case of HIV and SIV, the antigenic compositions comprise at least one protein, polypeptide, peptide or fragment derived from said protein. In some instances,

25   multiple HIV or SIV proteins, polypeptides, peptides and/or fragments are included in the antigenic composition.

The adjuvant combination formulations of this invention are also suitable for inclusion as an adjuvant in polynucleotide vaccines (also known as DNA vaccines). Such vaccines may further include facilitating agents such as bupivicaine (see U.S.

30   Patent Number 5,593,972 (49), which is hereby incorporated by reference).

Uses of IL-21/IL-21R Antagonists to Decrease Immune Cell Activity

In yet another aspect, the invention features a method for inhibiting the activity of an immune cell, e.g., mature T cells (mature CD8+T cells, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, or a population thereof, by contacting a population of T cells with an IL-21/IL-21R antagonist in an amount

5   sufficient to inhibit the activity of the immune cell or population. Antagonists of IL-21 and/or IL-21R (e.g., a fusion protein or a neutralizing antibody, as described herein) can also be administered to subjects for which inhibition of an immune response is desired. These conditions include, e.g., autoimmune disorders (e.g., arthritic disorders), or organ transplantation.

10   Applicants have shown that a reduction of IL-21R activity by using a neutralizing fusion protein that includes the extracellular domain of the IL-21R fused to an Fc immunoglobulin region ameliorates inflammatory symptoms in mouse collagen-induced arthritis (CIA) animal models (Example 7). Expression of IL-21R mRNA is upregulated in the paws of CIA mice (Example 8). Accordingly, IL-21R binding agents that

15   antagonize IL-21/IL-21R activity can be used to induce immune suppression *in vivo*, e.g., for treating or preventing immune cell-associated pathologies, including transplant rejection and autoimmune disorders.

The IL-21R DNA also maps to the chromosomal locus for Crohn's disease. As a result, binding agents of the present invention may be used to treat Crohn's disease and

20   other inflammatory bowel diseases.

The subject method can also be used to modulate (e.g., inhibit) the activity, e.g., proliferation, differentiation, survival) of an immune or hematopoietic cell (e.g., a cell of myeloid, lymphoid, erythroid lineages, or precursor cells thereof), and, thus, can be used to treat or prevent a variety of immune disorders. Non-limiting examples of the disorders

25   that can be treated or prevented include, but are not limited to, transplant rejection, autoimmune diseases (including, for example, diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosis, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous

30   dermatitis), psoriasis, Sjögren's Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, spondyoarthropathy, ankylosing spondylitis, intrinsic asthma, allergic asthma, cutaneous lupus erythematosus,

scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis,

5   Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial lung fibrosis), graft-versus-host disease, and allergy such as, atopic allergy. Preferred disorders that can be treated using the binding agents of the invention include arthritic disorders (e.g., rheumatoid arthritis, juvenile rheumatoid

10   arthritis, osteoarthritis, psoriatic arthritis, and ankylosing spondylitis (preferably, rheumatoid arthritis)), multiple sclerosis, type I diabetes, lupus (SLE), IBD, Crohn's disease, asthma, vasculitis, allergy, scleroderma and psoriasis.

In another embodiment, IL-21/IL-21R antagonists, alone or in combination with, other therapeutic agents as described herein (e.g., TNF antagonists) can be used to treat

15   multiple myeloma and related B lymphocytic malignancies (Brenne, A. *et al.* (2002) *Blood* Vol. 99(10):3756-3762).

Using the IL-21/IL-21R antagonists, it is possible to modulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an

20   immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process that requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from

25   immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without

30   limitation B lymphocyte antigen functions, e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell

function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of an IL-21/IL-21R antagonist, in combination with a molecule which

5   inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without

10   transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity

15   of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in

20   humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci U.S.A., 89:11102-11105 (1992). In addition, murine models of GVHD (see

25   Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate

30   activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease

symptoms. Administration of IL-21/IL-21R antagonists in combination with reagents
which block costimulation of T cells by disrupting receptor:ligand interactions of B
lymphocyte antigens can be used to inhibit T cell activation and prevent production of
autoantibodies or T cell-derived cytokines which may be involved in the disease process.

5   Additionally, IL-21/IL-21R antagonists in combination with blocking reagents may
induce antigen-specific tolerance of autoreactive T cells which could lead to long-term
relief from the disease. The efficacy of these agents in preventing or alleviating
autoimmune disorders can be determined using a number of well-characterized animal
models of human autoimmune diseases. Examples include murine experimental

10   autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB
hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and
BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental
Immunology, Raven Press, New York, 1989, pp. 840-856).

        In one embodiment, the IL-21/IL-21R antagonists, e.g., pharmaceutical

15   compositions thereof, are administered in combination therapy, i.e., combined with other
agents, e.g., therapeutic agents, that are useful for treating pathological conditions or
disorders, such as immune and inflammatory disorders. The term "in combination" in
this context means that the agents are given substantially contemporaneously, either
simultaneously or sequentially. If given sequentially, at the onset of administration of the

20   second compound, the first of the two compounds is preferably still detectable at
effective concentrations at the site of treatment.

        For example, the combination therapy can include one or more IL-21/IL-21R
antagonists, e.g., an antibody or an antigen-binding fragment thereof (e.g., a chimeric,
humanized, human, or in vitro generated antibody or antigen-binding fragment thereof)

25   against IL-21 or IL-21 receptor, an IL-21 fusion protein, a soluble IL-21 receptor, peptide
inhibitor or a small molecule inhibitor) co-formulated with, and/or co-administered with,
one or more additional therapeutic agents, e.g., one or more cytokine and growth factor
inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme
inhibitors, and/or cytotoxic or cytostatic agents, as described in more detail below.

30   Furthermore, one or more IL-21/IL-21R antagonists described herein may be used in
combination with two or more of the therapeutic agents described herein. Such
combination therapies may advantageously utilize lower dosages of the administered

therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies. Moreover, the therapeutic agents disclosed herein act on pathways that differ from the IL-21/IL-21R receptor pathway, and thus are expected to enhance and/or synergize with the effects of the IL-21/IL-21R antagonists.

5   Preferred therapeutic agents used in combination with an IL-21/IL-21R antagonist are those agents that interfere at different stages in the autoimmune and subsequent inflammatory response. In one embodiment, one or more IL-21/IL-21R antagonist described herein may be co-formulated with, and/or co-administered with, one or more additional agents such as other cytokine or growth factor antagonists (e.g., soluble

10   receptors, peptide inhibitors, small molecules, ligand fusions); or antibodies or antigen-binding fragments thereof that bind to other targets (e.g., antibodies that bind to other cytokines or growth factors, their receptors, or other cell surface molecules); and anti-inflammatory cytokines or agonists thereof. Non-limiting examples of the agents that can be used in combination with the IL-21/IL-21R antagonists described herein, include,

15   but are not limited to, antagonists of one or more interleukins (ILs) or their receptors, e.g., antagonists of IL-1, IL-2, IL-6, IL-7, IL-8, IL-12, IL-13, IL-15, IL-16, IL-18, and IL-22; antagonists of cytokines or growth factors or their receptors, such as tumor necrosis factor (TNF), LT, EMAP-II, GM-CSF, FGF and PDGF. IL-21/IL-21R antagonists can also be combined with inhibitors of, e.g., antibodies to, cell surface molecules such as

20   CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80 (B7.1), CD86 (B7.2), CD90, or their ligands, including CD154 (gp39 or CD40L), or LFA-1/ICAM-1 and VLA-4/VCAM-1 (Yusuf-Makagiansar H. et al. (2002) *Med Res Rev* 22(2):146-67). Preferred antagonists that can be used in combination with IL-21/IL-21R antagonists described herein include antagonists of IL-1, IL-12, TNFa, IL-15, IL-17, IL-18, and IL-

25   22.

          Examples of those agents include IL-12 antagonists, such as chimeric, humanized, human or in vitro generated antibodies (or antigen-binding fragments thereof) that bind to IL-12 (preferably human IL-12), e.g., the antibody disclosed in WO 00/56772, Genetics Institute/BASF); IL-12 receptor inhibitors, e.g., antibodies to human

30   IL-12 receptor; and soluble fragments of the IL-12 receptor, e.g., human IL-12 receptor. Examples of IL-15 antagonists include antibodies (or antigen-binding fragments thereof) against IL-15 or its receptor, e.g., chimeric, humanized, human or *in vitro* generated

antibodies to human IL-15 or its receptor, soluble fragments of the IL-15 receptor, and IL-15-binding proteins. Examples of IL-18 antagonists include antibodies, e.g., chimeric, humanized, human or in vitro generated antibodies (or antigen-binding fragments thereof), to human IL-18, soluble fragments of the IL-18 receptor, and IL-18 binding proteins (IL-18BP, Mallet et al. (2001) Circ. Res. 28). Examples of IL-1 antagonists include Interleukin-1-converting enzyme (ICE) inhibitors, such as Vx740, IL-1 antagonists, e.g., IL-1RA (ANIKINRA, AMGEN), sIL1RII (Immunex), and anti-IL-1 receptor antibodies (or antigen-binding fragments thereof).

Examples of TNF antagonists include chimeric, humanized, human or in vitro generated antibodies (or antigen-binding fragments thereof) to TNF (e.g., human TNF a), such as D2E7, (human TNFa antibody, U.S. 6,258,562; BASF), CDP-571/CDP-870/BAY-10-3356 (humanized anti-TNFa antibody; Celltech/Pharmacia), cA2 (chimeric anti-TNFa antibody; RemicadeTM, Centocor); anti-TNF antibody fragments (e.g., CPD870); soluble fragments of the TNF receptors, e.g., p55 or p75 human TNF receptors or derivatives thereof, e.g., 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, EnbrelTM; Immunex; see e.g., Arthritis & Rheumatism (1994) Vol. 37, S295; J. Invest. Med. (1996) Vol. 44, 235A), p55 kdTNFR-IgG (55 kD TNF receptor-IgG fusion protein (Lenercept)); enzyme antagonists, e.g., TNFa converting enzyme (TACE) inhibitors (e.g., an alpha-sulfonyl hydroxamic acid derivative, WO 01/55112, and N-hydroxyformamide TACE inhibitor GW 3333, -005, or -022); and TNF-bp/s-TNFR (soluble TNF binding protein; see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S284; Amer. J. Physiol. - *Heart and Circulatory Physiology* (1995) Vol. 268, pp. 37-42). Preferred TNF antagonists are soluble fragments of the TNF receptors, e.g., p55 or p75 human TNF receptors or derivatives thereof, e.g., 75 kdTNFR-IgG, and TNFa converting enzyme (TACE) inhibitors.

In other embodiments, the IL-21-/IL21R binding agents described herein can be administered in combination with one or more of the following: IL-13 antagonists, e.g., soluble IL-13 receptors (sIL-13) and/or antibodies against IL-13; IL-2 antagonists, e.g., DAB 486-IL-2 and/or DAB 389-IL-2 (IL-2 fusion proteins; Seragen; see e.g., Arthritis & Rheumatism (1993) Vol. 36, 1223), and/or antibodies to IL-2R, e.g., anti-Tac (humanized anti-IL-2R; Protein Design Labs, Cancer Res. 1990 Mar 1;50(5):1495-502). Yet another combination includes IL-21 antagonists in combination with non-depleting

anti-CD4 inhibitors (IDEC-CE9.1/SB 210396 (non-depleting primatized anti-CD4 antibody; IDEC/SmithKline). Yet other preferred combinations include antagonists of the co-stimulatory pathway CD80 (B7.1) or CD86 (B7.2) including antibodies, soluble receptors or antagonistic ligands; as well as p-selectin glycoprotein ligand (PSGL), anti-

5 inflammatory cytokines, e.g., IL-4 (DNAX/Schering); IL-10 (SCH 52000; recombinant IL-10 DNAX/Schering); IL- 13 and TGF□, and agonists thereof (e.g., agonist antibodies).

In other embodiments, one or more IL-21-/IL21R binding agents can be co-formulated with, and/or co-administered with, one or more anti-inflammatory drugs,

10 immunosuppressants, or metabolic or enzymatic inhibitors. Non-limiting examples of the drugs or inhibitors that can be used in combination with the IL-21 antagonists described herein, include, but are not limited to, one or more of: non-steroidal anti-inflammatory drug(s) (NSAIDs), e.g., ibuprofen, Tenidap (see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S280)), Naproxen (see e.g., Neuro

15 Report (1996) Vol. 7, pp. 1209-1213), Meloxicam, Piroxicam, Diclofenac, and Indomethacin; Sulfasalazine (see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S281); corticosteroids such as prednisolone; cytokine suppressive anti-inflammatory drug(s) (CSAIDs); inhibitors of nucleotide biosynthesis, e.g., inhibitors of purine biosynthesis, folate antagonists (e.g., methotrexate (N-[4-[[(2,4-diamino-6-

20 pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid); and inhibitors of pyrimidine biosynthesis, e.g., dihydroorotate dehydrogenase (DHODH) inhibitors (e.g., leflunomide (see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S131; Inflammation Research (1996) Vol. 45, pp. 103-107). Preferred therapeutic agents for use in combination with IL-21/IL-21R antagonists include NSAIDs, CSAIDs, (DHODH)

25 inhibitors (e.g., leflunomide), and folate antagonists (e.g., methotrexate).

Examples of additional inhibitors include one or more of: corticosteroids (oral, inhaled and local injection); immunosuppresants, e.g., cyclosporin, tacrolimus (FK-506); and mTOR inhibitors, e.g., sirolimus (rapamycin) or rapamycin derivatives, e.g., soluble rapamycin derivatives (e.g., ester rapamycin derivatives, e.g., CCI-779 (Elit. L. (2002)

30 *Current Opinion Investig. Drugs* 3(8):1249-53; Huang, S. et al.. (2002) *Current Opinion Investig. Drugs* 3(2):295-304); agents which interfere with signaling by proinflammatory cytokines such as TNFa or IL-1 (e.g. IRAK, NIK, IKK, p38 or MAP kinase inhibitors);

COX2 inhibitors, e.g., celecoxib and variants thereof, MK-966, see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S81); phosphodiesterase inhibitors, e.g., R973401 (phosphodiesterase Type IV inhibitor; see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S282)); phospholipase inhibitors, e.g., inhibitors of

5   cytosolic phospholipase 2 (cPLA2) (e.g., trifluoromethyl ketone analogs (U.S. 6,350,892)); inhibitors of vascular endothelial cell growth factor or growth factor receptor, e.g., VEGF inhibitor and/or VEGF-R inhibitor; and inhibitors of angiogenesis. Preferred therapeutic agents for use in combination with IL-21/IL-21R antagonists immunosuppresants, e.g., cyclosporin, tacrolimus (FK-506); and mTOR inhibitors, e.g.,

10   sirolimus (rapamycin) or rapamycin derivatives, e.g., soluble rapamycin derivatives (e.g., ester rapamycin derivatives, e.g., CCI-779; COX2 inhibitors, e.g., celecoxib and variants thereof; and phospholipase inhibitors, e.g., inhibitors of cytosolic phospholipase 2 (cPLA2) (e.g., trifluoromethyl ketone analogs)

Additional examples of therapeutic agents that can be combined with an IL-

15   21/IL-21R antagonist include one or more of: 6-mercaptopurines (6-MP); azathioprine sulphasalazine; mesalazine; olsalazine chloroquinine/hydroxychloroquine; pencillamine; aurothiomalate (intramuscular and oral); azathioprine; cochicine; beta-2 adrenoreceptor agonists (salbutamol, terbutaline, salmeteral); xanthines (theophylline, aminophylline); cromoglycate; nedocromil; ketotifen; ipratropium and oxitropium; mycophenolate

20   mofetil; adenosine agonists; antithrombotic agents; complement inhibitors; and adrenergic agents.

The use of the IL-21-/IL21R binding agents disclosed herein in combination with other therapeutic agents to treat or prevent specific immune disorders is discussed in further detail below.

25   Non-limiting examples of agents for treating or preventing arthritic disorders (e.g., rheumatoid arthritis, inflammatory arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis and psoriatic arthritis), with which an IL-21-/IL21R binding agent can be combined include one or more of the following: IL-12 antagonists as described herein, NSAIDs; CSAIDs; TNF's, e.g., TNFa, antagonists as described

30   herein; non-depleting anti-CD4 antibodies as described herein; IL-2 antagonists as described herein; anti-inflammatory cytokines, e.g., IL-4, IL-10, IL- 13 and TGFa, or agonists thereof; IL-1 or IL-1 receptor antagonists as described herein);

phosphodiesterase inhibitors as described herein; COX-2 inhibitors as described herein; Iloprost (see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S82); methotrexate; thalidomide (see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S282) and thalidomide-related drugs (e.g., Celgen); leflunomide; inhibitor

5   of plasminogen activation, e.g., tranexamic acid; see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S284); cytokine inhibitor, e.g., T-614; see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S282); prostaglandin E1 (see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S282); azathioprine (see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S281); an inhibitor of

10   interleukin-1 converting enzyme (ICE); zap-70 and/or lck inhibitor (inhibitor of the tyrosine kinase zap-70 or lck); an inhibitor of vascular endothelial cell growth factor or vascular endothelial cell growth factor receptor as described herein; an inhibitor of angiogenesis as described herein; corticosteroid anti-inflammatory drugs (e.g., SB203580); TNF-convertase inhibitors; interleukin-11 (see e.g., Arthritis & Rheumatism

15   (1996) Vol. 39, No. 9 (supplement), S296); interleukin-13 (see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S308); interleukin-17 inhibitors (see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S120); gold; penicillamine; chloroquine; hydroxychloroquine; chlorambucil; cyclophosphamide; cyclosporine; total lymphoid irradiation; anti-thymocyte globulin; CD5-toxins; orally-

20   administered peptides and collagen; lobenzarit disodium; Cytokine Regulating Agents (CRAs) HP228 and HP466 (Houghten Pharmaceuticals, Inc.); ICAM-1 antisense phosphorothioate oligodeoxynucleotides (ISIS 2302; Isis Pharmaceuticals, Inc.); soluble complement receptor 1 (TP10; T Cell Sciences, Inc.); prednisone; orgotein; glycosaminoglycan polysulphate; minocycline; anti-IL2R antibodies; marine and

25   botanical lipids (fish and plant seed fatty acids; see e.g., DeLuca et al. (1995) Rheum. Dis. Clin. North Am. 21:759-777); auranofin; phenylbutazone; meclofenamic acid; flufenamic acid; intravenous immune globulin; zileuton; mycophenolic acid (RS-61443); tacrolimus (FK-506); sirolimus (rapamycin); amiprilose (therafectin); cladribine (2-chlorodeoxyadenosine); and azaribine. Preferred combinations include one or more IL-

30   21 antagonists in combination with methotrexate or leflunomide, and in moderate or severe rheumatoid arthritis cases, cyclosporine.

Preferred examples of inhibitors to use in combination with UL-21/IL-21R to treat arthritic disorders include TNF antagonists (e.g., chimeric, humanized, human or *in vitro* generated antibodies, or antigen-binding fragments thereof, that bind to TNF; soluble fragments of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives

5   thereof, e.g., 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, Enbrel™), p55 kD TNF receptor-IgG fusion protein; TNF enzyme antagonists, e.g., TNFa converting enzyme (TACE) inhibitors); antagonists of IL-12, IL-15, IL-17, IL-18, IL-22; T cell and B cell depleting agents (e.g., anti-CD4 or anti-CD22 antibodies); small molecule inhibitors, e.g., methotrexate and leflunomide; sirolimus (rapamycin) and analogs

10   thereof, e.g., CCI-779; Cox-2 and cPLA2 inhibitors; NSAIDs; p38 inhibitors, TPL-2, Mk-2 and NFkb inhibitors; RAGE or soluble RAGE; P-selectin or PSGL-1 inhibitors (e.g., small molecule inhibitors, antibodies thereto, e.g., antibodies to P-selectin); estrogen receptor beta (ERB) agonists or ERB-NFkb antagonists. Most preferred additional therapeutic agents that can be co-administered and/or co-formulated with one

15   or more IL-21/IL-21R antagonists include one or more of: a soluble fragment of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, Enbrel™); methotrexate, leflunomide, or a sirolimus (rapamycin) or an analog thereof, e.g., CCI-779.

Non-limiting examples of agents for treating or preventing multiple sclerosis with

20   which an IL-21-/IL21R binding agent can be combined include the following: interferons, e.g., interferon-alpha1a (e.g., Avonex™; Biogen) and interferon-1b (Betaseron™; Chiron/Berlex); Copolymer 1 (Cop-1; Copaxone™; Teva Pharmaceutical Industries, Inc.); hyperbaric oxygen; intravenous immunoglobulin; clabribine; TNF antagonists as described herein; corticosteroids; prednisolone; methylprednisolone;

25   azathioprine; cyclophosphamide; cyclosporine; methotrexate; 4-aminopyridine; and tizanidine. Additional antagonists that can be used in combination with IL-21 include antibodies to or antagonists of other human cytokines or growth factors, for example, TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-12 IL-15, IL-16, IL-18, EMAP-11, GM-CSF, FGF, and PDGF. IL-21 antagonists as described herein can be combined with antibodies

30   to cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or their ligands. The IL-21 antagonists may also be combined with agents, such as methotrexate, cyclosporine, FK506, rapamycin,

mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents which interfere with signaling by proinflammatory cytokines as described herein, IL- Ib converting enzyme inhibitors

5   (e.g., Vx740), anti-P7s, PSGL, TACE inhibitors, T-cell signaling inhibitors such as kinase inhibitors, metal loproteinase inhibitors, sulfasalazine, azathloprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof, as described herein, and anti-inflammatory cytokines (e.g. IL-4, IL- 10, IL-13 and TGF).

10   Preferred examples of therapeutic agents for multiple sclerosis with which the IL-21 antagonists can be combined include interferon-b, for example, IFNb-1a and IFNb-1b; copaxone, corticosteroids, IL- I inhibitors, TNF inhibitors, antibodies to CD40 ligand and CD80, IL-12 antagonists.

          Non-limiting examples of agents for treating or preventing inflammatory bowel

15   disease or Crohn's disease with which an IL-21/IL-21R antagonist can be combined include the following: budenoside; epidermal growth factor; corticosteroids; cyclosporin, sulfasalazine; aminosalicylates; 6-mercaptopurine; azathioprine; metronidazole; lipoxygenase inhibitors; mesalamine; olsalazine; balsalazide; antioxidants; thromboxane inhibitors; IL-1 receptor antagonists; anti-IL-1 monoclonal

20   antibodies; anti-IL-6 monoclonal antibodies; growth factors; elastase inhibitors; pyridinyl-imidazole compounds; TNF antagonists as described herein; IL-4, IL-10, IL- 13 and/or TGFb cytokines or agonists thereof (e.g., agonist antibodies); interleukin-11; glucuronide- or dextran-conjugated prodrugs of prednisolone, dexamethasone or budesonide; ICAM-1 antisense phosphorothioate oligodeoxynucleotides (ISIS 2302; Isis

25   Pharmaceuticals, Inc.); soluble complement receptor 1 (TP10; T Cell Sciences, Inc.); slow-release mesalazine; methotrexate; antagonists of Platelet Activating Factor (PAF); ciprofloxacin; and lignocaine.

          In one embodiment, an IL-21/IL21R antagonists can be used in combination with one or more antibodies directed at other targets involved in regulating immune responses,

30   e.g., transplant rejection or graft-v-host disease. Non-limiting examples of agents for treating or preventing immune responses with which an IL-21/IL21R antagonist of the invention can be combined include the following: antibodies against cell surface

molecules, including but not limited to CD25 (interleukin-2 receptor-a), CD11a (LFA-1), CD54 (ICAM-1), CD4, CD45, CD28/CTLA4, CD80 (B7-1) and/or CD86 (B7-2). In yet another embodiment, an IL-21/IL21R antagonist is used in combination with one or more general immunosuppressive agents, such as cyclosporin A or FK506.

5   Another aspect of the present invention accordingly relates to kits for carrying out the combined administration of the IL-21/IL21R antagonists with other therapeutic compounds. In one embodiment, the kit comprises one or more binding agents formulated in a pharmaceutical carrier, and at least one agent, e.g., therapeutic agent, formulated as appropriate, in one or more separate pharmaceutical preparations.

10 <u>Assays for Measuring the Activity of IL-21/IL21R Agonists as Immune Activators</u>

The activity of IL-21/IL21R agonists as activators of an immune system can, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.

15 M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. U.S.A. 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol.

20 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. U.S.A. 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowmanet al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341,

25 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In

30 vitro antibody production, Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing

5   Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins

10   expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science

15   264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate

20   lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

25   Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. U.S.A. 88:7548-7551, 1991.

Assays for Measuring the Activity of IL-21/IL21R Agonists or Antagonists as

30   Modulators of Cytokine Production and Cell Proliferation/Differentiation

The activity of IL-21/IL21R agonists or antagonists as modulator of cytokine production and cell proliferation/differentiation can be tested using any one of a number

of routine factor dependent cell proliferation assays for cell lines including, without

limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5,

DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

Assays for T-cell or thymocyte proliferation include without limitation those

described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D.

H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-

Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19;

Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500,

1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular

Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992;

Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or

thymocytes include, without limitation, those described in: Polyclonal T cell stimulation,

Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in Immunology. J. E.e.a.

Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and

Measurement of mouse and human Interferon .gamma., Schreiber, R. D. In Current

Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and

Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic

cells include, without limitation, those described in: Measurement of Human and Murine

Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current

Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and

Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al.,

Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-

2938, 1983; Measurement of mouse and human interleukin 6--Nordan, R. In Current

Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and

Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986;

Measurement of human Interleukin 11--Bennett, F., Giannotti, J., Clark, S. C. and

Turner, K. J. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.15.1

John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9--

Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in

Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. U.S.A. 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Assays for Measuring the Activity of IL-21/IL21R Agonists or Antagonists as Regulators of Hematopoiesis

IL-21/IL21R agonists or antagonists may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in

repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

5   The activity of the IL-21- or IL-21R binding agents may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others,

10   proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among

15   others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al., Proc. Natl. Acad. Sci. U.S.A. 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece,

20   I. K. and Briddell, R. A. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R. E. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal

25   cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, H. J. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.

The invention will be further illustrated in the following non-limiting examples.

30

68

Example 1: Isolation and Characterization of Murine MU-1 cDNAs:

A partial fragment of the murine homolog of the Mu-1 receptor was isolated by PCR using oligonucleotides derived from the human sequences. cDNA was prepared from RNA isolated from 17 day old murine thymus and from the murine 2D6 T cell line.

5   A DNA fragment of approximately 300 nucleotides was amplified from the cDNA by PCR with the following oligonucleotides, corresponding to regions 584-603 and 876-896, respectively, of the human cDNA sequence in FIG. 1 (corresponding to SEQ ID NO:1):

AGCATCAAG CCGGCTCCCCC (5p) (SEQ ID NO:11)

10   CTCCATTCAC TCCAGGTCCC (3p) (SEQ ID NO:12)

Amplification was carried out using Taq polymerase in 1X Taq buffer containing 1.5 mM of magnesium chloride for 30 cycles at 94° C for one minute, 50° C for 1 minute, and 72 ° C for one minute. The DNA sequence of this fragment was determined, and two oligonucleotides were derived from an internal portion of this fragment with the

15   following sequences:

TTGAACGTGACTGRGGCCTT (5P) (SEQ ID NO:13)

TGAATGAAGTGCCTGGCTGA (3P) (SEQ ID NO:14)

The oligonucleotides were used to amplify an internal 262 nucleotide fragment of

20   the original PCR product (corresponding to nucleotides 781-1043 of the murine cDNA sequence of figure 1, and SEQ ID NO:9) to use as a hybridization probe to screen a cDNA library isolated from the 2D6T T cell line. Filters were hybridized at 65° C using standard 5X SSC hybridization conditions and washed into SSC at 65 ° C. Twenty clones were hybridizes to the probe in a screen of 426,000 clones. DNA sequence was

25   determined from two independent clones. Full length sequence of clone #6 confirmed that it was the full-length murine homolog of human MU-1 (SEQ ID NO:9).

The full-length nucleotide sequence of murine MU-1 is shown in figure 1 (corresponding to SEQ ID NO:9). The nucleotide sequence has a predicted leader sequence at nucleotides 407-464, coding sequence at 407-1993, and a termination codon

30   at nucleotides 1994-1997. Nucleotides 1-406 correspond to the 5' untranslated region and nucleotides 1998-2868 correspond to the 3' untranslated region.

The predicted protein sequence of murine MU-1 is shown in figure 2 (corresponding to SEQ ID NO:10). This murine MU-1 protein contains a predicted

leader sequence determined by SPScan (score= 10.1)(corresponding to amino acids 1-19 of SEQ ID NO:10), and a predicted transmembrane domain (corresponding to amino acids 237-253 of SQ ID NO:10). Predicted signaling motifs include the following regions: Box 1: amino acids 265-274 of SEQ ID NO:10, Box 2: amino acids 310-324

5   of SEQ ID NO:10, six tyrosine residues at positions 281, 319, 361, 297, and 510 of SEQ ID NO:10. Potential STAT docking sites include: STAT5, EDDGYPA (SEQ ID NO:20), STAT3, YLQR.

The oligonucleotides were used to amplify an internal 262 nucleotide fragment of the original PCR product (corresponding to nucleotides 781-1043 in of the murine cDNA

10   sequence of figure 1, and SEQ ID NO:9) to use as a hybridization probe to screen a cDNA library isolated from the 2D6 T cell line. Filters were hybridized at 65° C using standard 5 X SSC hybridization conditions and washed into SSC at 65° C. Twenty clones were isolated that hybridized to the probe in a screen of 426,000 clones. DNA sequence was determined from two independent clones. Full length sequence of clone #6

15   confirmed that it was the full-length murine homolog of human MU-1 (SEQ ID NO:9).

The full-length nucleotide sequence of murine MU-1 is shown in figure 1 (corresponding to SEQ ID NO:9). The nucleotide sequence has a predicted leader sequence at nucleotides 407-464, coding sequence at nucleotides 407-1993, termination codon at nucleotides 1994-1997. Nucleotides 1-406 correspond to the 5' untranslated

20   region and nucleotides 1998-2628 correspond to the 3' untranslated region.

The predicted protein sequence of murine MU-1 is shown in figure 2 (corresponding to SEQ ID NO: 10). This murine MU-1 protein contains a predicted leader sequence determined by SPScan (score= 10.1) (corresponding to amino acids 1-19 of SEQ ID NO: 10), and a predicted transmembrane domain (corresponding to amino

25   acids 237-253 of SEQ ID NO:10). Predicted signaling motifs include the following regions: Box 1: amino acids 265-274 of SEQ ID NO: 10, Box 2: amino acids 310-324 of SEQ ID NO: 10, six tyrosine residues at positions 281, 319, 361, 368, 397, and 510 of SEQ ID NO:10. Potential STAT docking sites include: STAT5: EDDGYPA (SEQ ID NO:20); STAT 3:YLQR.

30

Example 2: Comparison of Human and Murine MU-1:

The GAP algorithm was used to compare the human and murine MU-1 amino

acids. A comparison of the murine and human predicted protein sequences is shown in

5   figure 4. The amino acids were 65.267% identical using the GAP algorithm. The

alignment was generated by BLOSUM62 amino acid substitution matrix (Henikoff, S.

and Henikoff, J. G. (1992)). Amino acid substitution matrices from protein blocks (Proc.

Natl. Acad. Sci. USA 89: 10915-10919). Gap parameters= Gap Weight: 8, Average

Match= 2.9 12, Length Weight= 2, Average Mismatch= -2.003. Percent Similarity=

10   69.466.

A comparison of the human and murine cDNA nucleotide sequences is shown in

figure 3. The DNA sequences are 66.116% identical when aligned using the GAP

algorithm. Gap Parameters: Gap Weight= 50, Average Match 10.000, Length Weight= 3,

Average Mismatch= 0.000. Percent Similarity= 66.198.

15   Both human and mouse MU-1 proteins are members of the Type 1 cytokine

receptor superfamily. Evaluation of the sequence of both murine and human MU-1

reveals the presence of potential Box-i and Box-2 signaling motifs. Six tyrosine residues

are present in the cytoplasmic domain, and could also be important in signaling functions

of MU-1. Comparison of the sequences of MU-1 with other members of the family

20   suggested the presence of potential docking sites for STAT 5 and STAT 3.

Example 3: Determination of STAT signaling pathways used by Human MU-1:

BAF-3 cells were engineered to express a chimeric cytokine receptor consisting

of the extracellular domain of the human EPO receptor and the intracellular domain of

25   the MU-1 receptor. BAF-3 cells that expressed huEPORJMU-l(cyto) chimeric receptors

proliferated in response to human soluble EPO. These cells were analyzed to determine

which STAT molecules were phosphorylated in response to EPO signaling. Briefly,

control unmodified parental BAF-3 cells and EPOR/MU chimeric BAF-3 cells were

rested from IL-3 containing growth medium, and restimulated with either IL-3 or EPO

30   for 0, 15, 30 and 60 minutes. The cells were pelleted and resuspended in ice cold lysis

buffer containing orthovanadate, to preserve phosphorylated tyrosines. Equal amounts of

cell lysate were electrophoresed by SDS-PAGE and blotted onto nitrocellulose

membranes for western analysis. Duplicate blots were stained for phosphorylated and nonphosphoraled forms of STAT 1, 3, 5, and 6 by using antibodies specific for each form of the STAT molecule. HELA cells, non-activated and activated with alpha-interferon were used as positive controls.

5   These results indicated that under these specific conditions, signaling through MU-1 results in the phosphorylation of STAT 5 at all time-points tested (1=0, T=15', T=30', 1=60'). Treatment of controls or the chimeric BAF-3 cells with IL-3 resulted in phosphorylation of STAT 3, but not STAT 1 or 5.

10   **Example 4: Tissue Expression of Murine and Human MU-1**

Northern Analysis

     Northern blots of polyA+ RNA from various tissues (Clonetech, Palo Alto, CA) were performed as recommended by the manufacturer. For the murine blots, a 262 nucleotide fragment corresponding to nucleotides 781-1043 of Fig. 1 and SEQ ID NO:9

15 was used for hybridization.

     A single transcript of murine MU-1 was detected in adult murine spleen, lung, and heart tissues. The larger transcript observed in human tissues was not observed in mouse tissues.

     Two transcripts of human MU-1 were detected in adult human lymphoid tissues,

20 PBLs, thymus, spleen and lymph node, and in fetal lung.

In Situ Hybridization

     In situ hybridization studies were performed by Phylogency Inc. of Columbus, OH (according to the method of Lyons et al., 1990, J. Cell. Biol: 111:2427-2436.) Briefly, serial 5-7 micron paraffin sections were deparaffinized, fixed, digested with

25 proteinase K, treated with tri-ethanolamine and dehydrated. cRNAs were prepared from linearized cDNA templates to generate antisense and sense probes. The cRNA transcripts were synthesized according to manufacturer's conditions (Ambion) and labeled with 35S-UTP. Sections were hybridized overnight, stringently washed and treated with RNAase A and dipped in nuclear track emulsion and exposed for 2-3 weeks. Control

30 sections were hybridized with sense probes to indicate the background level of the procedure. The murine probe consisted of a n 186bp fragment corresponding to

nucleotides 860-1064 (SEQ ID NO:9). The human probe was a 23 bp PCR product generated from human MU-1 DNA.

Murine MU-1 expression was observed in the lymph nodes of the adult small intestine at germinal centers and muscular is external. Specialized lymph nodes and

5 Peyers patches also exhibited murine MU-1 expression.

Human MU-1 expression was detected at germinal centers of the lymph nodules in the cortex. The medulla, which contains macrophages, was negative for human MU-1. In human spleen, human MU-1 expression was detected in the regions of white pulp but not red pulp.

10

Example 5: Expression of Human MU-1 in cells and cell lines:

RNAse protection analysis was performed on resting and activated human T cells and the B cell lines, Raji and RPMI 8866, and the I cell line Jurkat. Human T cells were activated with anti-CD3 and anti-CD28. The cell lines were activated by Phorbol ester

15 and ionomycin. MU-1 riboprobe-producing plasmid was constructed by inserting a 23 bp PCR product (PCR was performed by using 5' primer

CACAAAGCTTCAGTATGAGCTGCAGTACAGGAACCGGGGA (SEQ ID NO: 15) and 3' primer

CACAGGATCCCTTTAACTCCTCTGACTGGGTCTGAAAGAT (SEQ ID NO:16))

20 into the BamH I and HindIII sites of pGEM3zf(-) (Promega, Madison, WI) vector. To make the riboprobe, the riboprobe-producing plasmid was linearized with HindIII. The resulting DNA was phenol/chloroform extracted and precipitated with ethanol. T7 RNA polymerase was used to make the riboprobe according to the protocol suggested by the vendor (PharMingen, San Diego, CA). The RNAse protection assay was performed by

25 using PharMingen's RiboQuant Multi-Probe Ribonuclease Protection Assay system. 2.Oug of total RNA were included in each RPA reaction, after RNAse digestion, the protected riboprobes were run on a QuickPoint rapid nucleic acid separation system (Novex, San Diego, CA). Gels were dried and exposed according to the suggestion of the vendor.

30 Human MU-1 RNA is upregulated in anti-CD3 +anti-CD28 stimulated human purified CD3+ cells when compared with unstimulated populations. MU-1 is also upregulated upon restimulation in Th1 and Th2-skewed T cell populations. The B cell

lines, RPMI 8866 and Raji, constitutively express MU-1 while the Jurkat T cell line does not.

Example 6: Binding of Human MU-1 to Known Cytokines

Both human and murine Ig fusion proteins were constructed and immobilized on Biacore chips in an effort to identify the ligand for MU-1. A variety of cell culture conditioned media as well as a panel of known cytokines were evaluated for binding to MU-1. Some cytokines were also tested in combination with other receptor chains in the family to consider the possibility that MU-1 may require a second receptor chain for ligand binding. The following cytokines were tested and found to be negative for MU-1 binding: mIL-2, hIL-2, hIL-i5, mIL-7, TSLP, TSLP+IL7, TSLP+IL7R, TSLP+IL7g, TSLP+ IL-2, TSLP + 1L2 + IL2Rbeta, IL2Rbeta, IL2Rgamma, IL7R, 1L2+2Rbeta, 1L2+2Rgamma, IL1 5+IL2Rbeta, 1L15+2Rgamma, 1L7+2Rgamma, IL2+IL7R, ILl 5+IL7R, IL7+IL7R. Known receptors have been immobilized as well and tested for MUFc binding with negative results. IL-IS will bind to IL2Rb but not IL2Rg or MUFc.

Example 7: Effect of Modulation of IL-21/IL-21R Pathway on the Severity of Symptoms in Collagen-Induced Arthritis (CIA) Mice

This example shows that IL-21R antagonists, e.g., IL-21R-Ig fusion proteins (murine IL21RFc protein or "muIL21RFc") or anti-IL21R antibodies, ameliorate symptoms in a collagen-induce arthritis (CIA) murine model. In contrast, administration of IL-21 exacerbates the arthritic symptoms in CIA mice.

Male DBA/1 (Jackson Laboratories, Bar Harbor, Maine) mice were used for all experiments. Arthritis was induced with the use of bovine collagen type II (Chondrex, Redmond, WA). Bovine collagen type II (Chondrex, Redmond, WA) was dissolved in 0.1 M acetic acid and emulsified in an equal volume of CFA (Sigma) containing 1mg/ml *Mycobacterium tuberculosis* (strain H37RA). 100 µg of bovine collagen was injected subcutaneously in the base of the tail on day 0. On day 21, mice were injected subcutaneously, in the base of the tail, with a solution containing 100 µg of bovine collagen in 0.1M acetic acid that had been mixed with an equal volume of Incomplete Freund's adjuvant (Sigma). Naïve animals received the same sets of injections, minus collagen. The dosing protocol is shown schematically in Figure 16. MuIL21RFc was

administered prophylactically or therapeutically to DBA mice. In the therapeutic regimen, treatment was initiated if disease was observed for two consecutive days in a mouse.

Mice were monitored at least three times a week for disease progression.

5   Individual limbs were assigned a clinical score based on the index: 0 = normal, no swelling; 1 = visible erythema accompanied by 1-2 swollen digit, or mild swelling in ankle; 2 = pronounced erythema, characterized by mild to moderate paw swelling and/or two swollen digits; 3 = extensive swelling of the entire paw, i.e., extending into ankle or wrist joint; 4 = resolution of swelling, ankylosis of the paw; difficulty in use of limb or

10   joint rigidity. Thus, the sum of all limb scores for any given mouse yielded a maximum total body score of 16.

At various stages of disease, animals were euthanized, tissues were harvested and paws were fixed in 10% formalin for histology or 4% paraformaldeyde, pH 7.47, decalcified in 20% EDTA (pH 8.0) and embedded in paraffin for *in situ* hybridization.

15   Using light microscopy the paws were scored on a 5-grade scoring method (0-4) to characterize the intensity and extent of arthritis. Inflammatory infiltrates were used for scoring in addition to other changes related to the inflammation, such as pannus formation, fibrous of the synovial membrane, articular cartilage erosin and/or subchondral bone destruction. Hisotology grades were determined using readings of

20   individual paws: NAD=0 or nothing abnormal discovered; 1=Slight to moderate; 2: Mild to moderate; 3: Marked and 4:Massive.

A reduction in the severity of the symptoms was observed after prophylactic treatment of CIA mice using muIL21RFc (100 µg or 200 µg) administered intraperitoneally (ip) every other day starting one day before the collagen boost (data not

25   shown).

The effects of muIL21RFc (200 µg/mouse 3x/week) on a semi-therapeutic CIA mouse as a function of day post treatment are shown in *Figure 17*. Mouse Ig (200 µg/mouse 3x/week) was used as a control. A reduction in the severity score is shown starting from day 7 post treatment.

30   Administration of IL-21 exacerbates the arthritic symptoms in CIA mice. *Figure 18* is a graph depicting the mean CIA score as a function of days post collagen boost.

Mice administered with 1 mg of murine IL-21 intraperitoneally (ip) showed higher CIA scores that control PBS-treated mice.

These experiments demonstrate that administration of an IL-21R antagonist, e.g., IL-21R-Fc fusion proteins, to CIA mice either prophylactically or semi-therapeutically

5   significantly ameliorated arthritic symptoms. In contrast, administration of IL-21 exacerbates the symptoms.

Example 8: _In situ_ hybridization of IL-21R transcripts

The expression of IL-21R mRNA in arthritic paws of mice with CIA was

10   determined. Anti-sense murine IL-21R riboprobes were used (_Figure 19_, panel A); sense probes were used as negative controls (_Figure 19_, panel B).

Digoxygenin labeled probes were prepared with the use of a DIG RNA labeling mix (Roche Diagnostics, Mannheim,Germany), as described by the manufacturer. Expression of IL-21 receptor mRNA was detected in macrophages, neutrophils,

15   fibroblasts, a subpopulation of lymphocytes, synoviocytes and epidermis (_Figure 19_, panel A). Decreased staining was seen in the control paws or with sense probes (_Figure 19_, panel B). mIL-21R mRNA positive cells were: neutrophils (N), and macrophages (M). _In situ_ hybridization shows enhanced expression of IL-21R in the paws of arthritic mice.

20

Example 9: _In vivo_ Activation of IL-21 Receptor Generates Potent Anti-Tumor Responses

This example shows that administration of IL-21-expressing tumor cells enhances anti-tumor responses _in vivo_ in both immunogenic and non-immunogenic tumor models.

25   CD8$^+$ T cells and NK cells are necessary for tumor destruction and subsequent development of tumor antigen specific T cells. IL-21 present at the tumor microenvironment potentiates both innate and adaptive immunity _in vivo_ anti-tumor responses.

30   **Experimental Procedures**

Mice. Female C57BL/6, Balb/C, IFNγ$^{-/-}$ and IL-10$^{-/-}$ mice in C57BL/6 background were purchased from Jackson Laboratories (Bar Harbor, ME.). C57BL/6 scid and nude mice

were purchased from Taconic (Germantown, NY). IL-21R$^{-/-}$ mice were generated at Wyeth Research, MA. and maintained at Charles Rivers Laboratories (Andover, MA) (Kasaian, M.T. *et al.* (2002) *Immunity.* 16:559-569). Mice were maintained and treated in accordance with National Institutes of Health and American Association of Laboratory

5   Animal Care regulations.

Tumor cell lines and reagents. Two tumor cells lines, B16F1 melanoma and MethA fibrosarcoma, were used in the experiments described herein. B16F1 melanoma and MethA fibrosarcoma cells have been extensively used in tumor vaccination models to

10   study the *in vivo* anti-tumor effect of various cytokines. B16F1 tumor cells are poorly immunogenic, in that previous vaccination with irradiated wild-type tumor cells only protects 20% of vaccinated mice against subsequent live B16F1 challenge (Dranoff, G. *et al.* (1993) *PNAS* 90:3539-3543). In contrast, MethA, a methycholantheren induced fibrosarcoma, are highly immunogenic (i.e., vaccination with irradiated MethA cells

15   leads to almost 100% protection against subsequent live MethA challenge).

B16F1 melanoma cells were maintained in culture in DMEM medium supplemented with 10% heat in-activated fetal bovine serum, 2% glutamine, and 1% penicillin-streptomycin. MethA fibrosarcoma cells were maintained by intraperitoneal passage in Balb/C mice. B16F1 melanoma specific TRP-2 (SVYDFFVWL, SEQ ID

20   NO:__) (van Elsas, A. et al. (2001) *Journal of Experimental Medicine* 194:481-489; Sutmuller, R.P. et al. (2001) *Journal of Experimental Medicine.* 194:823-832) and control peptide OVA $_{257\text{-}264}$ (SIINFEKL, SEQ ID NO:__) were synthesized at the Wyeth Research, MA. Monoclonal Abs anti-CD3, anti-CD28 and rat IgG2a, and IL-2 cytokine used in this paper were all purchased from PharMingen (San Diego, CA).

25

Generation of IL-21 and green fluorescent protein (GFP) expressing tumor cells. B16F1 and MethA tumor cells were engineered to express IL-21 and GFP, or only GFP. Retroviral vectors encoding mIL21 -IRES-GFP or IRES-GFP were constructed using GFP-RV vector (Ranganath, S. *et al.* (1998) *Journal of Immunology* 161:3822-3826).

30   High titer retrovirus was obtained by transfecting 293-VSVg ecotropic packaging cell line (Ory, D.S. et al. (1996) *PNAS* 93:11400-11406). Spin infections were performed at 1800 rpm for 40 minutes at room temperature. Cells were infected 3 times. Tumor cells

expressing GFP were enriched by flow sorting and the purity of GFP expressing cells was greater than 90%.

In vivo tumor studies. C57BL/6 mice were shaved on the back and injected i.d. with 10^5

5   B16F1-IL-21 or control B16F1-GFP. Balb/C mice were injected with either 10^6 or $2x10^6$ MethA-IL-21 or control MethA-GFP cells. Tumor growth was monitored by measuring perpendicular diameters with a caliper. Mice were sacrificed when the tumors displayed severe ulceration or reached a size of 200mm^2. In general, 10 mice per group were used in each experiment and representative results are shown from experiments repeated two

10   or more times with similar results.

In vivo depletion studies. CD4$^+$ or CD8$^+$ T cell depletion was accomplished by i.p.injecting 400 ☐g per mouse of either anti-CD4 (GK1.5), anti-CD8 (53-6.7) mAbs or rat IgG isotype control for three consecutive days before tumor cell injection. Ab

15   injections were continued every other day post tumor cell injection for 12 days. For NK cell depletion, 50 µl of rabbit anti-mouse/rat asialo GM1 polyclonal ab (Cedarlane, Ontario, CA) was injected i.p. one day before tumor cell injection. Mice similarly injected with normal rabbit serum were used for control. After tumor cell inoculation, antibody injections were continued twice per week for two weeks. T- and NK cell-

20   depletion was confirmed in lymph nodes and spleens one day before tumor challenge (for T cells) or on the same day of tumor cell challenge (for NK cells) by flow cytometry using relevant antibodies. FACS analysis showed that greater than 99% of the relevant population of T cells or NK cells were depleted in mice treated with anti-CD4, anti-CD8, anti asialo GM1. In contrast, mice treated with isotype controls displayed T lymphocyte

25   profiles similar to the profiles of untreated mice.

IL-21 enzyme-linked immunosorbent assay (ELISA). Overnight supernatants from 10^6 B16F1-IL-21, B16F1-GFP, MethA-IL-21 and MethA-GFP tumor cells were assayed for IL-21 levels by ELISA as detailed in Dunussi-Joannopoulos, K. *et al.* (1998) *Blood*

30   91:222-230. In brief, mMu1-mutm IgG2a (Wyeth Research, MA.) was used as coating antibody and anti-mouse IL-21 (R&D systems, Minneapolis, MN.) was used as capture

Ab. Purified mIL-21 (Wyeth Research, MA) (Kasaian, M.T. *et al.* (2002) *supra*) was
used as control.

IL-21R mRNA expression detected by Taqman. RNA was isolated from different tumor

5   cell lines according to the manufacturer's instructions (Promega, Madison, WI). mRNA
extracted from splenocytes that had been activated with plate bound anti-CD3 (1 µg/ml)
and anti-CD28 (1 µg/ml) mAbs (BD PharMingen) for 24 hours was used for positive
control. Purified RNA was treated with DNase (Ambion Inc, Austin, Tx) and adjusted to
a concentration of 50 ng/µl before mRNA analysis by quantitative TaqMan polymerase

10   chain reaction (PCR) analysis. IL-21R and cyclophylin-specific primer pairs and probes
were designed using PrimerExpress software and were prepared by Wyeth Research
(primers: 5'-GCCTTCTCAGGACGCTATGAT-3' (SEQ ID NO:40) and 5'-
CCCTACAGCACGTAGTTGGA-3' (SEQ ID NO:41) and probe
TCCTGGGACTCAGCTTATGACGAACC) (SEQ ID NO:42). Standard curves for each

15   gene were generated with RNA from known IL-21R expressing cells. mRNA expression
in control and transduced cell lines was normalized based on cyclophilin expression in
each cell line and the results are presented as relative units (R.U.) of mRNA.

Proliferation Assay. Splenocytes ($2x10^5$ cells/well) from either C57BL/6 or Balb/C

20   mice were stimulated with various concentrations of syngeneic irradiated tumor cells that
expressed either GFP or IL-21 in 96-well plates. ^{3}H thymidine at 1 µCi/well
(PerkinElmer Life Sciences, Boston, MA) was added during the last 6 hours of culture.
After harvesting the supernatant onto glass fiber filter mats, ^{3}H-thymindine incorporation
was determined by liquid scintillation counting.

25

Elispot Assay. TRP-2 specific T cell responses were determined by IFN-γ Elispot kit
(R&D systems) following manufacturers instructions. In brief, $2x10^5$ to $4x10^5$ of
splenocytes (from tumor injected mice) in 200 µl complete medium containing 5 µg/ml
of specific TRP-2 peptides (van Elsas, A. (2001) *J. Exp. Med.* 194:481-489) or non-

30   specific OVA peptides and 20U/ml murine IL-2 (PharMingen) were placed into each
well. The plate was incubated for 24 hr at 37°C in a CO_2 incubator. Plates were then
incubated overnight at 4°C with detection Ab, followed by 2-hr incubation with

Streptavidin-alkaline phosphatase conjugate. Spots were visualized with 5-bromo-4

chloro-3' Indolylphosphate p-Toluidine Salt/Nitro Bluetetrazolium Chloride

(BCIP/NBT) alkaline phosphotase substrate (R&D systems). Plates were washed with

tap water and air-dried, and spots were counted with a stereomicroscope and re-

5   calculated to per 10^6 cells with background spots subtracted. Generally, less than 10

spots/well were detected when OVA peptide was used as antigen.

In vitro restimulation of splenocytes from tumor cell-inoculated mice. Tumor peptide

specific T cell lines were generated as described in Bloom, M.B. *et al.* (1997) *J. Exp.*

10   *Med.* 185:453-459. In brief, mice were inoculated with either B16F1-GFP or B16F1-IL-

21 cells. After 8-11 days, splenocytes were harvested and cultured with 5 µg/ml of TRP-

2 peptide (van Elsas, A et al. (2001) *supra*). On the third day of culture, 20 U/ml of IL-2

(BD PharMingen) was added to each culture. After 5 days, cells were used for ^{51}Cr

release assay.

15

CTL Assay. Cytotoxicity against targets was quantified using a 4-h ^{51}Cr release assay.

Briefly, RMA-S cells were pulsed with TRP-2 peptide at 10 µg/ml and labeled with

Na_2^{51}CrO4 (PerkinElmer Life Sciences) for 1 hr at 37^0C. After washing, ^{51}Cr labeled

target cells were incubated with T cell lines generated from C57BL/6 mice injected with

20   tumor cells described earlier at different E:T ratios in 96-round bottom plates. After 4-

hour incubation at 37°C, supernatants were collected and radioactivity was detected in a

scintillation counter (Wallac, Turku, Finland). Percentage specific lysis was calculated

as 100 x [(release by CTL-spontaneous release) / (maximal release-spontaneous release)].

Maximal release was determined by the addition of 1% Triton X-100. Spontaneous

25   release in the absence of CTL was generally less than 15% of maximal release.

IL-21 transduced B16F1 and MethA cells secrete biologically functional IL-21

B16F1 and MethA tumor cells were transduced to express GFP plus IL-21

(B16F1/MethA-IL21) or GFP (B16F1/MethA-GFP), respectively. Overnight

30   supernatants from 10^6 of B16F1-IL-21, B16F1-GFP, MethA-IL-21 or MethA-GFP tumor

cells were assayed by ELISA as described in Experimental Protocols, above. As shown

in Fig. 20A, B16F1-IL-21 and MethA-IL-21 cells, but not B16F1-GFP or MethA-GFP

tumor cells, secreted substantial amount of IL-21 in overnight cultures. To determine

whether the IL-21 cytokine secreted by the transduced cells was biological functional,

irradiated IL-21 or GFP expressing tumor cells were used to stimulate naïve syngenic

splenocytes from C56BL/6 or Balb/C mice in the presence of sub-optimal amount of

5   anti-CD3 (500 ng/ml) and anti-CD28 (10 μg/ml). As shown in *Fig. 20B and 20C*,

B16F1-IL-21 and MethA-IL-21 cells enhanced naïve splenocyte proliferation when

compared with control GFP expressing cells at all concentrations tested. These results

suggest that IL-21 secreted by transduced tumor cells is biologically functional.

10   *IL-21 does not affect tumor cell growth in vitro*

The effect of IL-21 on the *in vitro* growth characteristics of transduced B16F1 and

MethA cells was examined. B16F1-IL-21 and B16F1-GFP or MethA-IL-21 and MethA-

GFP tumor cells were cultured at a concentration of 10^5/ 1.5ml culture media in 12-well

plates. Cell numbers were monitored daily by trypan blue exclusion assay. The results

15   are presented as means of duplicates. RNA from anti-CD3 and anti-CD28 mAb activated

C57BL/6 splenocytes was used as positive control. Equal numbers of tumor cells were

cultured in 12-well plates, and viable cell numbers were determined at various time

points. As shown in Fig. 21A and 21B, the growth kinetics of IL-21 producing tumor

cells was very similar to that of the GFP expressing control tumor cells in a period of 5

20   days. This indicates that IL-21 did not have any apparent effect on the *in vitro* growth

characteristics of transduced tumor cells. The unresponsiveness of tumor cells to IL-21

was further confirmed with the lack of the IL-21R expression by tumor cells in

quantitative Taqman PCR analysis. *Figure 21C* is a bar graph depicting quantitation of

cyclophilin and IL-21R mRNA extracted from transduced tumor cells, determined by

25   Taqman PCR. Expression of IL-21R mRNA in the transfected cells was normalized to

cyclophilin values and expressed as relative unite (R.U.). RNA from anti-CD3 and anti-

CD28 mAb activated C57BL/6 splenocytes was used as positive control.

IL-21 inhibits tumor growth in vivo

30   To assess the *in vivo* effects of IL-21 on tumor growth, B16F1-IL-21 or MethA-IL-

21 tumor cells were inoculated i.d. into the flank of syngenic mice. As shown in Fig.

22A, no tumor formation was detected in any of the C57BL/6 mice inoculated with

B16F1-IL-21 tumor cells for more than 27 weeks post tumor injection. On the contrary, all C57BL/6 mice bearing B16F1-GFP cells grew tumors starting as early as day 9. Control tumors increased rapidly in size and these mice had to be sacrificed two to three weeks after tumor cell inoculation due to heavy tumor burden. In the MethA model,

5   small but palpable tumor masses were detected one week post tumor inoculation with either MethA-IL-21or MethA-GFP cells in Balb/C mice (Fig. 22B). However, MethA-IL-21 tumors gradually reduced in size starting from week two (day 11) and eventually regressed completely in 100% of mice, whereas 80% of control MethA-GFP tumors continued to grow in size until the mice were sacrificed. These results show that the

10 presence of IL-21 at the tumor microenvironment triggers potent immune responses that lead to rejection of both immunogenic and non-immunogenic tumors.

IL-21 cannot prevent tumor growth in scid and nude mice

In order to determine the relative roles of the cellular and humoral immune

15 responses in the rejection of IL-21-transduced tumor cells, equal numbers (10^5) of B16F1-IL-21 or control B16F1-GFP cells were injected into T and B cell deficient (scid) mice. Both B16F1-IL-21 and B16F1-GFP cells showed similar growth kinetics in scid mice (Fig. 23A), indicating that lymphocytes (B and/or T cells) are required for the IL-21 mediated tumor rejection. The role of T cells was also confirmed in experiments with

20 C57BL/6 nude/nude mice. As shown in Fig. 23B, all nude mice inoculated with B16F1-IL-21 cells developed tumors, albeit with slower growth kinetics. Taken together, these results indicate that IL-21 mediated anti-tumor responses require the participation of the adaptive immunity.

$CD8^+$ T, but not $CD4^+$ T cells are required for IL-21 mediated tumor rejection

To further dissect which T cell subset(s) is (are) important for the IL-21 induced effect, *in vivo* depletion of lymphocyte subpopulations by administering anti-CD4 or anti-CD8 mAbs was performed. As shown in Fig. 25A, B16F1-IL-21 tumors did not grow in $CD4^+$ T cell depleted mice and in control rat IgG treated mice. However, palpable

30 tumors grew out in seven out of ten $CD8^+$ T cell depleted mice suggesting that $CD8^+$ but not $CD4^+$ T cells are necessary for the IL-21 induced anti-tumor response. Of interest, the growth of B16F1-IL-21 in $CD8^+$ T cell depleted mice was significantly delayed

suggesting that cells other than CD8[+] T cells may be responsible for the suppression of early phase tumor growth.

NK cells are required for the IL-21 induced anti-tumor response

5   Accumulated experimental evidence supports the role of NK cells as first line of defense in promoting anti-tumor immunity (Smyth, M.J. et al. (2001) *International Immunology* 13:459-463; Smyth, M.J. et al. (2002) *Curr. Opin.Immunol.* 14:165-171; Smyth, M.J. et al. (2002) *Blood.* 99:1259-1266). This possibility was examined by injecting equal numbers of B16F1-IL-21 tumor cells into NK cell depleted mice or

10   control C57BL/6 mice. No detectable tumor formation was observed in control C57BL/6 mice, whereas, all of the NK cell depleted mice grew out tumors two weeks post B16F1-IL-21 tumor cell inoculation. This result shows that NK cells, in addition to CD8[+] T cells, are necessary for IL-21 induced anti-tumor response.

15   ## IL-21 supports the generation of IFNγ secreting tumor antigen specific T cells and enhances tumor antigen specific CTL activity

          It has been recently demonstrated that a nonameric peptide consisting of residues 180-188 of normal melanocyte differentiation antigen tyrosinase-related protein 2 (TPR-2), is one of the tumor rejection antigens for the B16 melanoma that is recognized by B16

20   melanoma-reactive cytotoxic T lymphocytes (van Elsas, A. et al. (2001) *supra*; Sutmuller, R.P. (2001) *J. Exp. Med.* 194:823-832). TPR-2 peptide was used to evaluate the *in vivo* effect of IL-21 on T cell responses. Splenocytes from mice injected with either IL-21 or GFP expressing B16F1 cells were stimulated *in vitro* with TPR-2 peptide in an IFNγ ELISPOT assay. As shown in Fig. 26A, the number of IFNγ producing cells

25   in B16F1-IL-21 injected mice was 3-fold higher than that of B16F1-GFP injected mice. To further characterize IL-21 mediated anti-tumor T cell responses, splenocytes from either IL-21 or GFP expressing tumor-injected mice were first stimulated *in vitro* with TRP-2 peptide as described herein and then used for *in vitro* CTL assays. B16F1 cell line used in the experiments described herein expresses low level of MHC class I

30   molecules, as determined with flow cytometry (van Elsas, A. et al. (2001) *supra*; Sutmuller, R.P. (2001) *supra.*; Lim, Y.S. et al. (1998) *Molecules & Cells* 8:629-636). Therefore, RMA-S cells were used as antigen presenting cells in our CTL assays. As

shown in Fig. 26B, splenocytes from B16F1-IL-21 injected mice had enhanced cytolytic activity towards TRP-2 peptide pulsed RMA-S cells compared to GFP expressing tumor (Fig. 26C) at all E:T ratios, despite some cross-reactivity observed towards OVA peptide. These results indicate that IL-21-mediated tumor rejection supports the development of
5   tumor antigen-specific cytolytic T cell responses. TRP-2 is one of the antigens that is shared between B16F1 tumor cells and normal malenocytes, thus CTLs detected here are actually autoreactive T cells. Indeed, 10-20% of C57BL/6 mice developed local hair and skin depigmentation at the site of B16F1-IL-21 tumor cell but not control cell injection (data not shown).

10   _IL-21 induced anti-tumor response is independent of IFN-γ and IL-10_

        IFNγ and IL-10 have been reported previously to be important for tumor rejection (Gerard, C.M. et al. (1996) _Human Gene Therapy._ 7:23-31; Lim, Y.S. _et al._ (1998) _Molecules & Cells_ 8:629-636). ELISOP results suggest that IL-21 enhanced tumor-specific cells producing IFNγ but not IL-10. To test the involvement of IFNγ and IL-10
15   in IL-21-mediated anti-tumor effect, equal numbers of B16F1-IL-21 or B16F1-GFP tumor cells were injected into either IFNγ$^{-/-}$ or IL-10$^{-/-}$ mice. As shown in Figs. 27A-27B, none of the aforementioned cytokine deficient mice formed tumors post B16F1-IL-21 cell injection. However, B16F1-GFP control cells grew out tumors in all of the IFNγ$^{-/-}$ and IL-10$^{-/-}$ mice. These data show that IL-21 mediated anti-tumor effect does not
20   require active participation of IFNγ or IL-10.

        Cytokine gene-therapy was used to study the _in vivo_ immunoregulatory potential of IL-21. This example shows that IL-21, when secreted at the tumor site by genetically modified B16F1 melanoma or MethA fibrosarcoma cells, fuels efficacious antitumor immune responses that require the presence of the cognate IL-21R (Fig. 23). CD8^{+} T
25   cells and NK cells are necessary for tumor destruction and subsequent development of tumor antigen specific T cells (Fig. 24A and 24B). Major Th1 and Th2 cytokines, IFNγ and IL-10 respectively, do not appear to be essential for the IL-21 mediated anti-tumor responses (Fig. 26A and 26B).

        The rapid and definitive elimination of IL-21-transduced B16 melanoma tumor
30   cells described herein is in contrast with data obtained in other cytokine gene vaccination models. Mice immunized with IL-4-, IL-5-, IL-6-, IL-12-, IFNγ-, TNFα- or GM-CSF-transduced B16 vaccines displayed moderate delay in tumor formation, albeit eventually

all mice succumbed to lethal tumors (Dranoff, G. *et al.* (1993) *PNAS* 90:3539-3543;

Nagai, H. et al. (2000) *J. Invest. Dermat.* 115:1059-1064). Furthermore, GM-CSF, IL-5,

IL-6, and TNF-α expressing cells caused significant side effects, ranging from

hepatosplenomegaly, wasting and shivering, to death. To date, only IL-2 and IL-10 have

5   been reported in the literature to induce complete regression of transduced B16 tumors *in*

vivo (Dranoff, G. *et al.* (1993) *supra*; Gerard, C.M. (1996) *Human Gene Therapy* 7:23-

31). In the studies described herein, syngeneic mice injected with live B16F1-IL-21 or

MethA-IL-21 transduced tumor cells did not develop clinically overt tumor for a period

of more than 27 weeks post tumor inoculation. Furthermore, flow cytometry analysis of

10   lymphoid cells from spleens and lymph nodes removed from immunized mice did not

show any major changes in cell population (data not shown), suggesting that the

paracrine secretion of IL-21 at the tumor microenvironment orchestrates efficacious anti-

tumor responses without causing detectable systemic side effects.

B16F1-IL-21 tumor grew out in IL-21R$^{-/-}$ mice but not in C57BL/6 (control)

15   mice. This strongly indicates that IL-21 and IL-21R interaction is critical for the IL-21-

mediated effect despite of the apparent redundancy in IL-21R signaling pathway with

other cytokine receptors (Parrish-Novak *et al.* (2000) *supra*; Ozaki et al. (2000) *supra*;

Asao *et al.* (2001) *supra*). The outgrowth of B16F1-IL-21 tumors in IL-21R$^{-/-}$ mice,

however, should not be attributed to an intrinsic defect in T and NK cell development, as

20   IL-21R$^{-/-}$ mice have normal NK and T cells which respond to cytokines other than IL-21

(Kasaian, M.T. *et al.* (2002) *supra*).

Innate and the adaptive immune system may participate in the immune responses

against tumors. IL-21 can enhance both NK and T cell activation *in vitro*. The *in vivo*

depletion experiment described herein showed that both NK cells and CD8$^+$ T cells are

25   required for complete IL21-B16F1 tumor rejection. Involvement of NK cells in tumor

surveillance is confirmed by the NK depletion experiment described herein (Fig. 24B).

Given that B16F1-IL-21 cells express very low level of MHC class I molecules (data not

shown), inoculation of live B16F1-IL-21 cells may generate an initial local inflammatory

response. NK cells can act as a first line of defense against tumor cells (Trinchieri, G.

30   (1994) *J. Exp. Med.* 180:417-421; Levitsky, H.I. et al. (1994) *J. Exp. Med.* 179:1215-

1224; Wu, T.C. (1995) *J. Exp. Med.* 182:1415-1421). This early phase of tumor killing

generates a plethora of tumor derived antigens, which in turn can be taken up by

professional APCs and presented to MHC-restricted cytotoxic T cells. The contribution of NK cells to the early surveillance of B16F1-IL-21 cells before adaptive immune responses being generated is further reflected by the significantly delayed B16F1-IL-21 tumor growth in $CD8^+$ T cell depleted mice (Fig. 24A).

5   Evidence of the involvement of T cells in IL-21 induced tumor regression is provided by the restoration of tumor growth in nude mice (Fig. 23B). Both $CD4^+$ and $CD8^+$ T cells have been described in various tumor cell-based vaccine strategies to be important for the induction of tumor regression and the development of protective immunity (Colombo, M.P., and G. Forni (1994) *Immunology Today* 15:48-51; Hock, H.

10   *et al.* (1993) PNAS 90:2774-2778; Hung, K. et al. (1998) *J. Exp. Med.* 188:2357-2368; Segal, B.M. *et al.* (2002) *J. Immunol.* 168:1-4). Studies have shown that $CD4^+$ T helper cells are required for the activation of naïve $CD8^+$ T cells (Clarke, S.R. (2000) *Journal of Leukocyte Biology.* 67:607-614). In contrast, the findings described above demonstrate that $CD8^+$ but not $CD4^+$ T cells are required for the anti-tumor response of IL-21. The

15   findings disclosed herein appear to be consistent with recent studies that have demonstrated that eliminating $CD4^+$ T cells may actually enhance the anti-tumor effect of cytokine gene therapy *in vivo* (Sutmuller, R.P. *et al.* (2001) *Journal of Experimental Medicine.* 194:823-832; Nagai, H. *et al.* (2000) *Journal of Investigative Dermatology* 115:1059-1064). IL-21 may also enhance the activation of naïve $CD8^+$ T cells by

20   lowering the threshold of co-stimulation necessary for T cell activation, and/or augmenting antigen presentation of the IL-21R bearing APCs (Schoenberger, S.P. *et al.* (1998) *Nature.* 393:480-483; Bennett, S.R. *et al.* (1998) *Nature* 393:478-480).

       Mice injected with B16F1-IL-21 tumor cells developed hair and skin de-pigmentation around the injection sites. It is likely that autoimmunity against normal

25   mouse melanocyte was induced through a common epitope shared with B16 tumor cells in the close proximity of tumor injection sites. Using cytokine gene transduced B16 melanoma cells in conjunction with anti-CD4 depletion or CTLA-4 blockade, other investigators have also reported similar observation. However, the skin de-pigmentation is vitiligo-like, suggesting a more systemic involvement of the putative autoimmune cells

30   against melanocytes (Sutmuller, R.P. *et al.* (2001) *Journal of Experimental Medicine.* 194:823-832; Nagai, H. (2000) *Journal of Investigative Dermatology.* 115:1059-1064; van Elsas, A. *et al.* (1999) *Journal of Experimental Medicine.* 190:355-366). TRP-2 is

one of such shared epitopes between B16F1 tumor cells and normal melanocytes. As T

cells with high affinity to self-antigens are deleted in the thymus, TRP-2 specific T cells

escaping thymic deletion must be of low avidity. Nevertheless, B16F1-IL-21 tumor

injected mice have more than three fold of TRP-2 specific T cells than B16F1-GFP

5   (control) tumor injected mice, suggesting that IL-21 lowers the threshold for naïve T cell

activation in B16F1-IL-21 injected mice.

The anti-tumor activity of IL-21 also correlates with enhanced CD8$^+$ T cell

functions, as demonstrated by both increased antigen specific IFNγ production, and by

augmented tumor specific CTL activities. Although IFNγ and IL-10 have both been

10   described to play an essential role in tumor rejection, our experiments with IFNγ and IL-

10 deficient mice indicate that their presence is not required for IL-21 mediated tumor

rejection.

In summary, the results presented herein suggest that at least three mutually

nonexclusive mechanisms underlie the IL-21-mediated anti-tumor response: (1)

15   paracrine secretion of IL-21 in the tumor microenvironment triggers and supports the

initial innate tumor surveillance mediated by NK cells; (2) IL-21 activates APCs and

facilitates uptake of tumor debris and subsequent tumor antigen presentation to naïve T

cells, hence the adaptive immune response by CD8+ T cells; (3) IL-21 lowers the

threshold for naïve T cell activation, thereby allowing the recruitment and activation of

20   low-affinity autoreactive T cells that escaped central tolerance.

Example 10:IL-21 Enhances Antigen-Specific CD8+ T Cell Responses

This Example shows that an analysis of IL-21 and IL-21R mRNA expression, and

the effects of IL-21 on the responses of, murine CD8+ T cells. Naive CD8+ T cells

25   express IL-21R and expression is upregulated upon stimulation. CD8+ T cells only

express detectable IL-21 mRNA when stimulated in the presence of exogenous IL-21.

IL-21 specifically enhances proliferation of antigen- or anti-CD3 mAb-stimulated CD8+

T cells although it is not as potent as IL-2 at limiting levels of stimulation. However,

compared to IL-2, the presence of IL-21 during *in vitro* priming of CD8+ T cells results

30   in the development of effector cells with increased ability to lyse target cells and produce

IFNγ. These findings support a role for IL-21 in the generation of CD8+ T cell

responses.

Experimental Protocols

Reagents. Murine IL-21 was produced by transfection of COS cells and concentration of
the supernatant; activity was referenced to rmIL-21 (R&D Systems, Minneapolis, MN)
by bioassay. Equivalent volumes of concentrated mock transfectant supernatant were
used as a control. IL-21R.Fc was constructed linking the predicted extracellular domain
of human IL-21R to murine IgG2a carboxy tail with mutations to minimize Fc binding
and complement fixation. rhIL-2 (R&D Systems, Minneapolis, MN), rmIL-12 (Wyeth,
Cambridge, MA), rmIL-15 (R&D Systems), rmIL-21 (R&D Systems) were used as
indicated.

Mice. 2C TCR Tg mice whose TCR is specific for the Ld allo-antigen were bred and
maintained at Charles River Laboratories (Wilmington, MA).
RPAs

T cell assays. T cells were purified from 2C TCR Tg lymph nodes using negative
selection columns (R&D Systems) or sorted based on CD8 and CD62L expression.
Purified T cells (2x105/ml) were stimulated with plate-bound anti-CD3 mAb (2C11;
Wyeth, Cambridge, MA) or irradiated Balb/c splenocytes (2000R; 1-5x106/ml) and
cytokines as indicated. Proliferation was determined by 3H-thymidine incorporation
(1uCi/well). For priming, cultures were set as above with the indicated cytokines for 4-6
days. Cells were harvested, washed, counted and used in 4hr CTL assays with 5x103
51Cr-labeled P815 (specific) or EL4 (non-specific) targets at the effector:target ratios
noted or restimulated on anti-CD3 mAb coated plates (1ug/ml) for 40hrs.

IL-21R and IL-21 expression by CD8+ T cells. Previous reports have shown
lymphoid-restricted expression of IL-21R and IL-21 expression by activated human
CD4+ T cells. Using RNAse protection assays we have analyzed the expression of IL-
21R and IL-21 mRNA by naïve murine CD8+ T cells. CD8+CD62L+ 2C TCR+ cells
were sorted and stimulated with anti-CD3 mAb in the presence of mock- or IL-21-
transfected COS supernatant or anti-CD28 mAb and RNA was prepared for IL-21R or
IL-21 RNAse protection assays (Figure 27A).

88 .

Freshly isolated CD8+ T cells expressed IL-21R mRNA implying that these cells are capable of responding to IL-21. Quantitation of signal intensity relative to an internal standard showed that TCR-mediated activation resulted in ~2-fold increase in IL-21R mRNA levels (Figure 27A). TCR-activation with CD28 costimulation resulted in ~4-

5   fold increase of IL-21R mRNA, suggesting that physiologic, 2-signal activation of CD8+ T cells would result in up-regulation of IL-21R expression and increased sensitivity to IL-21. Interestingly, the presence of IL-21 during stimulation also induced a ~4-fold increase in IL-21R expression, providing evidence for a mechanism for IL-21 to amplify IL-21-responsiveness during CD8+ T cell activation. The expression of IL-21R by naïve

10   CD8+ T cells distinguishes it from receptors of other cytokines which also act on CD8+ T cells such as those for IL-2, IL-12 or IL-15 which require activation for expression. Nearly identical results were observed in non-transgenic CD8+ T cells (data not shown).

       IL-21 mRNA expression was analyzed from the same purified murine CD8+ T cells. Naive, anti-CD3, or anti-CD3/anti-CD28 mAb-activated murine CD8+ T cells

15   were found not express significant IL-21 mRNA (Figure 28B). This is in agreement with results using human CD8+ T cells and contrasts with observations in CD4+ T cells where activation has been shown to up-regulate IL-21 mRNA expression. Interestingly, stimulation with anti-CD3 mAb and exogenous IL-21 resulted in strong upregulation of IL-21 mRNA expression (2-fold after 36 hours and 8-fold after 60 hours of stimulation)

20   showing that CD8+ T cells are capable of producing this cytokine.

       Thus, CD8+ T cells express IL-21R mRNA, and in the presence of exogenous IL-21 up-regulate further IL-21R expression as well as de novo IL-21 expression. Activated CD4+ T cells are the likely source of the initial IL-21 driving these events. In this way, IL-21 is similar to IL-2 which is also produced predominantly by CD4+ T cells and

25   utilized by CD8+ T cells. Our results suggest a mechanism exists for maintaining IL-21 responsiveness during CD8+ T cell activation independent of CD4+ T cell-derived IL-21.
       IL-21 enhances proliferation of CD8+ T cells.

       IL-21 has been shown to augment the proliferation of human B cells stimulated with anti-CD40 and human and murine T cells stimulated with immobilized anti-CD3

30   mAb [1, 2]. Here, we analyzed the effect of IL-21 on antigen-stimulation of purified CD8+ murine T cells and found that proliferation of 2C CD8+ T cells was enhanced by

IL-21 in a dose-dependent manner (Figure 29A). IL-21 exhibited similar potency to IL-15, but was not as potent as IL-2 or IL-12 (Figure 29B).

Because IL-21 can affect B cell function [1], the next experiment assesses whether IL-21 was augmenting 2C CD8+ T cell proliferation by acting directly on T cells
5   or indirectly via effects on the APCs in this system. Purified 2C CD8+ T cells were stimulated with immobilized anti-CD3 mAb in the presence of increasing amounts of IL-21 (Figure 28C). As with antigen responses, IL-21 enhanced CD8+ T cell proliferation to anti-CD3 stimulation in a dose-dependent manner. While this does not rule out a possible effect of IL-21 on APCs, it does support that this cytokine can act directly on T
10   cells to modulate their function. Comparison of cytokine effects using anti-CD3 stimulation of CD8+ T cells revealed that IL-21 and IL-15 induce similar levels of proliferation, however IL-2 and IL-12 are more potent than IL-21 at inducing proliferation (Figure 28D).

Because the IL-21 used in the majority of these studies was supernatant
15   concentrated from COS transfectants, an IL-21R.Fc fusion protein was used to specifically neutralize IL-21 responses. ELISAs were done to show that mIL-21R.Fc bound to mIL-21, and that it was capable of neutralizing binding of IL-21 to its receptor (data not shown). 2C CD8+ T cells were stimulated with immobilized anti-CD3 mAb and increasing amounts of IL-21 in the presence or absence of IL-21R.Fc (Figure 28C).
20   IL-21-induced responsiveness was inhibited by the addition of soluble IL-21R.Fc showing that the enhanced proliferation observed in the presence of IL-21-transfectant supernatant was specifically due to IL-21. IL-21R.Fc had no effect on IL-2 or IL-15-mediated proliferation (data not shown).

IL-21 specifically enhanced antigen-induced proliferation of murine CD8+ T
25   cells, on average resulting in 3-fold and 6-fold increased proliferation with antigen or anti-CD3 stimulation, respectively (n=5). This may be the result of comparatively lower levels of IL-21R expression, competition for gammac in the case of IL-2 and IL-15, or the biological effect of this cytokine. The data shown here extends our previous results showing IL-21 enhanced proliferation of allo-antigen stimulation of unseparated T cells
30   and underscores the potential importance of IL-21 in physiologic responses mediated by CD8+ T cells. In contrast to its ability to potentiate CD8+ T cell proliferation, IL-21 does not support the growth of murine NK cells and inhibits IL-15-mediated NK cell

growth. These results suggest that IL-21 may activate distinct signaling programs in different cell types. In agreement with results using unseparated T cells, it was found that IL-21 was most effective at augmenting the proliferation of purified CD8+ T cells at suboptimal levels of anti-CD3 or antigen stimulation (data not shown). This suggests

5   that IL-21 serves as an accessory signal enhancing the sensitivity of cells responding to limiting antigen. Like IL-2, IL-21 is made by activated CD4+ T cells and acts on CD8+ T cells to enhance their proliferation and may contribute to the T-helper activity attributed to CD4+ T cells. Thus, although IL-21 does enhance CD8+ T cell proliferation it is not as potent as T-cell-derived IL-2 or macrophage-derived IL-12 suggesting non-

10 redundant roles for these cytokines.

IL-21 enhances lytic activity of CD8+ effector T cells.

Having demonstrated that IL-21 enhances CD8+ T cell proliferation, we next examined the effects of IL-21 on CD8+ T cell differentiation. 2C TCR Tg CD8+ T cells were primed in vitro in the presence of the indicated cytokine(s) then harvested and equal

15 numbers of cells were assayed for CTL activity (Figure 29A). The presence of IL-21 during priming resulted in the generation of CD8+ effector T cells with higher lytic activity on a per cell basis than cells primed in the absence of IL-21. This increased lytic activity was even more pronounced when IL-2 was also present during priming (Figure 29B). None of these priming conditions resulted in the ability to kill non-specific target

20 cells (data not shown). Thus, IL-21 potently enhances the development of antigen-specific CD8+ T cell effector function. Other cytokines such as IL-12 and IL-15 have also been shown to enhance CTL differentiation. IL-21 was compared to these cytokines and was comparable in its ability to induce potent CTLs (Figure 29B).

Previously, we have shown that IL-21 can augment IL-15-induced development

25 of allo-antigen specific CTL and IL-15-induced NK lytic activity. The data presented here, using defined antigen-specific priming and target cells, extends this result by showing that IL-21 alone or in combination with IL-2 can enhance CTL development from naïve CD8+ T cells. Several mechanisms could account for this including increased sensitivity to antigen levels, increased expression of adhesion molecules or

30 increased expression of granule enzymes. Studies are underway to examine these possibilities, preliminary data suggests that IL-21 induced higher granzyme A mRNA expression. Importantly, although IL-2 was much more potent than IL-21 in stimulating

CD8+ T cell proliferation, priming in the presence of IL-21 generated significantly more lytic activity. Despite the fact they share homology, a receptor chain and are both made by CD4+ T cells, the findings presented here underscore the unique roles of IL-2 and IL-21 and suggest an important role for IL-21 in the generation of CD8+ T cell responses.

5   *IL-21 CD8+ T cell IFNgamma (or IFNg) production.*

In addition to CTL activity, differentiated CD8+ effector T cells secrete high levels of IFN□ when restimulated with antigen. Therefore, we analyzed whether IL-21 present during priming modulated the ability of CD8+ T cells to produce IFNg and compared this to other cytokines known to affect CD8+ T cell responses. 2C TCR Tg T

10   cells were primed with antigen/APCs, IL-2 and the indicated cytokine for 5 days then equal numbers of cells were restimulated with anti-CD3 mAb (Figure 29C). IL-21 treatment during CD8+ T cell priming resulted in the generation of cells producing higher titers of IFNg than cells primed in the absence of IL-21 (13-fold increase). Using cytokine doses that generated equivalent CTL activity, CD8+ T cells primed in the

15   presence of IL-12 or IL-21 produced similar titers of IFNg IL-15 was most effective at inducing IFNg producing CD8+ T cells. As both IL-15 and IL-21 similarly enhanced the development of CD8+ T cell lytic activity (Figure 29B), this differential ability to induce IFNgamma production suggests non-redundant roles for these related cytokines. These results are particularly interesting as IL-21 has recently been shown to antagonize IL-12-

20   induced IFNgamma production by CD4+ T cells. Thus, IL-21 plays opposing roles in the differentiation of CD4+ and CD8+ T cells into IFNg-producing cells. This is consistent with the ability of CD8+ T cells to produce IFNg in an IL-12/Stat4 independent manner. In conclusion, exposure to IL-21 results in increased ability to secrete IFNg consistent with its role as differentiation factor for CD8+ T cells.

25   The experiments described herein show that IL-21 is a potent growth and differentiation factor for CD8+ T cells responding to antigen. IL-21R-deficient animals have functional CD8+ T cells. This finding, coupled with the data presented herein, implies that IL-21 responses are not required for CD8+ T cell development/maintenance but rather that IL-21 augments the generation of effector function. Like IL-2, IL-21 is

30   made by activated CD4+ T cells and our results comparing the actions of these two cytokines suggest that although IL-2 potently drives the proliferation of CD8+ T cells, IL-21 is much more effective at promoting CD8+ T effector differentiation. Recently,

IL-21 has been shown to be produced primarily by Th2 cells, suggesting a mechanism for the development IFNg-producing CTLs during Th2 responses. IL-15 is similar to IL-21 in its ability to induce naïve cell proliferation and CTL development but is much more effective at eliciting IFNg production. Like IL-2, IL-12 also induces strong CD8+ T cell

5   proliferation and like IL-21 it induces potent CTL activity and IFNg production. Thus IL-2, IL-12, IL-15 and IL-21 are effective at enhancing different aspects of naïve CD8+ T cell responses. In addition, these cytokines are made by different cell types: IL-2 and IL-21 are secreted by activated CD4+ T cells while IL-12 is made by activated macrophages and IL-15 is produced by stromal cells, endothelial cells as well as macrophages. Taken

10   together, this suggests that IL-2, IL-12, IL-15 and IL-21 act at distinct phases and sites of immune responses are not redundant. We have previously proposed that IL-21 may be a mediator of the transition between innate and adaptive immune responses, the data presented here showing enhancement of CD8+ T cell responses support this hypothesis. Given its potent effects on CD8+ T cells, it will be interesting to analyze the role of IL-

15   21 in CD8+ responses to tumors and viral infections *in vivo*.

Example 11:Primary Macrophages Express IL-21R and Respond to IL-21 by Proliferating and Secreting Increased Levels of Cytokines and Chemokines

This Example describes the finding that IL-21 acts as a proliferation factor for

20   hematopoietic cells specifically promoting the growth of macrophages and bone marrow progenitor cells.

The effect of IL-21 alone and in combination with other factors in modulating hematopoeitic cell growth was examined. It was found that IL-21 acts as a proliferation factor for mouse and human hematopoietic cells specifically promoting the growth of

25   macrophage colonies in methylcellulose from lineage negative murine bone marrow progenitors. IL-21 also acts to enhance proliferation of human CD34+ cells and results in increased expression of the macrophage specific marker CD14. Utilizing CD14+ cells sorted from human bone marrow, it has been shown by RNAse Protection Analysis (RPA) that the IL-21R is expressed on macrophages, and is upregulated by TNF and IL-1

30   following growth in GMCSF. Thus, suggesting a role of other inflammatory cytokines in regulating IL-21 responsiveness. Expression of IL-21R protein on mouse and human macrophages has been detected using FACS analysis. IL-21 acts directly on these cells

resulting in activation, growth and increased secretion of chemokines and cytokines. Taken together, these results show that the IL-21/IL-21R complex is important in regulating macrophage growth and function, and in influencing macrophage responses at inflammatory sites.

5   The contents of all references, pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention

10   described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed is:

1. A method of treating or preventing an arthritic disorder, in a subject, comprising administering to the subject an IL-21/IL-21R antagonist, in an amount sufficient to

5   inhibit or reduce immune cell activity in the subject, thereby treating or preventing the arthritic disorder.

2. A method of treating or preventing an arthritic disorder, in a subject, comprising, administering to the subject an IL-21/IL-21R antagonist in combination with another

10   therapeutic agent, in an amount sufficient to inhibit or reduce immune cell activity in the subject, thereby treating or preventing the arthritic disorder.

3. The method of claim 2, wherein the therapeutic agent is selected from the group consisting of a cytokine inhibitor, a growth factor inhibitor, an immunosuppressant, an

15   anti-inflammatory agent, a metabolic inhibitor, an enzyme inhibitor, a cytotoxic agent, and a cytostatic agent.

4. The method of claim 2, wherein the therapeutic agent is selected from the group consisting of a TNF antagonist, an IL-12 antagonist, an IL-15 antagonist, an IL-17

20   antagonist, an IL-18 antagonist, an IL-22 antagonist, a T cell depleting agent, a B cell depleting agent, methotrexate, leflunomide, sirolimus (rapamycin) or an analog thereof, a Cox-2 inhibitor, a cPLA2 inhibitor, an NSAID, and a p38 inhibitor.

5. The method of claim 4, wherein the TNF antagonist is a soluble fragments of a TNF

25   receptor.

6. The method of claim 4, wherein the TNF antagonist is a p75 human TNF receptor-IgG fusion protein.

30   7. The method of claim 4, wherein the therapeutic agent is an IL-15 antagonist.

8. The method of claim 4, wherein the therapeutic agent is methotrexate or leflunomide.

9. The method of claim 4, wherein the rapamycin analog is CCI-779.

10. The method of any of claims 1-9, wherein the arthritic disorder is selected from the
group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis,
psoriatic arthritis, and ankylosing spondylitis.

11. The method of claim 10, wherein the arthritic disorder is rheumatoid arthritis.

12. The method of claim 10, wherein the arthritic disorder is selected from the group
consisting of juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and
ankylosing spondylitis.

13. The method of either of claim 1 or 2, wherein the subject is a mammal.

14. The method of claim 13, wherein the subject is a human.

15. The method of any of claim 1-14, wherein the IL-21/IL-21R antagonist is an anti-
IL21R or anti-IL21 antibody, or an antigen-binding fragment thereof.

16. The method of any of claim 1-14, wherein the IL-21/IL-21R antagonist comprises a
fragment of a human IL-21 receptor (IL-21R) polypeptide.

17. The method of claim 16, wherein the fragment comprises the extracellular domain of
human IL-21R and an Fc fragment of a human immunoglobulin (Ig).

18. The method of claim 17, wherein the extracellular domain of human IL-21R
comprises about amino acids 20-235 of SEQ ID NO:2.

19. The method of claim 18, wherein the extracellular domain of human IL-21R
comprises about amino acids 1-235 of SEQ ID NO:2.

20. The method of claim 19, wherein the extracellular domain of human IL-21R comprises about amino acids 1-235 of SEQ ID NO:2 and an Fc fragment of a human IgG1.

5   21. The method of claim 17, wherein the Fc fragment does not bind to an Fc receptor.

22. The method of claim 16, wherein the IL-21/IL-21R antagonist comprises the amino acid sequence of SEQ ID NO:29 (Figures 10A-10C), or a sequence at least 90% or more identical thereto.

10

23. The method of claim 16, wherein the IL-21/IL-21R antagonist comprises the amino acid sequence of SEQ ID NO:25 (Figures 8A-8C), or a sequence at least 90% or more identical thereto.

15   24. A method of treating or preventing a cancer or an infectious disorder, in a subject, comprising, administering to the subject an IL-21/IL-21R agonist, in an amount sufficient to increase immune cell activity, thereby treating or preventing said disorder.

25. The method of claim 24, wherein the immune cell is a CD8+ cell, and the activity is
20   increased effector cell activity.

26. The method of claim 24, wherein the cancer is selected from the group consiting of a solid tumor, a soft tissue tumor, and a metastatic lesion.

25   26. The method of claim 24, wherein the infectious disorder is a bacterial, viral or parasitic infection.

27. The method of claim 24, wherein the IL-21/IL-21R agonist is administered alone.

30   28. The method of claim 24, wherein the IL-21/IL-21R agonist is administered in combination with an antigen from a cancer or tumor cell, or a pathogen.

29. A method for increasing the ability of a vaccine composition containing an antigen to elicit a protective immune response in a subject against the antigen, comprising administering to the subject, either simultaneously with or sequentially, to the vaccine composition, an effective adjuvanting amount of an IL-21/IL-21R agonist, such that the ability of the vaccine composition to elicit the protective immune is increased.

30. The method of claim 29, wherein the antigen is from a pathogen selected from the group consisting of a virus, bacterium, and protozoan.

31. The method of claim 29, wherein the antigen is from a cancer or tumor cell antigen.

32. The method of claim 31, wherein the antigen is expressed on the surface of a cancer cell.

33. The method of any of claim 24-32, wherein the IL-21/IL-21R agonist is administered in combination with one or more cytokines chosen from IL-2, GM-CSF or IL-15.

34. The method of any of claim 24-32, wherein the subject is a mammal.

35. The method of claim 34, wherein the subject is a human.

36. The method of any of claim 24-35, wherein the IL-21/IL-21R agonist is a human IL-21 polypeptide comprising the amino acid sequence shown as SEQ ID NO:19, or a sequence at least 90% or more identical thereto.

37. A method for modulating the activity of an immune cell chosen from one or more of a mature CD8+ T cell, CD4+ T cell, mature NK cell, macrophage or megakaryocyte, comprising contacting the immune cell, with an IL-21/IL-21R agonist or antagonist, in an amount sufficient to modulate immune cell activity.

38. A fusion protein comprising an extracellular domain of human IL-21R and an Fc fragment of a human immunoglobulin (Ig).

39. The fusion protein of claim 38, wherein the extracellular domain of human IL-21R comprises about amino acids 20-235 of SEQ ID NO:2.

5   40. The fusion protein of claim 38, wherein the extracellular domain of human IL-21R comprises about amino acids 1-235 of SEQ ID NO:2.

41. The fusion protein of claim 38, wherein the extracellular domain of human IL-21R comprises about amino acids 1-235 of SEQ ID NO:2 and an Fc fragment of a human

10   IgG1.

42. The fusion protein of claim 38, wherein the Fc fragment does not bind to an Fc receptor.

15   43. The fusion protein of claim 38, wherein the IL-21/IL-21R antagonist comprises the amino acid sequence of SEQ ID NO:29 (Figures 10A-10C), or a sequence at least 90% or more identical thereto.

44. The fusion protein of claim 38, wherein the IL-21/IL-21R antagonist comprises the

20   amino acid sequence of SEQ ID NO:25 (Figures 8A-8C), or a sequence at least 90% or more identical thereto.

45. A host cell comprising a nucleotide sequence encoding the fusion protein of claim 38.

25   46. An vector comprising a nucleotide sequence encoding the fusion protein of claim 38.

47. A process for producing the fusion protein of claim 38, comprising, (a) growing a culture of the host cell of the present invention in a suitable culture medium; and (b) purifying the fusion protein from the culture.

30

48. A pharmaceutical composition comprising an IL-21/IL-21R antagonist and a therapeutic agent selected from the group consisting of a cytokine inhibitor, a growth

factor inhibitor, an immunosuppressant, an anti-inflammatory agent, a metabolic
inhibitor, an enzyme inhibitor, a cytotoxic agent, and a cytostatic agent, in a
pharmaceutically acceptable carrier.

5   49. The pharmaceutical composition of claim 48, wherein the therapeutic agent is
selected from the group consisting of a TNF antagonist, an IL-12 antagonist, an IL-15
antagonist, an IL-17 antagonist, an IL-18 antagonist, an IL-22 antagonist, a T cell
depleting agent, a B cell depleting agent, methotrexate, leflunomide, sirolimus
(rapamycin) or an analog thereof, a Cox-2 inhibitor, a cPLA2 inhibitor, an NSAID, and a
10   p38 inhibitor.

50. The pharmaceutical composition of claim 49, wherein the TNF antagonist is a soluble
fragments of a TNF receptor.

15   51. The pharmaceutical composition of claim 50, wherein the TNF antagonist is a p75
human TNF receptor-IgG fusion protein.

52. The pharmaceutical composition of claim 50, wherein the therapeutic agent is an IL-
15 antagonist.

20
53. The pharmaceutical composition of claim 50, wherein the therapeutic agent is
methotrexate or leflunomide.

54. The pharmaceutical composition of claim 50, wherein the rapamycin analog is CCI-
25   779.

55. The pharmaceutical composition of any of claim 50-54, wherein the IL-21/IL-21R
antagonist is an anti-IL-21- or an anti-IL-21R antibody, or a fragment of a human IL-21R.

30

56. The pharmaceutical composition of claim 55, wherein the IL-21/IL-21R antagonist comprises the extracellular domain of human IL-21R and an Fc fragment of a human immunoglobulin (Ig).

5 57. The pharmaceutical composition of claim 56, wherein the extracellular domain of human IL-21R comprises about amino acids 20-235 of SEQ ID NO:2.

58. The pharmaceutical composition of claim 56, wherein the extracellular domain of human IL-21R comprises about amino acids 1-235 of SEQ ID NO:2.

10

59. The pharmaceutical composition of claim 56, wherein the extracellular domain of human IL-21R comprises about amino acids 1-235 of SEQ ID NO:2 and an Fc fragment of a human IgG1.

15 60. The pharmaceutical composition of claim 59, wherein the Fc fragment does not bind to an Fc receptor.

61. The pharmaceutical composition of claim 50, wherein the IL-21/IL-21R antagonist comprises the amino acid sequence of SEQ ID NO:29 (Figures 10A-10C), or a sequence

20 at least 90% or more identical thereto.

61. The pharmaceutical composition of claim 50, wherein the IL-21/IL-21R antagonist comprises the amino acid sequence of SEQ ID NO:25 (Figures 8A-8C), or a sequence at least 90% or more identical thereto.

25

62. A pharmaceutical composition useful as a vaccine, comprising an antigen from a pathogenic microorganism selected from the group consisting of a viral, bacterial and parasitic microorganism, and an effective adjuvanting amount of an IL-21/IL-21R agonist, in a pharmaceutically acceptable carrier.

30

63. A pharmaceutical composition comprising a cancer cell- or tumor cell-antigen in combination with an IL-21/IL-21R agonist, in a pharmaceutically acceptable carrier.

FIG.1

```
   1  GTCGACGGGG-CGGTACCAEC TGTCTGCCCA CTTCTCCTGT GGTGTGCCTC

  51  ACGGTCACTT GCTTGTCTGA CCGCAAGTCT GCCCATCCCT GGGGCAGCCA

 101  ACTGGCCTCA GCCCGTGCCC CAGGCGTGCC CTGTCTCTGT CTGGCTGCCC

 151  CAGCCCTACT GTCTTCCTCT GTGTAGGCTC TGCCCAGATG CCCGGCTGGT

 201  CCTCAGCCTC AGGACTATCT CAGCAGTGAC TCCCCTGATT CTGGACTTGC

 251  ACCTGACTGA ACTCCTGCCC ACCTCAAACC TTCACCTCCC ACCACCACCA

 301  CTCCGAGTCC CGCTGTGACT CCCACGCCCA GGAGACCACC CAAGTGCCCC

 351  AGCCTAAAGA ATGGCTTTCT GAGAAAGACC CTGAAGGAGT AGGTCTGGGA

 401  CACAGCATGC CCCGGGGCCC AGTGGCTGCC TTACTCCTGC TGATTCTCCA

 451  TGGAGCTTGG AGCTGCCTGG ACCTCACTTG CTACACTGAC TACCTCTGGA

 501  CCATCACCTG TGTCCTGGAG ACACGGAGCC CCAACCCCAG CATACTCAGT

 551  CTCACCTGGC AAGATGAATA TGAGGAACTT CAGGACCAAG AGACCTTCTG

 601  CAGCCTACAC AGGTCTGGCC ACAACACCAC ACATATATGG TACACGTGCC

 651  ATATGCGCTT GTCTCAATTC CTGTCCGATG AAGTTTTCAT TGTCAATGTG

 701  ACGGACCAGT CTGGCAACAA CTCCCAAGAG TGTGGCAGCT TTGTCCTGGC

 751  TGAGAGCATC AAACCAGCTC CCCCCTTGAA CGTGACTGTG GCCTTCTCAG

 801  GACGCTATGA TATCTCCTGG GACTCAGCTT ATGACGAACC CTCCAACTAC

 851  GTGCTGAGGG GCAAGCTACA ATATGAGCTG CAGTATCGGA ACCTCAGAGA

 901  CCCCTATGCT GTGAGGCCGG TGACCAAGCT GATCTCAGTG GACTCAAGAA

 951  ACGTCTCTCT TCTCCCTGAA GAGTTCCACA AAGATTCTAG CTACCAGCTG

1001  CAGGTGCGGG CAGCGCCTCA GCCAGGCACT TCATTCAGGG GGACCTGGAG

1051  TGAGTGGAGT GACCCCGTCA TCTTTCAGAC CCAGGCTGGG GAGCCCGAGG

1101  CAGGCTGGGA CCCTCACATG CTGCTGCTCC TGGCTGTCTT GATCATTGTC

1151  CTGGTTTTCA TGGGTCTGAA GATCCACCTG CCTTGGAGGC TATGGAAAAA

1201  GATATGGGCA CCAGTGCCCA CCCCTGAGAG TTTCTTCCAG CCCCTGTACA

1251  GGGAGCACAG CGGGAACTTC AAGAAATGGG TTAATACCCC TTTCACGGCC

1301  TCCAGCATAG AGTTGGTGCC ACAGAGTTCC ACAACAACAT CAGCCTTACA

1351  TCTGTCATTG TATCCAGCCA AGGAGAAGAA GTTCCCGGGG CTGCCGGGTC

1401  TGGAAGAGCA ACTGGAGTGT GATGGAATGT CTGAGCCTGG TCACTGGTGC
```

FIG.1 (continued)

```
1451   ATAATCCCCT TGGCAGCTGG CCAAGCGGTC TCAGCCTACA GTGAGGAGAG

1501   AGACCGGCCA TATGGTCTGG TGTCCATTGA CACAGTGACT GTGGGAGATG

1551   CAGAGGGCCT GTGTGTCTGG CCCTGTAGCT GTGAGGATGA TGGCTATCCA

1601   GCCATGAACC TGGATGCTGG CCGAGAGTCT GGCCCTAATT CAGAGGATCT

1651   GCTCTTGGTC ACAGACCCTG CTTTTCTGTC TTGCGGCTGT GTCTCAGGTA

1701   GTGGTCTCAG GCTTGGAGGC TCCCCAGGCA GCCTACTGGA CAGGTTGAGG

1751   CTGTCATTTG CAAAGGAAGG GGACTGGACA GCAGACCCAA CCTGGAGAAC

1801   TGGGTCCCCA GGAGGGGGCT CTGAGAGTGA AGCAGGTTCC CCCCCTGGTC

1851   TGGACATGGA CACATTTGAC AGTGGCTTTG CAGGTTCAGA CTGTGGCAGC

1901   CCCGTGGAGA CTGATGAAGG ACCCCCTCGA AGCTATCTCC GCCAGTGGGT

1951   GGTCAGGACC CCTCCACCTG TGGACAGTGG AGCCCAGAGC AGCTAGCATA

2001   TAATAACCAG CTATAGTGAG AAGAGGCCTC TGAGCCTGGC ATTTACAGTG

2051   TGAACATGTA GGGGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG

2101   TGTGTGTGTG TGTGTGTGTG TGTCTTGGGT TGTGTGTTAG CACATCCATG

2151   TTGGGATTTG GTCTGTTGCT ATGTATTGTA ATGCTAAATT CTCTACCCAA

2201   AGTTCTAGGC CTACGAGTGA ATTCTCATGT TTACAAACTT GCTGTGTAAA

2251   CCTTGTTCCT TAATTTAATA CCATTGGTTA AATAAAATTG GCTGCAACCA

2301   ATTACTGGAG GGATTAGAGG TAGGGGGCTT TTGAGTTACC TGTTTGGAGA

2351   TGGAGAAGGA GAGAGGAGAG ACCAAGAGGA GAAGGAGGAA GGAGAGGAGA

2401   GGAGAGGAGA GGAGAGGAGA GGAGAGGAGA GGAGAGGAGA GGAGAGGAGA

2451   GGCTGCCGTG AGGGGAGAGG GACCATGAGC CTGTGGCCAG GAGAAACAGC

2501   AAGTATCTGG GGTACACTGG TGAGGAGGTG GCCAGGCCAG CAGTTAGAAG

2551   AGTAGATTAG GGGTGACCTC CAGTATTTGT CAAAGCCAAT TAAAATAACA

2601   AAAAAAAAAA AAAAGCGGCC GCTCTAGA
```

FIG.2A

```
  1   MPRGPVAALL   LLILHGAWSC   LDLTCYTDYL   WTITCVLETR   SPNPSILSLT

 51   WQDEYEELQD   QETFCSLHRS   GHNTTHIWYT   CHMRLSQFLS   DEVFIVNVTD

101   QSGNNSQECG   SFVLAESIKP   APPLNVTVAF   SGRYDISWDS   AYDEPSNYVL

151   RGKLQYELQY   RNLRDPYAVR   PVTKLISVDS   RNVSLLPEEF   HKDSSYQLQV

201   RAAPQPGTSF   RGTWSEWSDP   VIFQTQAGEP   EAGWDPHMLL   LLAVLIIVLV

251   FMGLKIHLPW   RLWKKIWAPV   PTPESFFQPL   YREHSGNFKK   WVNTPFTASS

301   IELVPQSSTT   TSALHLSLYP   AKEKKFPGLP   GLEEQLECDG   MSEPGHWCII

351   PLAAGQAVSA   YSEERDRPYG   LVSIDTVTVG   DAEGLCVWPC   SCEDDGYPAM

401   NLDAGRESGP   NSEDLLLVTD   PAFLSCGCVS   GSGLRLGGSP   GSLLDRLRLS

451   FAKEGDWTAD   PTWRTGSPGG   GSESEAGSPP   GLDMDTFDSG   FAGSDCGSPV

501   ETDEGPPRSY   LRQWVVRTPP   PVDSGAQSS
```

Figure 2B

FIG.3

```
huMU-1    ..................NNGTCGACTGGAGGCCCAGCTGCCCGTCATCA 32
                          ::|| |       |||||| ||||||| |
murMU-1   CAGCCCTACTGTCTTCCTCTGTGTAGGCTCTGCCCAGATGCCCGGC.... 196

huMU-1    GAGTGACAGGTCTTATGACAGCCTGATTGGTGACTCGGGCTGGGTGTGGA 82
              ||    | || | |||   || |  ||||||||   ||| | ||||
murMU-1   TGGTCCTCAGCCTCAGGACTATCTCAGCAGTGACTC.CCCTGATTCTGGA 245

huMU-1    TTCTCACCCCAGGCCTCTGCCTGCTTTCTCAGACCCTCATCT...GTCAC 129
           |  |||| |     || |   |    |||| ||| ||| ||    |||
murMU-1   CTTGCACCTGACTGAACTCCTGCCCACCTCAAACCTTCACCTCCCACCAC 295

huMU-1    CCCCACGCTGAACCCAGCTG......CCACCCCCAGAAGCCCATCAGACT 173
           | |||| | || ||| ||||      |||| ||||| || ||| |  | |
murMU-1   CACCACTCCGAGTCCCGCTGTGACTCCCACGCCCAGGAGACCACCCAAGT 345

huMU-1    GCCCCCAGCACACGGAATGGATTTCTGAGAAAGAAGCCGAAACAGAAGGC 223
          | |||||||  |  ||||||| |||||||||||||| | ||| || |||
murMU-1   G.CCCCAGCCTAAAGAATGGCTTTCTGAGAAAGACCCTGAAGGAGTAGGT 394

huMU-1    CCGTGGGAGTCAGCATGCCGCGTGGCTGGGCCGCCCCCTTGCTCCTGCTG 273
          |  ||||||  ||||||||| |||| || |||    ||||| |||||||||
murMU-1   C..TGGGACACAGCATGCCCCGGGGCCCAGTGGCTGCCTTACTCCTGCTG 442

huMU-1    .CTGCTCCAGGGAGGCTGGGGCTGCCCCGACCTCGTCTGCTACACCGATTA 323
            | |||||| ||||   ||| ||||||| |||||   ||||||| || ||
murMU-1   ATTCTCCATGGAGCTTGGAGCTGCCTGGACCTCACTTGCTACACTGACTA 492

huMU-1    CCTCCAGACGGTCATCTGCATCCTGGAAATGTGGAACCTCCACCCCAGCA 373
          ||||   |||   ||| |||  |||||||| |    ||| || |  |||||||||
murMU-1   CCTCTGGACCATCACCTGTGTCCTGGAGACACGGAGCCCCAACCCCAGCA 542

huMU-1    CGCTCACCCTTACCTGGCAAGACCAGTATGAAGAGCTGAAGGACGAGGCC 423
          ||||   || ||||||||||||   | |||||| || || ||||| | ·|
murMU-1   TACTCAGTCTCACCTGGCAAGATGAATATGAGGAACTTCAGGACCAAGAG 592

huMU-1    ACCTCCTGCAGCCTCCACAGGTCGGCCCACAATGCCACGCATGCCACCTA 473
          ||||  ||||||||| ||||||||  |·||||||    ||||  |||       ||
murMU-1   ACCTTCTGCAGCCTACACAGGTCTGGCCACAACACCACACATATATGGTA 642

huMU-1    CACCTGCCACATGGATGTATTCCACTTCATGGCCGACGACATTTTCAGTG 523
          ||| |||||| |||     | |  || ||| || |||| |  ||||||| ||
murMU-1   CACGTGCCATATGCGCTTGTCTCAATTCCTGTCCGATGAAGTTTTCATTG 692

huMU-1    TCAACATCACAGACCAGTCTGGCAACTACTCCCAGGAGTGTGGCAGCTTT 573
          ||||  |  || |||||||||||||||  ||||||| |||||||||||||||
murMU-1   TCAATGTGACGGACCAGTCTGGCAACAACTCCCAAGAGTGTGGCAGCTTT 742

huMU-1    CTCCTGGCTGAGAGCATCAAGCCGGCTCCCCCTTTCAACGTGACTGTGAC 623
          ||||||||||||||||||||| || ||||||||| || |||||||||||| |
murMU-1   GTCCTGGCTGAGAGCATCAAACCAGCTCCCCCCTTGAACGTGACTGTGGC 792

huMU-1    CTTCTCAGGACAGTATAATATCTCCTGGCGCTCAGATTACGAAGACCCTG 673
          |||||||||| ||| ||| || ||||||||||  ||||| ||| ||  || ||
murMU-1   CTTCTCAGGACGCTATGATATCTCCTGGGACTCAGCTTATGACGAACCCT 842

huMU-1    CCTTCTACATGCTGAAGGGCAAGCTTCAGTATGAGCTGCAGTACAGGAAC 723
          ||  |||| |||||| |||||||| || |||||||||||||||||  |||||
murMU-1   CCAACTACGTGCTGAGGGGCAAGCTACAATATGAGCTGCAGTATCGGAAC 892

huMU-1    CGGGGAGACCCCTGGGCTGTGAGTCCGAGGAGAAAGCTGATCTCAGTGGA 773
          |  |||||||||  ||||||||   || ||  |||||||||||||||||||
murMU-1   CTCAGAGACCCCTATGCTGTGAGGCCGGTGACCAAGCTGATCTCAGTGGA 942

huMU-1    CTCAAGAAGTGTCTCCCTCCTCCCCCTGGAGTTCCGCAAAGACTCGAGCT 823
```

FIG.3 (continued)

```
                IIIIIIII  IIIII II IIIII    IIIIIII IIIIII II IIII
murMU-1    CTCAAGAAACGTCTCTCTTCTCCCTGAAGAGTTCCACAAAGATTCTAGCT 992

huMU-1     ATGAGCTGCAGGTGCGGGCAGGGCCCATGCCTGGCTCCTCCTACCAGGGG 873
           i  iiiiiiiiiiiiiiiii iii   iii iii i ii i i  iiii
murMU-1    ACCAGCTGCAGGTGCGGGCAGCGCCTCAGCCAGGCACTTCATTCAGGGGG 1042

huMU-1     ACCTGGAGTGAATGGAGTGACCCGGTCATCTTTCAGACCCAGTCAGAGGA 923
           IIIIIIIIIII IIIIIIIIIII IIIIIIIIIIIIIIIIII I I III
murMU-1    ACCTGGAGTGAGTGGAGTGACCCCGTCATCTTTCAGACCCAGGCTGGGGA 1092

huMU-1     GTTAAAGGAAGGCTGGAACCCTCACCTGCTGCTTCTCCTCCTGCTTGTCA 973
           I   III IIIIIII IIIIIIII IIIII   II IIIIII IIII
murMU-1    GCCCGAGGCAGGCTGGGACCCTCACATGCTG...CTGCTCCTGGCTGTCT 1139

huMU-1     TAGTCTTCATTCCTGCCTTCTGGAGCCTGAAGACCCATCCATTGTGGAGG 1023
           I  II I  I I  I  III  I I IIIIIIII III I   IIIIII
murMU-1    TGATCATTGTCCTGGTTTTCATGGGTCTGAAGATCCACCTGCCTTGGAGG 1189

huMU-1     CTATGGAAGAAGATATGGG...CCGTCCCCAGCCCTGAGCGGTTCTTCAT 1070
           IIIIIIII IIIIIIIII   I II IIII IIIIII I IIIIII
murMU-1    CTATGGAAAAAGATATGGGCACCAGTGCCCACCCCTGAGAGTTTCTTCCA 1239

huMU-1     GCCCCTGTACAAGGGCTGCAGCGGAGACTTCAAGAAATGGGTGGGTGCAC 1120
           IIIIIIIIIII II    IIIIII IIIIIIIIIIIIIIIII I I I
murMU-1    GCCCCTGTACAGGGAGCACAGCGGGAACTTCAAGAAATGGGTTAATACCC 1289

huMU-1     CCTTCACTGGCTCCAGCCTGGAGCTGGGACCCTGGAGCCCAGAGGTGCCC 1170
           I IIIIII I IIIIIII I III III  II   III I        I
murMU-1    CTTTCACGGCCTCCAGCATAGAGTTGGTGCCACAGAGTTCCACAACAACA 1339

huMU-1     TCCACCCTGGAGGTGTACAGCTGCCACCCACCACGGAGCCCGGCCAAGAG 1220
           II  II I  I  III          II  I  II IIIIII
murMU-1    TCAGCCTTACATCTGT...............CATTGTATCCAGCCAAGGA 1374

huMU-1     GCTGCAGCTCACGGAGCTACAAGAACCAGCAGAGCTGGTGGAGTCTGACG 1270
           I  I II II III III I  I  I  I IIIII   IIIIII III I
murMU-1    GAAGAAGTTCCCGGGGGCTGCCGGGTCTGGAAGAGCAACTGGAGTGTGATG 1424

huMU-1     GTGTGCCCAAGCCCAGCTTCTGG.........CCGACAGCCCAGAACTCG 1311
           I  II I  IIII I  IIII     II  II       I
murMU-1    GAATGTCTGAGCCTGGTCACTGGTGCATAATCCCCTTGGCAGCTGGCCAA 1474

huMU-1     GGGGGCTCAGCTTACAGTGAGGAGAGGGATCGGCCATACGGCCTGGTGTC 1361
           I II IIIIII IIIIIIIIIIIIIII II IIIIIIII II IIIIIIII
murMU-1    GCGGTCTCAGCCTACAGTGAGGAGAGAGACCGGCCATATGGTCTGGTGTC 1524

huMU-1     CATTGACACAGTGACTGTGCTAGATGCAGAGGGGCCCATGCACCTGGCCCT 1411
           IIIIIIIIIIIIIIIIIII IIIIIIIIIIII I II  IIIIIIII
murMU-1    CATTGACACAGTGACTGTGGGAGATGCAGAGGGCCTGTGTGTCTGGCCCT 1574

huMU-1     GCAGCTGTGAGGATGACGGCTACCCAGCCCTGGACCTGGATGCTGGCCTG 1461
           I IIIIIIIIIIIII IIIII IIIIII II IIIIIIIIIIIIIII
murMU-1    GTAGCTGTGAGGATGATGGCTATCCAGCCATGAACCTGGATGCTGGCCGA 1624

huMU-1     GAGCCCAGCCCAGGCCTAGAGGACCCACTCTTGGATGCAGGGACCACAGT 1511
           III I IIII     IIIIII I IIIIIII III  I I I
murMU-1    GAGTCTGGCCCTAATTCAGAGGATCTGCTCTTGGTCACAGACCCTGCTTT 1674

huMU-1     CCTGTCCTGTGGCTGTGTCTCAGCTGGCAGCCCTGGGCTAGGAGGGCCCC 1561
           IIIII II IIIIIIIIIIIIII I I  I I   IIII IIIII III
murMU-1    TCTGTCTTGCGGCTGTGTCTCAGGTAGTGGTCTCAGGCTTGGAGGCTCCC 1724

huMU-1     TGGGAAGCCTCCTGGACAGACTAAAGCCACCCCTTGCAGATGGGGAGGAC 1611
           II IIIIII .IIIIIIII I I II  I  IIIII I I  I IIII
murMU-1    CAGGCAGCCTACTGGACAGGTTGAGGCTGTCATTTGCAAAGGAAGGGGAC 1774

huMU-1     TGGGCTGGGGGACTGCCCTGGGGTGGCCGGTCACCTGGAGGGGTCTCAGA 1661
```

FIG.3 (continued)

```
                   III  I  I    I   I     IIIII I      IIII II IIIIIII III II
murMU-1  TGGACAGCAGACCCAACCTGGAGAACTGGGTCCCCAGGAGGGGGCTCTGA 1824

huMU-1   GAGTGAGGCGGGCTCACCCCTGGCCGGCCTGGATATGGACACGTTTGACA 1711
                   IIIIII II II II IIII   I II IIIII IIIIIIIII IIIIIIII
murMU-1  GAGTGAAGCAGGTTCCCCCC...CTGGTCTGGACATGGACACATTTGACA 1871

huMU-1   GTGGCTTTGTGGGCTCTGACTGCAGCAGCCCTGTGGAGTGTGACTTCACC 1761
                   IIIIIIIII  II II IIIII  IIIIIII IIIIII  I
murMU-1  GTGGCTTTGCAGGTTCAGACTGTGGCAGCCCCGTGGAGACT......... 1912

huMU-1   AGCCCCGGGGACGAAGGACCCCCCCGGAGCTACCTCCGCCAGTGGGTGGT 1811
                   II IIIIIIIIIIII II IIIII IIIIIIIIIIIIIIILII
murMU-1  ........GATGAAGGACCCCCTCGAAGCTATCTCCGCCAGTGGGTGGT 1953

huMU-1   CATTCCTCCGCCACTTTCGAGCCCTGGACCCCAGGCCAGCTAATGAGGCT 1861
                   II   I II IIII I  I  I  IIII IIIII  IIIIII
murMU-1  CAGGACCCCTCCACCTGTGGACAGTGGAGCCCAGAGCAGCTA........ 1995

huMU-1   GACTGGATGTCCAGAGCTGGCCAGGCCACTGGGCCCTGAGCCAGAGACAA 1911
                   I   I    IIII     I    I II I IIIIIII
murMU-1  .GCATATAATAACCAGCTATAGTGAGAAGAGGCCTCTGAGCC........ 2036

huMU-1   TGGGCCTTTGAGCCTGATGTTTACAGTGTCTGTGTGTGTGTGCATATG 2011
                   III   II  II   III    I    I II IIIIIIIIIIIIIIII I II
murMU-1  TGGCATTTACAGTGTGAACATGTAGGGGTGTGTGTGTGTGTGTGTGTGTG 2086

huMU-1   TGTGTGTGTGCATATGCATGTGTGTGTGTGTGTGTGTGTCTTACTGGACTCA 2061
                   IIIIIIIIII  I II  IIIIIIIIIIIIIIIIIIIIIIII   I  I
murMU-1  TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTCTT.GGGTTGTGT 2135

huMU-1   CGGAGCTCACCCATGTGCACAAGTGTGCACAGTAAACGTGTTTGTGGTCA 2111
                   III II IIIIIII   I  II          II III I  I
murMU-1  GTTAGCACATCCATGTTGGGATTTG..............GTCTGTTGCTA 2171

huMU-1   ACAGATGACAACAGCCGTCCTCCCTCCTAGGGTCTTGTGTTGCAAGTTGG 2161
                   II  I         I III   II I I III   I I III
murMU-1  TGTATTGTAATGCTAAATTCTCTACCCAAAGTTCTAGGCCTACGAGTGAA 2221

huMU-1   TCCACAGCATCTCCGGGGCTTTGTGGGATCAGGGCATTGCCTGTGACTGA 2211
                   I I II  I I    IIII I  I  I I III   I I
murMU-1  TTCTCATGTTTACAAACTTGCTGTGTAAACCTTG...TTCCTTAATTTAA 2268

huMU-1   GGCGGAGCCCAGCCCTCCAGCGTCTGCCTCCAGGAGCTGCAAGAAGTCCA 2261
                   I           I I IIIII III   III I I II I
murMU-1  TACCATTGGTTAAATAAAATTGGCTGCAACCAATTACTGGAGGGATTAGA 2318

huMU-1   TATTG.....TTCCTTATCACCTGCCAACAGGAAGCGAAAGGGGATGGAG 2306
                   I I    II    I IIIII   II  I III I I   IIII
murMU-1  GGTAGGGGGCTTTTGAGTTACCTGTTTGGAGATGGAGAAGGAGAGAGGAG 2368

huMU-1   TGAGCCCATGGTGACCTCGGGAATGGCAATTTTTTGGGCGGCCCCTGGAC 2356
                   II I    II II II    II I    I        I I I
murMU-1  AGACCAAGAGGAGAAGGAGGAAGGAGAGGAGAGGAGAGGAGAGGAGAGGA 2418

huMU-1   GAAGGTCTGAATCCCGACTCTGATACCTTCTGGCTGTGCTACCTGAGCCA 2406
                   II I   II    II     II      I   III    I I
murMU-1  GAGGAGAGGAGAGGAGA.GGAGAGGAGAGGAGAGGCTGCCGTGAGGGGAG 2467

huMU-1   AGTCGCCTCCCCTCTCTGGGCTAGAGTTTCCTTATCCAGACAGTGGGGAA 2456
                   II   II      II III I III  I   I          I I
murMU-1  AGGGACCATGAGCCTGTGGCCAGGAGAAACAGCA...........AGTA 2505

huMU-1   GGCATGACACACCTGGGGGAAATTGGCGATGTCACCCGTGTACGGTACGC 2506
                   I IIIII I I I I IIII I I II I  II  I    I
murMU-1  TCTGGGGTACACTGGTGAGGAGGTGGCCAGGCCAGC..AGTTAGAAGAGT 2553

huMU-1   AGCCCAGAGCAGACCCTCAATAAACGTCAGCTTCCTTCAAAAAAAAAAAA 2556
```

FIG.3 (continued)

```
           | |    | |  |   | | | |   | |  | |      | | | |        |   |  | | | |  | |  | | | |
murMU-1    AGATTAGGGGTGACCTCCAGTATTTGTCAAAGCCAATTAAAATAACAAAA 2603
                        .                    .
huMU-1     AAAAATCTAGA.............. 2567
           | | | | |    |  |
murMU-1    AAAAAAAAAAAAGCGGCCGCTCTAGA 2628
```

FIG.4

```
Human MU-1    MPRGWAAPLLLLLLQGGWGCPDLVCYTDYLQTVICILEMWNLHPSTLTLT 50
              ||||   | ||||:| | | | || |||||| |: |:||  . .|| |-||
MurineMU-1    MPRGPVAALLLLILHGAWSCLDLTCYTDYLWTITCVLETRSPNPSILSLT 50

Human MU-1    WQDQYEELKDEATSCSLHRSAHNATHATYTCHMDVFHFMADDIFSVNITD 100
              |||:||||.|: | ||||| || || |||||  . |:.|::| ||:||
MurineMU-1    WQDEYEELQDQETFCSLHRSGHNTTHIWYTCHMRLSQFLSDEVFIVNVTD 100

Human MU-1    QSGNYSQECGSFLLAESIKPAPPFNVTVTFSGQYNISWRSDYEDPAFYML 150
              |||| |||||||.|||||||||| |||| |||.|-||| | |::|. |.|
MurineMU-1    QSGNNSQECGSFVLAESIKPAPPLNVTVAFSGRYDISWDSAYDEPSNYVL 150

Human MU-1    KGKLQYELQYRNRGDPWAVSPRRKLISVDSRSVSLLPLEFRKDSSYELQV 200
              :||||||||||| ||:|| |  ||||||||||.|||||:||| |||:|||
MurineMU-1    RGKLQYELQYRNLRDPYAVRPVTKLISVDSRNVSLLPEEFHKDSSYQLQV 200

Human MU-1    RAGPMPGSSYQGTWSEWSDPVIFQTQSEELKEGWNPHLLLLLLLVIVFIP 250
              || | ||.|:.||||||||||||||||||. | - ||.||:|||| ..|: :
MurineMU-1    RAAPQPGTSFRGTWSEWSDPVIFQTQAGEPEAGWDPHMLLLLAVLIIVL. 249

Human MU-1    AFWSLKTHPLWRLWKKIWA.VPSPERFFMPLYKGCSGDFKKWVGAPFTGS 299
              | || | |||||||| |||: ||.|||||| ||| ||| 
MurineMU-1    VFMGLKIHLPWRLWKKIWAPVPTPESFFQPLYREHSGNFKKWVNTPFTAS 299

Human MU-1    SLELGPWSPEVPSTLEVYSCHPPRSPAKRLQLTELQEPAELVESDGVPKP 349
              |:|| | |    | |     |      ||| .    |   | -| ||. .|
MurineMU-1    SIELVPQSSTTTSAL.....HLSLYPAKEKKFPGLPGLEEQLECDGMSEP 344

Human MU-1    SFW...PTAQNSGGSAYSEERDRPYGLVSIDTVTVLDAEGPCTWPCSCED 396
              |   | |       ||||||||||||||||||||||| |||| | |||||||
MurineMU-1    GHWCIIPLAAGQAVSAYSEERDRPYGLVSIDTVTVGDAEGLCVWPCSCED 394

Human MU-1    DGYPALDLDAGLEPSPGLEDPLLDAGTTVLSCGCVSAGSPGLGGPLGSLL 446
              |||||:-|||| | | || || |||||| ||| |||
MurineMU-1    DGYPAMNLDAGRESGPNSEDLLLVTDPAFLSCGCVSGSGLRLGGSPGSLL 444

Human MU-1    DRLKPPLADGEDWAGGLPWGGRSPGGVSESEAGSPLAGLDMDTFDSGFVG 496
              |||:    |  ||     |    |||| |||||||| |||||||||||| |
MurineMU-1    DRLRLSFAKEGDWTADPTWRTGSPGGGSESEAGSP.PGLDMDTFDSGFAG 493

Human MU-1    SDCSSPVECDFTSPGDEGPPRSYLRQWVV.IPPPLSSPGPQAS* 539
              ||| ||||       |||||||||||| |||. | | |.|
MurineMU-1    SDCGSPVET......DEGPPRSYLRQWVVRTPPPVDS.GAQSS. 529
```

FIG.5

```
            1                                                            50
humu        ---MPRGWAA PLLLLL..LQ GGWG...... CPDLVCYTDY LQTVICILEM
mousemu     ---MPRGPVA ALLLLI..LH GAWG...... CLDLTCYTDY LWTITCVLET
humil2rbc   MAAPALSWRL PLLILLLPLA TSWASAAVNG TSOFTCFYNS RANISCVWSQ
            51                                                          100
humu        WN..LHPSTL TLTWQDQYEE LKDEATSCSL HRSAHNATHA TYTCHM....
mousemu     RS..PNPSIL SLTWQDEYEE LQDQETFCSL HRSGHNTTHI WYTCHM....
humil2rbc   DGALQDTSCQ VHAWPDR... .RRWNQTCEL ....LPVSQA SWACNLILGA
            101                                                         150
humu        .DVFHFMADD IFSVNITDQS GN..YSQECG SFLLAESIKP APPFNVTVTF
mousemu     .RLSQFLSDE VFIVNVTDQS GN..NSQECG SFVLAESIKP APPLNVTVAF
humil2rbc   PDSQKLTTVD IVTLRVLCRE GVRWRVMAIQ DFKPFENLRL MAPISLQVVH
            151                                                         200
humu        ..SGQYNISW RSDYEDPAFY MLKGKLQYEL QYRNRGDPWA VSPRRKLISV
mousemu     ..SGRYDISW DSAYDEPSNY VLRGKLQYEL QYRNLRDPYA VRPVTKLISV
humil2rbc   VETHRCNISW E..ISQASHY FER.HLEFEA RTLSPGHTWE EAP...LLTL
            201                                                         250
humu        DSRSVSLLPL EFRKDSSYEL QVRAGPMPGS SYQGTWSEWS DPVIFQTQS.
mousemu     DSRNVSLLPE EFHKDSSYQL QVRAAPQPGT SFRGTWSEWS DPVIFQTQA.
humil2rbc   KQKQEWICLE TLTPDTQYEF QVRVKPLQGE F..TTWSPWS QPLAFRTKPA
            251                                                         300
humu        ..EELKEGWN PHLLLLL... LLVIVFIPAF WSLKTHPLWR LWKKIWA.VP
mousemu     ..GEPEAGWD PHMLLLL... AVLIIVL.VF MGLKIHLPWR LWKKIWAPVP
humil2rbc   ALGKDTIPWL GHLLVGLSGA FGFIILVYLL INCRNTGPW. LKKVLKCNTP
            301                                                         350
humu        SPERFFMPLY KGCSGDFKKW VGAPFTGSSL ELGPWSPEVP STLEVYSCHP
mousemu     TPESFFQPLY REHSGNFKKW VNTPFTASSI ELVPQSSTTT SAL.....HL
humil2rbc   DPSKFFSQLS SEHGGDVQKW LSSPFPSSSF SPGGLAPEIS PLEVLERDKV
            351                                                         400
humu        PRSPAKRLQL TELQEPA..E LVESDGVPKP SFW...PTAQ NSGGSAYSEE
mousemu     SLYPAKEKKF PGLPGLE..E QLECDGMSEP GHWCIIPLAA GQAVSAYSEE
humil2rbc   TQLLLQQDKV PEPASLSSNH SLTSCFTNQG YFFFHLPDAL EIEACQVYFT
            401                                                         450
humu        RDRPYGLVSI DTVTVLDAEG PC...TWPCS CEDDGYPALD LDAGLEPSPG
mousemu     RDRPYGLVSI DTVTVGDAEG LC...VWPCS CEDDGYPAMN LDAGRESGPN
humil2rbc   YD.PYSEEDP DEGVAGAPTG SSPQPLQPLS GEDDAYCTF. ........PS
            451                                                         500
humu        LEDPLLDAGT TVLSCGCVSA GSPGLGGPLG SLLDRLKPPL AD..GEDWAG
mousemu     SEDLLLVTDP AFLSCGCVSG SGLRLGGSPG SLLDRLRLSF AK..EGDWTA
humil2rbc   RDDLLLFS.P SLL..GGPSP PSTAPGGS.G AGEERMPPSL QERVPRDWDP
            501                                                         550
humu        GLPWGGRSPG GVSESEAGSP LAGLDMDTFD SGFVGSDCSS PVECDFTSPG
mousemu     DPTWRTGSPG GGSESEAGSP .PGLDMDTFD SGFAGSDCGS PVET......
humil2rbc   Q.PLGPPTPG VPDLVDFQPP P...ELVLRE AGEEVPDAG. PRE.GVSFPW
            551                                      588
humu        DEGPPRSYLR QWVVIPPPLS SPGPQAS*~~ ~~~~~~~~
mousemu     DEGPPRSYLR QWVVRTPPPV DSGAQSS~~~ ~~~~~~~~
humil2rbc   SRPPGQGEFR ALNARLPLNT DAYLSLQELQ GQDPTHLV
```

FIG.6

Signaling through MU-1

pSTAT 1

STAT 3

pSTAT 3

STAT 5

pSTAT 5

Hela neg
Hela pos
T = 0
T = 15' IL-3
T = 15' EPO

T = 0
T = 15' IL-3
T = 30' IL-3
T = 60' IL-3
T = 15' EPO
T = 30' EPO
T = 60' EPO

Lowe 7556-
152

Lowe 7556-
115

```
atg aaa ttc tta gtc aac gtt gcc ctt gtt ttt atg gtc gtg tac att      48
Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
1                 5                  10                 15

tct tac atc tat gcc ggc agc gga cac cac cat cat cac cac ggt agc      96
Ser Tyr Ile Tyr Ala Gly Ser Gly His His His His His His Gly Ser
                20                  25                 30

ggc gac tat aaa gac gat gac gat aag ggt tcc gga tgc ccc gac ctc     144
Gly Asp Tyr Lys Asp Asp Asp Asp Lys Gly Ser Gly Cys Pro Asp Leu
            35                  40                 45

gtc tgc tac acc gat tac ctc cag acg gtc atc tgc atc ctg gaa atg     192
Val Cys Tyr Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met
        50                  55                 60

tgg aac ctc cac ccc agc acg ctc acc ctt acc tgg caa gac cag tat     240
Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp Gln Asp Gln Tyr
65                  70                  75                 80

gaa gag ctg aag gac gag gcc acc tcc tgc agc ctc cac agg tcg gcc     288
Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala
                85                  90                 95

cac aat gcc acg cat gcc acc tac acc tgc cac atg gat gta ttc cac     336
His Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp Val Phe His
            100                 105                110

ttc atg gcc gac gac att ttc agt gtc aac atc aca gac cag tct ggc     384
Phe Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly
            115                 120                125

aac tac tcc cag gag tgt ggc agc ttt ctc ctg gct gag agc atc aag     432
Asn Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu Ser Ile Lys
        130                 135                 140

ccg gct ccc cct ttc aac gtg act gtg acc ttc tca gga cag tat aat     480
Pro Ala Pro Pro Phe Asn Val Thr Val Thr Phe Ser Gly Gln Tyr Asn
145                 150                 155                160

atc tcc tgg cgc tca gat tac gaa gac cct gcc ttc tac atg ctg aag     528
Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu Lys
                165                 170                175

ggc aag ctt cag tat gag ctg cag tac agg aac cgg gga gac ccc tgg     576
Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro Trp
            180                 185                190

gct gtg agt ccg agg aga aag ctg atc tca gtg gac tca aga agt gtc     624
Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp Ser Arg Ser Val
            195                 200                205

tcc ctc ctc ccc ctg gag ttc cgc aaa gac tcg agc tat gag ctg cag     672
Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu Gln
        210                 215                 220
```

Figure 7A

```
gtg cgg gca ggg ccc atg cct ggc tcc tcc tac cag ggg acc tgg agt      720
Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp Ser
225             230             235             240

gaa tgg agt gac ccg gtc atc ttt cag acc cag tca gag gag tta aag      768
Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser Glu Glu Leu Lys
                245             250             255

gaa ggc tgg aac taa tga  SEQ ID NO: 22                               786
Glu Gly Trp Asn SEQ ID NO: 23
        260
```

Figure 7B

```
gcggccgcac cacc atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg        50
               Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu
               1             5               10

ctg ctc cag gga ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat        98
Leu Leu Gln Gly Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp
          15              20              25

tac ctc cag acg gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc       146
Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro
         30              35              40

agc acg ctc acc ctt acc tgg caa gac cag tat gaa gag ctg aag gac       194
Ser Thr Leu Thr Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp
45               50              55                  60

gag gcc acc tcc tgc agc ctc cac agg tcg gcc cac aat gcc acg cat       242
Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His
                 65              70                  75

gcc acc tac acc tgc cac atg gat gta ttc cac ttc atg gcc gac gac       290
Ala Thr Tyr Thr Cys His Met Asp Val Phe His Phe Met Ala Asp Asp
                 80              85              90

att ttc agt gtc aac atc aca gac cag tct ggc aac tac tcc cag gag       338
Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu
             95              100             105

tgt ggc agc ttt ctc ctg gct gag agc atc aag ccg gct ccc cct ttc       386
Cys Gly Ser Phe Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe
        110             115             120

aac gtg act gtg acc ttc tca gga cag tat aat atc tcc tgg cgc tca       434
Asn Val Thr Val Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser
125             130             135                 140

gat tac gaa gac cct gcc ttc tac atg ctg aag ggc aag ctt cag tat       482
Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr
            145             150             155

gag ctg cag tac agg aac cgg gga gac ccc tgg gct gtg agt ccg agg       530
Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg
        160             165             170

aga aag ctg atc tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg       578
Arg Lys Leu Ile Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu
        175             180             185

gag ttc cgc aaa gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc       626
Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro
        190             195             200

atg cct ggc tcc tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg       674
Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro
205             210             215             220
```

Figure 8A

```
gtc atc ttt cag acc cag tca gag gag tta aag gaa ggc tgg aac ggc          722
Val Ile Phe Gln Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Gly
                225                     230                 235

tcc ggc tct aga gac aaa act cac aca tgc cca ccg tgc cca gca cct          770
Ser Gly Ser Arg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
                240                     245                 250

gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag          818
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
            255                     260                 265

gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg          866
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
        270                     275                 280

gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac          914
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
285                     290                     295 ·                 300

ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac          962
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
                305 ·                     310                 315

aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac         1010
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
                320                     325                 330

tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc         1058
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
                335                     340                 345

cca gtc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga         1106
Pro Val Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
        350                     355                 360

gaa cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag         1154
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
365                     370                     375                 380

aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac         1202
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
                385                     390                 395

atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag         1250
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
                400                     405                 410

acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc         1298
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
                415                     420 ·               425

aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca         1346
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
        430                     435                 440
```

Figure 8B

```
tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc      1394
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
445             450                 455                 460

ctc tcc ctg tcc ccg ggt aaa tgagtgaatt c SEQ ID NO: 24             1426
Leu Ser Leu Ser Pro Gly Lys SEQ ID NO: 25
                465
```

Figure 8C

```
Q ID NO:26 gcggccgcac cacc atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg        50
Q ID NO:27                Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu
                          1             5                   10

           ctg ctc cag gga ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat         98
           Leu Leu Gln Gly Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp
                   15          20                  25

           tac ctc cag acg gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc        146
           Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro
               30          35                  40

           agc acg ctc acc ctt acc tgg caa gac cag tat gaa gag ctg aag gac        194
           Ser Thr Leu Thr Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp
           45              50                  55                  60

           gag gcc acc tcc tgc agc ctc cac agg tcg gcc cac aat gcc acg cat        242
           Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His
                           65                  70                  75

           gcc acc tac acc tgc cac atg gat gta ttc cac ttc atg gcc gac gac        290
           Ala Thr Tyr Thr Cys His Met Asp Val Phe His Phe Met Ala Asp Asp
                       80                  85                  90

           att ttc agt gtc aac atc aca gac cag tct ggc aac tac tcc cag gag        338
           Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu
                       95                  100                 105

           tgt ggc agc ttt ctc ctg gct gag agc atc aag ccg gct ccc cct ttc        386
           Cys Gly Ser Phe Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe
                   110                 115                 120

           aac gtg act gtg acc ttc tca gga cag tat aat atc tcc tgg cgc tca        434
           Asn Val Thr Val Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser
           125                 130                 135                 140

           gat tac gaa gac cct gcc ttc tac atg ctg aag ggc aag ctt cag tat        482
           Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr
                           145                 150                 155

           gag ctg cag tac agg aac cgg gga gac ccc tgg gct gtg agt ccg agg        530
           Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg
                       160                 165                 170

           aga aag ctg atc tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg        578
           Arg Lys Leu Ile Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu
                   175                 180                 185

           gag ttc cgc aaa gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc        626
           Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro
                   190                 195                 200

           atg cct ggc tcc tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg        674
           Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro
           205                 210                 215                 220
```

Figure 9A

```
gtc atc ttt cag acc cag tca gag gag tta aag gaa ggc tgg aac ggc    722
Val Ile Phe Gln Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Gly
            225             230             235

tcc ggc tct aga gac aaa act cac aca tgc cca ccg tgc cca gca cct    770
Ser Gly Ser Arg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
            240             245             250

gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag    818
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
            255             260             265

gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg    866
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
            270             275             280

gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac    914
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
285             290             295             300

ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac    962
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
            305             310             315

aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac    1010
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
            320             325             330

tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc    1058
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
            335             340             345

cca gtc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga    1106
Pro Val Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
            350             355             360

gaa cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag    1154
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
365             370             375             380

aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac    1202
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
            385             390             395

atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag    1250
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
            400             405             410

acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc    1298
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
            415             420             425

aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca    1346
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
            430             435             440
```

Figure 9B

```
tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc        1394
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
445             450             455             460

ctc tcc ctg tcc ccg ggt aaa tca gga atg gca tca atg aca gga ggt        1442
Leu Ser Leu Ser Pro Gly Lys Ser Gly Met Ala Ser Met Thr Gly Gly
            465             470             475

caa caa atg ggt tct gga tct cat cat cat cat cat cat tct gga ggt        1490
Gln Gln Met Gly Ser Gly Ser His His His His His His Ser Gly Gly
            480             485             490

tgagaattc                                                              1499
```

Figure 9C

```
gcggccgcac cacc atg ccg cgt ggc tgg gcc gcc ccc ctg ctc ctg ctg      50
               Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu
               1               5                   10


ctg ctc cag gga ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat      98
Leu Leu Gln Gly Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp
            15              20                  25


tac ctc cag acg gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc     146
Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro
        30              35                  40


agc acg ctc acc ctt acc tgg caa gac cag tat gaa gag ctg aag gac     194
Ser Thr Leu Thr Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp
45                  50                  55                  60


gag gcc acc tcc tgc agc ctc cac agg tcg gcc cac aat gcc acg cat     242
Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His
                65                  70                  75


gcc acc tac acc tgc cac atg gat gta ttc cac ttc atg gcc gac gac     290
Ala Thr Tyr Thr Cys His Met Asp Val Phe His Phe Met Ala Asp Asp
                80                  85                  90


att ttc agt gtc aac atc aca gac cag tct ggc aac tac tcc cag gag     338
Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu
            95                  100                 105


tgt ggc agc ttt ctc ctg gct gag agc atc aag ccg gct ccc cct ttc     386
Cys Gly Ser Phe Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe
        110                 115                 120


aac gtg act gtg acc ttc tca gga cag tat aat atc tcc tgg cgc tca     434
Asn Val Thr Val Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser
125                 130                 135                 140


gat tac gaa gac cct gcc ttc tac atg ctg aag ggc aag ctt cag tat     482
Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr
                145                 150                 155


gag ctg cag tac agg aac cgg gga gac ccc tgg gct gtg agt ccg agg     530
Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg
            160                 165                 170


aga aag ctg atc tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg     578
Arg Lys Leu Ile Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu
            175                 180                 185


gag ttc cgc aaa gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc     626
Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro
        190                 195                 200


atg cct ggc tcc tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg     674
Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro
205                 210                 215                 220
```

Figure 10A

```
gtc atc ttt cag acc cag tca gag gag tta aag gaa ggc tgg aac ggc     722
Val Ile Phe Gln Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Gly
                225                 230                 235

tcc ggc tct aga gac aaa act cac aca tgc cca ccg tgc cca gca cct     770
Ser Gly Ser Arg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
                240                 245                 250

gaa gcc ctg ggg gca ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag     818
Glu Ala Leu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
                255                 260                 265

gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg     866
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
                270                 275                 280

gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac     914
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
285                 290                 295                 300

ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac     962
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
                305                 310                 315

aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac    1010
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
                320                 325                 330

tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc    1058
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
                335                 340                 345

cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga    1106
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
                350                 355                 360

gaa cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag    1154
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
365                 370                 375                 380

aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac    1202
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
                385                 390                 395

atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag    1250
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
                400                 405                 410

acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc    1298
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
                415                 420                 425

aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca    1346
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
                430                 435                 440
```

Figure 10B

```
tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc        1394
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
445             450             455             460

ctc tcc ctg tcc ccg ggt aaa tgagtgaatt c SEQ ID NO: 28                 1426
Leu Ser Leu Ser Pro Gly Lys SEQ ID NO: 29
            465
```

Figure 10C

```
atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc cag gga      48
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly
1               5                   10                  15

ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag acg      96
Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
                20                  25                  30

gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc acc     144
Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
            35                  40                  45

ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc acc tcc     192
Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
        50                  55                  60

tgc agc ctc cac agg tcg gcc cac aat gcc acg cat gcc acc tac acc     240
Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
65                  70                  75                  80

tgc cac atg gat gta ttc cac ttc atg gcc gac gac att ttc agt gtc     288
Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
                85                  90                  95

aac atc aca gac cag tct ggc aac tac tcc cag gag tgt ggc agc ttt     336
Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
            100                 105                 110

ctc ctg gct gag agc atc aag ccg gct ccc cct ttc aac gtg act gtg     384
Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
            115                 120                 125

acc ttc tca gga cag tat aat atc tcc tgg cgc tca gat tac gaa gac     432
Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
        130                 135                 140

cct gcc ttc tac atg ctg aag ggc aag ctt cag tat gag ctg cag tac     480
Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145                 150                 155                 160

agg aac cgg gga gac ccc tgg gct gtg agt ccg agg aga aag ctg atc     528
Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
                165                 170                 175

tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc aaa     576
Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
            180                 185                 190

gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc tcc     624
Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
            195                 200                 205

tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg gtc atc ttt cag     672
Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
            210                 215                 220
```

Figure 11A

```
acc cag tca gag gag tta aag gaa ggc tgg aac aaa acc gaa acc tcc      720
Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Lys Thr Glu Thr Ser
225             230             235             240

cag gtt gct ccg gca taa tga SEQ ID NO: 30                            741
Gln Val Ala Pro Ala SEQ ID NO: 31
                245
```

Figure 11B

```
atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc cag gga    48
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly
1               5                   10                  15

ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag acg    96
Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
                20                  25                  30

gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc acc   144
Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
            35                  40                  45

ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc acc tcc   192
Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
        50                  55                  60

tgc agc ctc cac agg tcg gcc cac aat gcc acg cat gcc acc tac acc   240
Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
65                  70                  75                  80

tgc cac atg gat gta ttc cac ttc atg gcc gac gac att ttc agt gtc   288
Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
                85                  90                  95

aac atc aca gac cag tct ggc aac tac tcc cag gag tgt ggc agc ttt   336
Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
                100                 105                 110

ctc ctg gct gag agc atc aag ccg gct ccc cct ttc aac gtg act gtg   384
Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
            115                 120                 125

acc ttc tca gga cag tat aat atc tcc tgg cgc tca gat tac gaa gac   432
Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
        130                 135                 140

cct gcc ttc tac atg ctg aag ggc aag ctt cag tat gag ctg cag tac   480
Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145                 150                 155                 160

agg aac cgg gga gac ccc tgg gct gtg agt ccg agg aga aag ctg atc   528
Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
                165                 170                 175

tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc aaa   576
Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
                180                 185                 190

gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc tcc   624
Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
            195                 200                 205

tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg gtc atc ttt cag   672
Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
            210                 215                 220
```

Figure 12A

25/47

```
acc cag tca gag gag tta aag gaa ggc tgg aac gat gac gat gac aag        720
Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Asp Asp Asp Asp Lys
225             230             235             240

ggc tcc ggc gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa        768
Gly Ser Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
            245             250             255

gcc ctg ggg gca ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac        816
Ala Leu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
            260             265             270

acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac        864
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
            275             280             285

gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc        912
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
290             295             300

gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac        960
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305             310             315             320

agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg       1008
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
            325             330             335

ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca       1056
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
            340             345             350

gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa       1104
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
            355             360             365

cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag aac       1152
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
370             375             380

cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc       1200
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385             390             395             400

gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc       1248
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
            405             410             415

acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc aag       1296
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
            420             425             430

ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc       1344
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
            435             440             445
```

Figure 12B

```
tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc      1392
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
    450                 455                 460

tcc ctg tcc ccg ggt aaa tga SEQ ID NO: 32                            1413
Ser Leu Ser Pro Gly Lys SEQ ID NO: 33
465             470
```

Figure 12C

```
:Q ID NO:34 atg ccc cgg ggc cca gtg gct gcc tta ctc ctg ctg att ctc cat gga      48
:Q ID NO:35 Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Leu Ile Leu His Gly
            1               5                   10                  15

            gct tgg agc tgc ctg gac ctc act tgc tac act gac tac ctc tgg acc      96
            Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr
                        20                  25                  30

            atc acc tgt gtc ctg gag aca cgg agc ccc aac ccc agc ata ctc agt     144
            Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser
                    35                  40                  45

            ctc acc tgg caa gat gaa tat gag gaa ctt cag gac caa gag acc ttc     192
            Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe
                50                  55                  60

            tgc agc cta cac agg tct ggc cac aac acc aca cat ata tgg tac acg     240
            Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr
            65                  70                  75                  80

            tgc cat atg cgc ttg tct caa ttc ctg tcc gat gaa gtt ttc att gtc     288
            Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val
                            85                  90                  95

            aat gtg acg gac cag tct ggc aac aac tcc caa gag tgt ggc agc ttt     336
            Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe
                        100                 105                 110

            gtc ctg gct gag agc atc aaa cca gct ccc ccc ttg aac gtg act gtg     384
            Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val
                    115                 120                 125

            gcc ttc tca gga cgc tat gat atc tcc tgg gac tca gct tat gac gaa     432
            Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu
                130                 135                 140

            ccc tcc aac tac gtg ctg agg ggc aag cta caa tat gag ctg cag tat     480
            Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
            145                 150                 155                 160

            cgg aac ctc aga gac ccc tat gct gtg agg ccg gtg acc aag ctg atc     528
            Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile
                            165                 170                 175

            tca gtg gac tca aga aac gtc tct ctt ctc cct gaa gag ttc cac aaa     576
            Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys
                        180                 185                 190

            gat tct agc tac cag ctg cag gtg cgg gca gcg cct cag cca ggc act     624
            Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr
                        195                 200                 205

            tca ttc agg ggg acc tgg agt gag tgg agt gac ccc gtc atc ttt cag     672
            Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
                210                 215                 220
```

Figure 13A

```
acc cag gct ggg gag ccc gag gca ggc tgg gac ggc tcc ggc tct aga    720
Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Gly Ser Gly Ser Arg
225                 230             235                 240

gagccccgcg gaccgacaat caagccctgt cctccatgca aatgcccagg taagtcacta    780

gaccagagct ccactcccgg gagaatggta agtgctataa acatccctgc actagaggat    840

aagccatgta cagatccatt tccatctctc ctcatcagca cctaacctcg agggtggacc    900

atccgtcttc atcttccctc caaagatcaa ggatgtactc atgatctccc tgagccccat    960

agtcacatgt gtggtggtgg atgtgagcga ggatgaccca gatgtccaga tcagctggtt   1020

tgtgaacaac gtggaagtac acacagctca gacacaaacc catagagagg attacaacag   1080

tactctccgg gtggtcagtg ccctccccat ccagcaccag gactggatga gtggcaaggc   1140

tttcgcatgc gccgtcaaca acaaagacct cccagcgccc atcgagagaa ccatctcaaa   1200

acccaaaggt gagagctgca gcctgactgc atgggggctg ggatgggcat aaggataaag   1260

gtctgtgtgg acagccttct gcttcagcca tgacctttgt gtatgtttct accctcacag   1320

ggtcagtaag agctccacag gtatatgtct tgcctccacc agaagaagag atgactaaga   1380

aacaggtcac tctgacctgc atggtcacag acttcatgcc tgaagacatt tacgtggagt   1440

ggaccaacaa cgggaaaaca gagctaaact acaagaacac tgaaccagtc ctggactctg   1500

atggttctta cttcatgtac agcaagctga gagtggaaaa gaagaactgg gtggaagaa   1560

atagctactc ctgttcagtg gtccacgagg gtctgcacaa tcaccacacg actaagagct   1620

tctcccggac tccgggtaaa tgagctcagc acccacaaaa ctctcaggtc caaagagaca   1680

cccacactca tctccatgct tcccttgtat aaataaagca cccagcaatg cctgggacca   1740

tgtaatagga attc                                                    1754
```

Figure 13B

```
ctgcaggtcg acaccacc atg ccc cgg ggc cca gtg gct gcc tta ctc ctg        51
                    Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu
                     1           5                     10

ctg att ctc cat gga gct tgg agc tgc ctg gac ctc act tgc tac act        99
Leu Ile Leu His Gly Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr
             15              20                  25

gac tac ctc tgg acc atc acc tgt gtc ctg gag aca cgg agc ccc aac       147
Asp Tyr Leu Trp Thr Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn
         30                  35              40

ccc agc ata ctc agt ctc acc tgg caa gat gaa tat gag gaa ctt cag       195
Pro Ser Ile Leu Ser Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln
     45                  50                  55

gac caa gag acc ttc tgc agc cta cac agg tct ggc cac aac acc aca       243
Asp Gln Glu Thr Phe Cys Ser Leu His Arg Ser Gly His Asn Thr Thr
60              65                  70                  75

cat ata tgg tac acg tgc cat atg cgc ttg tct caa ttc ctg tcc gat       291
His Ile Trp Tyr Thr Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp
             80                  85                  90

gaa gtt ttc att gtc aat gtg acg gac cag tct ggc aac aac tcc caa       339
Glu Val Phe Ile Val Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln
             95                 100                 105

gag tgt ggc agc ttt gtc ctg gct gag agc atc aaa cca gct ccc ccc       387
Glu Cys Gly Ser Phe Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro
        110                 115                 120

ttg aac gtg act gtg gcc ttc tca gga cgc tat gat atc tcc tgg gac       435
Leu Asn Val Thr Val Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp
        125                 130                 135

tca gct tat gac gaa ccc tcc aac tac gtg ctg agg ggc aag cta caa       483
Ser Ala Tyr Asp Glu Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln
140                 145                 150                 155

tat gag ctg cag tat cgg aac ctc aga gac ccc tat gct gtg agg ccg       531
Tyr Glu Leu Gln Tyr Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro
                160                 165                 170

gtg acc aag ctg atc tca gtg gac tca aga aac gtc tct ctt ctc cct       579
Val Thr Lys Leu Ile Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro
                175                 180                 185

gaa gag ttc cac aaa gat tct agc tac cag ctg cag gtg cgg gca gcg       627
Glu Glu Phe His Lys Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala
                190                 195                 200

cct cag cca ggc act tca ttc agg ggg acc tgg agt gag tgg agt gac       675
Pro Gln Pro Gly Thr Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp
        205                 210                 215
```

Figure 14A

```
ccc gtc atc ttt cag acc cag gct ggg gag ccc gag gca ggc tgg gac        723
Pro Val Ile Phe Gln Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp
220             225             230             235

ggc agc gga cac cac cat cat cac cac ggt agc ggc gac tat aaa gac        771
Gly Ser Gly His His His His His His Gly Ser Gly Asp Tyr Lys Asp
                240             245             250

gat gac gat aag tagtgagaat tc SEQ ID NO: 36                             795
Asp Asp Asp Lys SEQ ID NO: 37
                255
```

Figure 14B

```
atg aaa ttc tta gtc aac gtt gcc ctt gtt ttt atg gtc gtg tac att        48
Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
1               5                   10                  15

tct tac atc tat gcc ggc agc gga cac cac cat cat cac cac ggt agc        96
Ser Tyr Ile Tyr Ala Gly Ser Gly His His His His His His Gly Ser
            20                  25                  30

ggc gac tat aaa gac gat gac gat aag ggt tcc gga tgc ctg gac ctc       144
Gly Asp Tyr Lys Asp Asp Asp Asp Lys Gly Ser Gly Cys Leu Asp Leu
        ·35              40                  45

act tgc tac act gac tac ctc tgg acc atc acc tgt gtc ctg gag aca       192
Thr Cys Tyr Thr Asp Tyr Leu Trp Thr Ile Thr Cys Val Leu Glu Thr
        50                  55                  60

cgg agc ccc aac ccc agc ata ctc agt ctc acc tgg caa gat gaa tat       240
Arg Ser Pro Asn Pro Ser Ile Leu Ser Leu Thr Trp Gln Asp Glu Tyr
65                  70                  75                  80

gag gaa ctt cag gac caa gag acc ttc tgc agc cta cac agg tct ggc       288
Glu Glu Leu Gln Asp Gln Glu Thr Phe Cys Ser Leu His Arg Ser Gly
                85                  90                  95

cac aac acc aca cat ata tgg tac acg tgc cat atg cgc ttg tct caa       336
His Asn Thr Thr His Ile Trp Tyr Thr Cys His Met Arg Leu Ser Gln
                100                 105                 110

ttc ctg tcc gat gaa gtt ttc att gtc aat gtg acg gac cag tct ggc       384
Phe Leu Ser Asp Glu Val Phe Ile Val Asn Val Thr Asp Gln Ser Gly
            115                 . 120                 125

aac aac tcc caa gag tgt ggc agc ttt gtc ctg gct gag agc atc aaa       432
Asn Asn Ser Gln Glu Cys Gly Ser Phe Val Leu Ala Glu Ser Ile Lys
· 130                 135                 140

cca gct ccc ccc ttg aac gtg act gtg gcc ttc tca gga cgc tat gat       480
Pro Ala Pro Pro Leu Asn Val Thr Val Ala Phe Ser Gly Arg Tyr Asp
145                 150                 155                 160

atc tcc tgg gac tca gct tat gac gaa ccc tcc aac tac gtg ctg agg       528
Ile Ser Trp Asp Ser Ala Tyr Asp Glu Pro Ser Asn Tyr Val Leu Arg
            165                 170                 175

ggc aag cta caa tat gag ctg cag tat cgg aac ctc aga gac ccc tat       576
Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Leu Arg Asp Pro Tyr
            180                 185                 190

gct gtg agg ccg gtg acc aag ctg atc tca gtg gac tca aga aac gtc       624
Ala Val Arg Pro Val Thr Lys Leu Ile Ser Val Asp Ser Arg Asn Val
            195                 200                 205

tct ctt ctc cct gaa gag ttc cac aaa gat tct agc tac cag ctg cag       672
Ser Leu Leu Pro Glu Glu Phe His Lys Asp Ser Ser Tyr Gln Leu Gln
            210                 215                 220
```

Figure 15A

32/47

```
gtg cgg gca gcg cct cag cca ggc act tca ttc agg ggg acc tgg agt      720
Val Arg Ala Ala Pro Gln Pro Gly Thr Ser Phe Arg Gly Thr Trp Ser
225             230             235             240

gag tgg agt gac ccc gtc atc ttt cag acc cag gct ggg gag ccc gag      768
Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ala Gly Glu Pro Glu
                245             250             255

gca ggc tgg gac tagtgagaat tc SEQ ID NO: 38                          792
Ala Gly Trp Asp             SEQ ID NO: 39
                260
```

Figure 15B

Timetable for the CIA Model

Day 0

Immunization

100 ug Bovine CII/CFA

Day 21

Boost

100 ug Bovine CII/IFA

Day 20
Prophylactic Treatment

Day 23-24
Therapeutic Treatment
(Treatment as gets sick)

Day 26
Semi-Therapeutic Treatment
(Start when 10% of mice are sick)

FIG.16

FIG.17

FIG.18

FIG.19

Figures 20A-20C

Figures 21A-21C

Figures 22A-22B

Figures 23A-23B

Figures 24A-24B

Figures 25A-25C

Figures 26A-26B

Figures 27A-27B

Figures 28A-28D

Figures 29A-29C

SEQUENCE LISTING

<110> Wyeth

<120> Methods and Composition for Modulating Interleukin-21 Receptor Activity

<130> GI5320-PCT-P2

<140> Not Yet Assigned
<141> 2002-10-04

<150> 09/972,218
<151> 2001-10-04

<160> 44

<170> PatentIn version 3.1

<210> 1
<211> 2665
<212> DNA
<213> Human

<400> 1

```
gtcgactgga ggcccagctg cccgtcatca gagtgacagg tcttatgaca gcctgattgg      60

tgactcgggc tgggtgtgga ttctcacccc aggcctctgc ctgctttctc agaccctcat     120

ctgtcacccc cacgctgaac ccagctgcca cccccagaag cccatcagac tgcccccagc     180

acacggaatg gatttctgag aaagaagccg aaacagaagg cccgtgggag tcagcatgcc     240

gcgtggctgg gccgcccct tgctcctgct gctgctccag ggaggctggg gctgccccga     300

cctcgtctgc tacaccgatt acctccagac ggtcatctgc atcctggaaa tgtggaacct     360

ccaccccagc acgctcaccc ttacctggca agaccagtat gaagagctga aggacgaggc     420

cacctcctgc agcctccaca ggtcggccca caatgccacg catgccacct acacctgcca     480

catggatgta ttccacttca tggccgacga catttttcagt gtcaacatca cagaccagtc     540

tggcaactac tcccaggagt gtggcagctt tctcctggct gagagcatca gccggctcc     600

cccttttcaac gtgactgtga ccttctcagg acagtataat atctcctggc gctcagatta     660

cgaagaccct gccttctaca tgctgaaggg caagcttcag tatgagctgc agtacaggaa     720

ccggggagac ccctgggctg tgagtccgag gagaaagctg atctcagtgg actcaagaag     780

tgtctccctc ctcccccctgg agttccgcaa agactcgagc tatgagctgc aggtgcgggc     840

agggcccatg cctggctcct cctaccaggg gacctggagt gaatggagtg acccggtcat     900

ctttcagacc cagtcagagg agttaaagga aggctggaac cctcacctgc tgcttctcct     960

cctgcttgtc atagtcttca ttcctgcctt ctggagcctg aagacccatc cattgtggag    1020

gctatggaag aagatatggg ccgtccccag ccctgagcgg ttcttcatgc ccctgtacaa    1080

gggctgcagc ggagacttca agaaatgggt gggtgcaccc ttcactggct ccagcctgga    1140

gctgggaccc tggagcccag aggtgccctc caccctggag gtgtacagct gccacccacc    1200

acggagcccg gccaagaggc tgcagctcac ggagctacaa gaaccagcag agctggtgga    1260

gtctgacggt gtgcccaagc ccagcttctg gccgacagcc cagaactcgg ggggctcagc    1320
```

```
ttacagtgag gagagggatc ggccatacgg cctggtgtcc attgacacag tgactgtgct    1380

agatgcagag gggccatgca cctggccctg cagctgtgag gatgacggct acccagccct    1440

ggacctggat gctggcctgg agcccagccc aggcctagag gacccactct ggatgcagg     1500

gaccacagtc ctgtcctgtg gctgtgtctc agctggcagc cctgggctag agggccct     1560

gggaagcctc ctggacagac taaagccacc ccttgcagat ggggaggact gggctggggg    1620

actgccctgg ggtggccggt cacctggagg ggtctcagag agtgaggcgg gctcacccct    1680

ggccggcctg gatatggaca cgtttgacag tggctttgtg ggctctgact gcagcagccc    1740

tgtggagtgt gacttcacca gccccggga cgaaggaccc ccggagct acctccgcca       1800

gtgggtggtc attcctccgc cactttcgag ccctggaccc caggccagct aatgaggctg    1860

actggatgtc cagagctggc caggccactg ggccctgagc cagagacaag gtcacctggg    1920

ctgtgatgtg aagacacctg cagcctttgg tctcctggat gggcctttga gcctgatgtt    1980

tacagtgtct gtgtgtgtgt gtgcatatgt gtgtgtgtgc atatgcatgt gtgtgtgtgt    2040

gtgtgtctta ggtgcgcagt ggcatgtcca cgtgtgtgtg tgattgcacg tgcctgtggg    2100

cctgggataa tgcccatggt actccatgca ttcacctgcc ctgtgcatgt ctggactcac    2160

ggagctcacc catgtgcaca agtgtgcaca gtaaacgtgt ttgtggtcaa cagatgacaa    2220

cagccgtcct ccctcctagg gtcttgtgtt gcaagttggt ccacagcatc tccggggctt    2280

tgtgggatca gggcattgcc tgtgactgag gcggagccca gccctccagc gtctgcctcc    2340

aggagctgca agaagtccat attgttcctt atcacctgcc aacaggaagc gaaaggggat    2400

ggagtgagcc catggtgacc tcgggaatgg caattttttg ggcggcccct ggacgaaggt    2460

ctgaatcccg actctgatac cttctggctg tgctacctga gccaagtcgc ctcccctctc    2520

tgggctagag tttccttatc cagacagtgg ggaaggcatg acacacctgg gggaaattgg    2580

cgatgtcacc cgtgtacggt acgcagccca gagcagaccc tcaataaacg tcagcttcct    2640

tcaaaaaaaa aaaaaaaaat ctaga                                          2665
```

<210> 2
<211> 538
<212> PRT
<213> Human

<400> 2

```
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly Gly
1               5                   10                  15

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
                20                  25                  30

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
            35                  40                  45

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
        50                  55                  60

Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
65                  70                  75                  80
```

Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
                85   90   95

Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
                100   105   110

Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
            115   120   125

Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
    130   135   140

Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145   150   155   160

Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
            165   170   175

Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
            180   185   190

Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
        195   200   205

Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
    210   215   220

Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Leu Leu Leu
225   230   235   240

Leu Leu Leu Leu Val Ile Val Phe Ile Pro Ala Phe Trp Ser Leu Lys
            245   250   255

Thr His Pro Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala Val Pro Ser
            260   265   270

Pro Glu Arg Phe Phe Met Pro Leu Tyr Lys Gly Cys Ser Gly Asp Phe
        275   280   285

Lys Lys Trp Val Gly Ala Pro Phe Thr Gly Ser Ser Leu Glu Leu Gly
    290   295   300

Pro Trp Ser Pro Glu Val Pro Ser Thr Leu Glu Val Tyr Ser Cys His
305   310   315   320

Pro Pro Arg Ser Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu
            325   330   335

Pro Ala Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp
            340   345   350

Pro Thr Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp
        355   360   365

Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala
    370   375   380

Glu Gly Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro
385   390   395   400

Ala Leu Asp Leu Asp Ala Gly Leu Glu Pro Ser Pro Gly Leu Glu Asp
            405   410   415

Pro Leu Leu Asp Ala Gly Thr Thr Val Leu Ser Cys Gly Cys Val Ser
            420   425   430

Ala Gly Ser Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg
        435   440   445

3/28

```
Leu Lys Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro
    450                 455             460
```

```
Trp Gly Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser
465             470             475                     480
```

```
Pro Leu Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly
                485             490                 495
```

```
Ser Asp Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp
            500             505                 510
```

```
Glu Gly Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro
            515             520             525
```

```
Pro Leu Ser Ser Pro Gly Pro Gln Ala Ser
    530                 535
```

<210> 3
<211> 70
<212> PRT
<213> Human

<400> 3

```
Leu Met Thr Asn Ala Phe Ile Ser Ile Ile Asp Asp Leu Ser Lys Tyr
1               5               10                  15
```

```
Asp Val Gln Val Arg Ala Ala Val Ser Ser Met Cys Arg Glu Ala Gly
            20              25              30
```

```
Leu Trp Ser Glu Trp Ser Gln Pro Ile Tyr Val Gly Asn Asp Glu His
        35              40              45
```

```
Lys Pro Leu Arg Glu Trp Phe Val Ile Val Ile Met Ala Thr Ile Cys
    50              55              60
```

```
Phe Ile Leu Leu Ile Leu
65                  70
```

<210> 4
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 4
gagtccgagg agaaagctga tctca   25

<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 5
gaaagatgac cgggtcactc catt   24

<210> 6
<211> 29
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Labelled Hybridization
Oligonucleotide

<400> 6
actcgagcta tgagctgcag gtgcgggca   29

<210> 7
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: NN14-1b (MU-1) Labelled
Hybridization Oligonucleotide

<400> 7
actcgagcta tgagctgcag gtgcgggca   29

<210> 8
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Motif Characteristic of the
Hematopoietin Receptor Family

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Wherein Xaa is any amino acid.

<400> 8

Trp Ser Xaa Trp Ser
1   5

<210> 9
<211> 2628
<212> DNA
<213> Mouse

<400> 9
gtcgacgcgg cggtaccagc tgtctgccca cttctcctgt ggtgtgcctc acggtcactt   60

gcttgtctga ccgcaagtct gcccatccct ggggcagcca actggcctca gcccgtgccc   120

caggcgtgcc ctgtctctgt ctggctgccc cagccctact gtcttcctct gtgtaggctc   180

tgcccagatg cccggctggt cctcagcctc aggactatct cagcagtgac tcccctgatt   240

ctggacttgc acctgactga actcctgccc acctcaaacc ttcacctccc accaccacca   300

ctccgagtcc cgctgtgact cccacgccca ggagaccacc caagtgcccc agcctaaaga   360

atggctttct gagaaagacc ctgaaggagt aggtctggga cacagcatgc cccgggggccc   420

actggctgcc ttactcctgc tgattctcca tggagcttgg agctgcctgg acctcacttg   480

ctacactgac tacctctgga ccatcacctg tgtcctggag acacggagcc ccaacccccag   540

catactcagt ctcacctggc aagatgaata tgaggaactt caggaccaag agaccttctg   600

```
cagcctacac aggtctggcc acaacaccac acatatatgg tacacgtgcc atatgcgctt      660

gtctcaattc ctgtccgatg aagttttcat tgtcaatgtg acggaccagt ctggcaacaa      720

ctcccaagag tgtggcagct ttgtcctggc tgagagcatc aaaccagctc cccccttgaa      780

cgtgactgtg gccttctcag gacgctatga tatctcctgg gactcagctt atgacgaacc      840

ctccaactac gtgctgaggg gcaagctaca atatgagctg cagtatcgga acctcagaga      900

cccctatgct gtgaggccgg tgaccaagct gatctcagtg gactcaagaa acgtctctct      960

tctccctgaa gagttccaca agattctag ctaccagctg caggtgcggg cagcgcctca     1020

gccaggcact tcattcaggg ggacctggag tgagtggagt gaccccgtca tctttcagac     1080

ccaggctggg gagcccgagg caggctggga ccctcacatg ctgctgctcc tggctgtctt     1140

gatcattgtc ctggttttca tgggtctgaa gatccacctg ccttggaggc tatggaaaaa     1200

gatatgggca ccagtgccca cccctgagag tttcttccag cccctgtaca gggagcacag     1260

cgggaacttc aagaaatggg ttaataccccc tttcacggcc tccagcatag agttggtgcc     1320

acagagttcc acaacaacat cagccttaca tctgtcattg tatccagcca aggagaagaa     1380

gttcccgggg ctgccgggtc tggaagagca actggagtgt gatggaatgt ctgagcctgg     1440

tcactggtgc ataatcccct tggcagctgg ccaagcggtc tcagcctaca gtgaggagag     1500

agaccggcca tatggtctgg tgtccattga cacagtgact gtgggagatg cagagggcct     1560

gtgtgtctgg ccctgtagct gtgaggatga tggctatcca gccatgaacc tggatgctgg     1620

ccgagagtct ggccctaatt cagaggatct gctcttggtc acagaccctg cttttctgtc     1680

ttgcggctgt gtctcaggta gtggtctcag gcttggaggc tccccaggca gcctactgga     1740

caggttgagg ctgtcatttg caaaggaagg ggactggaca gcagacccaa cctggagaac     1800

tgggtcccca ggaggggggct ctgagagtga agcaggttcc cccectggtc tggacatgga     1860

cacatttgac agtggctttg caggttcaga ctgtggcagc cccgtggaga ctgatgaagg     1920

accccctcga agctatctcc gccagtgggt ggtcaggacc cctccacctg tggacagtgg     1980

agcccagagc agctagcata taataaccag ctatagtgag aagaggcctc tgagcctggc     2040

atttacagtg tgaacatgta ggggtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg     2100

tgtgtgtgtg tgtgtgtgtg tgtcttgggt tgtgtgttag cacatccatg ttgggatttg     2160

gtctgttgct atgtattgta atgctaaatt ctctacccaa agttctaggc ctacgagtga     2220

attctcatgt ttacaaactt gctgtgtaaa ccttgttcct taatttaata ccattggtta     2280

aataaaattg gctgcaacca attactggag ggattagagg tagggggctt ttgagttacc     2340

tgtttggaga tggagaagga gagaggagag accaagagga gaaggaggaa ggagaggaga     2400

ggagaggaga ggagaggaga ggagaggaga ggagaggaga ggagaggaga ggctgccgtg     2460

aggggagagg gaccatgagc ctgtggccag gagaaacagc aagtatctgg ggtacactgg     2520

tgaggaggtg gccaggccag cagttagaag agtagattag gggtgacctc cagtatttgt     2580

caaagccaat taaaataaca aaaaaaaaaa aaaagcggcc gctctaga               2628
```

<210> 10
<211> 529
<212> PRT
<213> Mouse

<400> 10

Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Leu Ile Leu His Gly
1   5   10   15

Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr
            20   25   30

Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser
        35   40   45

Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe
    50   55   60

Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr
65   70   75   80

Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val
                85   90   95

Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe
            100   105   110

Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val
        115   120   125

Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu
    130   135   140

Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145   150   155   160

Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile
            165   170   175

Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys
        180   185   190

Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr
    195   200   205

Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
    210   215   220

Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Pro His Met Leu Leu
225   230   235   240

Leu Leu Ala Val Leu Ile Ile Val Leu Val Phe Met Gly Leu Lys Ile
            245   250   255

His Leu Pro Trp Arg Leu Trp Lys Lys Ile Trp Ala Pro Val Pro Thr
            260   265   270

Pro Glu Ser Phe Phe Gln Pro Leu Tyr Arg Glu His Ser Gly Asn Phe
    275   280   285

Lys Lys Trp Val Asn Thr Pro Phe Thr Ala Ser Ser Ile Glu Leu Val
    290   295   300

Pro Gln Ser Ser Thr Thr Thr Ser Ala Leu His Leu Ser Leu Tyr Pro
305   310   315   320

Ala Lys Glu Lys Lys Phe Pro Gly Leu Pro Gly Leu Glu Glu Gln Leu
            325   330   335

```
Glu Cys Asp Gly Met Ser Glu Pro Gly His Trp Cys Ile Ile Pro Leu
            340             345             350

Ala Ala Gly Gln Ala Val Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro
            355             360             365

Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Gly Asp Ala Glu Gly
    370             375             380

Leu Cys Val Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro Ala Met
385             390             395             400

Asn Leu Asp Ala Gly Arg Glu Ser Gly Pro Asn Ser Glu Asp Leu Leu
            405             410             415

Leu Val Thr Asp Pro Ala Phe Leu Ser Cys Gly Cys Val Ser Gly Ser
            420             425             430

Gly Leu Arg Leu Gly Gly Ser Pro Gly Ser Leu Leu Asp Arg Leu Arg
            435             440             445

Leu Ser Phe Ala Lys Glu Gly Asp Trp Thr Ala Asp Pro Thr Trp Arg
    450             455             460

Thr Gly Ser Pro Gly Gly Gly Ser Glu Ser Glu Ala Gly Ser Pro Pro
465             470             475             480

Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Ala Gly Ser Asp Cys
            485             490             495

Gly Ser Pro Val Glu Thr Asp Glu Gly Pro Pro Arg Ser Tyr Leu Arg
            500             505             510

Gln Trp Val Val Arg Thr Pro Pro Pro Val Asp Ser Gly Ala Gln Ser
    515             520             525

Ser
```

```
<210>   11
<211>   20
<212>   DNA
<213>   Artificial Sequence

<220>
<223>   Description of Artificial Sequence: PCR Primer

<400>   11
agcatcaagc cggctccccc                                              20


<210>   12
<211>   20
<212>   DNA
<213>   Artificial Primer

<220>
<223>   Description of Artificial Sequence: PCR Primer

<400>   12
ctccattcac tccaggtccc                                              20


<210>   13
<211>   20
<212>   DNA
<213>   Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 13
ttgaacgtga ctgrggcctt   20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Murine MU-1 cDNA Internal
      oligonucleotide

<400> 14
tgaatgaagt gcctggctga   20

<210> 15
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: 5' PCR Primer

<400> 15
cacaaagctt cagtatgagc tgcagtacag gaaccgggga   40

<210> 16
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: 3' PCR primer

<400> 16
cacaggatcc ctttaactcc tctgactggg tctgaaagat   40

<210> 17
<211> 224
<212> PRT
<213> Unknown Organism

<220>
<221> Unknown Organism
<222> (1)..(224)
<223> Description of Unknown Organism: Second polypeptide comprising an
      FC region

<400> 17

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Leu Gly Ala Pro Ser
1   5   10   15

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
            20   25   30

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
        35   40   45

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
    50   55   60

```
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65              70                  75                  80

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
            85                  90                  95

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Val Pro Ile Glu Lys Thr
            100                 105                 110

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
        115                 120                 125

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
    130                 135                 140

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145                 150                 155                 160

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
                165                 170                 175

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
            180                 185                 190

Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
        195                 200                 205

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
    210                 215                 220
```

```
<210>   18
<211>   617
<212>   DNA
<213>   Human

<400>   18
gctgaagtga aaacgagacc aaggtctagc tctactgttg gtacttatga gatccagtcc    60

tggcaacatg gagaggattg tcatctgtct gatggtcatc ttccttgggga cactggtcca   120

caaatcaagc tcccaaggtc aagatcgcca catgattaga atgcgtcaac ttatagatat   180

tgttgatcag ctgaaaaatt atgtgaatga cttggtccct gaatttctgc cagctccaga   240

agatgtagag acaaactgtg agtggtcagc ttttttcctgc tttcagaagg cccaactaaa   300

gtcagcaaat acaggaaaca atgaaaggat aatcaatgta tcaattaaaa agctgaagag   360

gaaaccacct tccacaaatg cagggagaag acagaaacac agactaacat gcccttcatg   420

tgattcttat gagaaaaaac cacccaaaga attcctagaa agattcaaat cacttctcca   480

aaagatgatt catcagcatc tgtcctctag aacacacgga agtgaagatt cctgaggatc   540

taacttgcag ttggacacta tgttacatac tctaatatag tagtgaaagt catttctttg   600

tattccaagt ggaggag                                                    617
```

```
<210>   19
<211>   162
<212>   PRT
<213>   Human

<400>   19

Met Arg Ser Ser Pro Gly Asn Met Glu Arg Ile Val Ile Cys Leu Met
1               5                   10                  15
```

Val Ile Phe Leu Gly Thr Leu Val His Lys Ser Ser Ser Gln Gly Gln
            20   25   30

Asp Arg His Met Ile Arg Met Arg Gln Leu Ile Asp Ile Val Asp Gln
            35   40   45

Leu Lys Asn Tyr Val Asn Asp Leu Val Pro Glu Phe Leu Pro Ala Pro
        50   55   60

Glu Asp Val Glu Thr Asn Cys Glu Trp Ser Ala Phe Ser Cys Phe Gln
65   70   75   80

Lys Ala Gln Leu Lys Ser Ala Asn Thr Gly Asn Asn Glu Arg Ile Ile
                85   90   95

Asn Val Ser Ile Lys Lys Leu Lys Arg Lys Pro Pro Ser Thr Asn Ala
            100   105   110

Gly Arg Arg Gln Lys His Arg Leu Thr Cys Pro Ser Cys Asp Ser Tyr
        115   120   125

Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg Phe Lys Ser Leu Leu
        130   135   140

Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His Gly Ser Glu
145   150   155   160

Asp Ser

<210> 20
<211> 7
<212> PRT
<213> Human

<400> 20

Glu Asp Asp Gly Tyr Pro Ala
1   5

<210> 21
<211> 16
<212> PRT
<213> Human

<400> 21

Met Pro Leu Leu Leu Leu Leu Leu Leu Pro Ser Pro Leu His Pro
1   5   10   15

<210> 22
<211> 786
<212> DNA
<213> Human

<400> 22
atgaaattct tagtcaacgt tgcccttgtt tttatggtcg tgtacatttc ttacatctat   60

gccggcagcg gacaccacca tcatcaccac ggtagcggcg actataaaga cgatgacgat   120

aagggttccg gatgccccga cctcgtctgc tacaccgatt acctccagac ggtcatctgc   180

atcctggaaa tgtggaacct ccaccccagc acgctcaccc ttacctggca agaccagtat   240

gaagagctga aggacgaggc cacctcctgc agcctccaca ggtcggccca caatgccacg   300

```
catgccacct acacctgcca catggatgta ttccacttca tggccgacga cattttcagt   360

gtcaacatca cagaccagtc tggcaactac tcccaggagt gtggcagctt tctcctggct   420

gagagcatca agccggctcc ccctttcaac gtgactgtga ccttctcagg acagtataat   480

atctcctggc gctcagatta cgaagaccct gccttctaca tgctgaaggg caagcttcag   540

tatgagctgc agtacaggaa ccggggagac ccctgggctg tgagtccgag gagaaagctg   600

atctcagtgg actcaagaag tgtctccctc ctcccccctgg agttccgcaa agactcgagc   660

tatgagctgc aggtgcgggc agggcccatg cctggctcct cctaccaggg gacctggagt   720

gaatggagtg acccggtcat ctttcagacc cagtcagagg agttaaagga aggctggaac   780

taatga                                                             786
```

<210> 23
<211> 260
<212> PRT
<213> Human

<400> 23

```
Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
1               5                   10                  15

Ser Tyr Ile Tyr Ala Gly Ser Gly His His His His His Gly Ser
            20              25              30

Gly Asp Tyr Lys Asp Asp Asp Lys Gly Ser Gly Cys Pro Asp Leu
        35              40              45

Val Cys Tyr Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met
    50              55              60

Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp Gln Asp Gln Tyr
65              70              75              80

Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala
                85              90              95

His Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp Val Phe His
            100             105             110

Phe Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly
        115             120             125

Asn Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu Ser Ile Lys
    130             135             140

Pro Ala Pro Pro Phe Asn Val Thr Val Thr Phe Ser Gly Gln Tyr Asn
145             150             155             160

Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu Lys
                165             170             175

Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro Trp
            180             185             190

Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp Ser Arg Ser Val
            195             200             205

Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu Gln
    210             215             220
```

Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp Ser
225   230   235   240

Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser Glu Glu Leu Lys
                245   250   255

Glu Gly Trp Asn
            260

<210>   24
<211>   1426
<212>   DNA
<213>   Human

<400>   24
gcggccgcac caccatgccg cgtggctggg ccgccccctt gctcctgctg ctgctccagg   60

gaggctgggg ctgccccgac ctcgtctgct acaccgatta cctccagacg gtcatctgca   120

tcctggaaat gtggaacctc accccagca cgctcaccct tacctggcaa gaccagtatg   180

aagagctgaa ggacgaggcc acctcctgca gcctccacag gtcggcccac aatgccacgc   240

atgccaccta cacctgccac atggatgtat tccacttcat ggccgacgac attttcagtg   300

tcaacatcac agaccagtct ggcaactact cccaggagtg tggcagcttt ctcctggctg   360

agagcatcaa gccggctccc cctttcaacg tgactgtgac cttctcagga cagtataata   420

tctcctggcg ctcagattac gaagaccctg ccttctacat gctgaagggc aagcttcagt   480

atgagctgca gtacaggaac cggggagacc cctgggctgt gagtccgagg agaaagctga   540

tctcagtgga ctcaagaagt gtctccctcc tccccctgga gttccgcaaa gactcgagct   600

atgagctgca ggtgcgggca gggcccatgc ctggctcctc ctaccagggg acctggagtg   660

aatggagtga cccggtcatc tttcagaccc agtcagagga gttaaaggaa ggctggaacg   720

gctccggctc tagagacaaa actcacacat gcccaccgtg cccagcacct gaactcctgg   780

ggggaccgtc agtcttcctc ttccccccaa aacccaagga caccctcatg atctcccgga   840

cccctgaggt cacatgcgtg gtggtggacg tgagccacga agaccctgag gtcaagttca   900

actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgcgg gaggagcagt   960

acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg   1020

gcaaggagta caagtgcaag gtctccaaca aagccctccc agtccccatc gagaaaacca   1080

tctccaaagc caaagggcag ccccgagaac acaggtgta cacccctgccc ccatcccggg   1140

aggagatgac caagaaccag gtcagcctga cctgcctggt caaaggcttc tatcccagcg   1200

acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag accacgcctc   1260

ccgtgctgga ctccgacggc tccttcttcc tctatagcaa gctcaccgtg gacaagagca   1320

ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg cacaaccact   1380

acacgcagaa gagcctctcc ctgtccccgg gtaaatgagt gaattc   1426

<210>   25
<211>   467
<212>   PRT
<213>   Human

<400> 25

```
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly
1             5                 10                15

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
            20              25              30

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
        35              40              45

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
    50              55              60

Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
65              70              75              80

Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
            85              90              95

Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
            100             105             110

Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
    115             120             125

Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
    130             135             140

Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145             150             155             160

Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
            165             170             175

Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
            180             185             190

Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
    195             200             205

Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
    210             215             220

Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Gly Ser Gly Ser Arg
225             230             235             240

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
            245             250             255

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
            260             265             270

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
        275             280             285

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
    290             295             300

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
305             310             315             320

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
            325             330             335

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Val Pro Ile
            340             345             350
```

```
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
        355             360             365
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
    370             375             380
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
385             390             395             400
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
            405             410             415
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
        420             425             430
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
        435             440             445
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
    450             455             460
Pro Gly Lys
465
```

```
<210>  26
<211>  1499
<212>  DNA
<213>  Human

<400>  26
gcggccgcac caccatgccg cgtggctggg ccgcccccctt gctcctgctg ctgctccagg      60
gaggctgggg ctgccccgac ctcgtctgct acaccgatta cctccagacg gtcatctgca     120
tcctggaaat gtggaacctc caccccagca cgctcaccct tacctggcaa gaccagtatg     180
aagagctgaa ggacgaggcc acctcctgca gcctccacag gtcggcccac aatgccacgc     240
atgccaccta cacctgccac atggatgtat tccacttcat ggccgacgac attttcagtg     300
tcaacatcac agaccagtct ggcaactact cccaggagtg tggcagcttt ctcctggctg     360
agagcatcaa gccggctccc cctttcaacg tgactgtgac cttctcagga cagtataata     420
tctcctggcg ctcagattac gaagaccctg ccttctacat gctgaagggc aagcttcagt     480
atgagctgca gtacaggaac cggggagacc cctgggctgt gagtccgagg agaaagctga     540
tctcagtgga ctcaagaagt gtctccctcc tccccctgga gttccgcaaa gactcgagct     600
atgagctgca ggtgcgggca gggcccatgc ctggctcctc ctaccagggg acctggagtg     660
aatggagtga cccggtcatc tttcagaccc agtcagagga gttaaaggaa ggctggaacg     720
gctccggctc tagagacaaa actcacacat gcccaccgtg cccagcacct gaactcctgg     780
ggggaccgtc agtcttcctc ttccccccaa aacccaagga caccctcatg atctcccgga     840
cccctgaggt cacatgcgtg gtggtggacg tgagccacga agaccctgag gtcaagttca     900
actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgcgg gaggagcagt     960
acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg    1020
gcaaggagta caagtgcaag gtctccaaca aagccctccc agtccccatc gagaaaacca    1080
tctccaaagc caaagggcag ccccgagaac acaggtgta caccctgccc ccatcccggg    1140
```

```
aggagatgac caagaaccag gtcagcctga cctgcctggt caaaggcttc tatcccagcg   1200

acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag accacgcctc   1260

ccgtgctgga ctccgacggc tccttcttcc tctatagcaa gctcaccgtg gacaagagca   1320

ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg cacaaccact   1380

acacgcagaa gagcctctcc ctgtccccgg gtaaatcagg aatggcatca atgacaggag   1440

gtcaacaaat gggttctgga tctcatcatc atcatcatca ttctggaggt tgagaattc    1499
```

<210> 27
<211> 492
<212> PRT
<213> Human

<400> 27

```
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly
1               5                   10                  15

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
            20                  25                  30

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
            35                  40                  45

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
        50                  55                  60

Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
65                  70                  75                  80

Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
                85                  90                  95

Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
            100                 105                 110

Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
        115                 120                 125

Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
        130                 135                 140

Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145                 150                 155                 160

Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
                165                 170                 175

Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
            180                 185                 190

Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
            195                 200                 205

Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
        210                 215                 220

Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Gly Ser Gly Ser Arg
225                 230                 235                 240

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
                245                 250                 255
```

```
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
            260             265             270

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
        275             280             285

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
    290             295             300

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
305             310             315             320

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
            325             330             335

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Val Pro Ile
            340             345             350

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
        355             360             365

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
370             375             380

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
385             390             395             400

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
            405             410             415

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
            420             425             430

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
            435             440             445

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
    450             455             460

Pro Gly Lys Ser Gly Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly
465             470             475             480

Ser Gly Ser His His His His His Ser Gly Gly
            485             490
```

```
<210>   28
<211>   1426
<212>   DNA
<213>   Human

<400>   28
gcggccgcac caccatgccg cgtggctggg ccgccccctt gctcctgctg ctgctccagg      60

gaggctgggg ctgccccgac ctcgtctgct acaccgatta cctccagacg gtcatctgca     120

tcctggaaat gtggaacctc caccccagca cgctcaccct acctggcaa gaccagtatg     180

aagagctgaa ggacgaggcc acctcctgca gcctccacag gtcggcccac aatgccacgc     240

atgccaccta cacctgccac atggatgtat tccacttcat ggccgacgac attttcagtg     300

tcaacatcac agaccagtct ggcaactact cccaggagtg tggcagcttt ctcctggctg     360

agagcatcaa gccggctccc cctttcaacg tgactgtgac cttctcagga cagtataata     420

tctcctggcg ctcagattac gaagaccctg ccttctacat gctgaagggc aagcttcagt     480

atgagctgca gtacaggaac cggggagacc cctgggctgt gagtccgagg agaaagctga     540
```

```
tctcagtgga ctcaagaagt gtctccctcc tccccctgga gttccgcaaa gactcgagct    600

atgagctgca ggtgcgggca gggcccatgc ctggctcctc ctaccagggg acctggagtg    660

aatggagtga cccggtcatc tttcagaccc agtcagagga gttaaaggaa ggctggaacg    720

gctccggctc tagagacaaa actcacacat gcccaccgtg cccagcacct gaagccctgg    780

gggcaccgtc agtcttcctc ttccccccaa aacccaagga caccctcatg atctcccgga    840

cccctgaggt cacatgcgtg gtggtggacg tgagccacga agaccctgag gtcaagttca    900

actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgcgg gaggagcagt    960

acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg   1020

gcaaggagta caagtgcaag gtctccaaca agccctccc agcccccatc gagaaaacca   1080

tctccaaagc caaagggcag ccccgagaac cacaggtgta caccctgccc ccatcccggg   1140

aggagatgac caagaaccag gtcagcctga cctgcctggt caaaggcttc tatcccagcg   1200

acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag accacgcctc   1260

ccgtgctgga ctccgacggc tccttcttcc tctatagcaa gctcaccgtg gacaagagca   1320

ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg cacaaccact   1380

acacgcagaa gagcctctcc ctgtccccgg gtaaatgagt gaattc                  1426
```

<210> 29
<211> 467
<212> PRT
<213> Human

<400> 29

```
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly
1               5                   10                  15

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
            20                  25                  30

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
            35                  40                  45

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
    50                  55                  60

Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
65                  70                  75                  80

Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
                85                  90                  95

Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
            100                 105                 110

Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
        115                 120                 125

Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
    130                 135                 140

Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145                 150                 155                 160
```

Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
                165   170   175

Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
            180   185   190

Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
            195   200   205

Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
210   215   220

Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Gly Ser Gly Ser Arg
225   230   235   240

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Leu Gly
            245   250   255

Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
            260   265   270

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
            275   280   285

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
    290   295   300

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
305   310   315   320

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
            325   330   335

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
            340   345   350

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
            355   360   365

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
    370   375   380

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
385   390   395   400

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
            405   410   415

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
            420   425   430

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
            435   440   445

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
450   455   460

Pro Gly Lys
465

19/28

<210> 30
<211> 741
<212> DNA
<213> Human

<400> 30

```
atgccgcgtg gctgggccgc ccccttgctc ctgctgctgc tccagggagg ctggggctgc    60

cccgacctcg tctgctacac cgattacctc cagacggtca tctgcatcct ggaaatgtgg   120

aacctccacc ccagcacgct caccccttacc tggcaagacc agtatgaaga gctgaaggac   180

gaggccacct cctgcagcct ccacaggtcg gcccacaatg ccacgcatgc cacctacacc   240

tgccacatgg atgtattcca cttcatggcc gacgacattt tcagtgtcaa catcacagac   300

cagtctggca actactccca ggagtgtggc agctttctcc tggctgagag catcaagccg   360

gctccccctt tcaacgtgac tgtgaccttc tcaggacagt ataatatctc ctggcgctca   420

gattacgaag accctgcctt ctacatgctg aagggcaagc ttcagtatga gctgcagtac   480

aggaaccggg gagacccctg ggctgtgagt ccgaggagaa agctgatctc agtggactca   540

agaagtgtct ccctcctccc cctggagttc cgcaaagact cgagctatga gctgcaggtg   600

cgggcagggc ccatgcctgg ctcctcctac caggggacct ggagtgaatg gagtgacccg   660

gtcatctttc agacccagtc agaggagtta aaggaaggct ggaacaaaac cgaaacctcc   720

caggttgctc cggcataatg a                                              741
```

<210> 31
<211> 245
<212> PRT
<213> Human

<400> 31

```
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly
1               5                   10                  15

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
            20                  25                  30

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
            35                  40                  45

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
    50                  55                  60

Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
65                  70                  75                  80

Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
                85                  90                  95

Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
                100                 105                 110

Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
            115                 120                 125

Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
    130                 135                 140
```

```
Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145                 150                 155                 160

Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
                165                 170                 175

Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
            180                 185                 190
Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
        195                 200                 205

Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
    210                 215                 220

Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Lys Thr Glu Thr Ser
225                 230                 235                 240

Gln Val Ala Pro Ala
            245
```

```
<210>   32
<211>   1413
<212>   DNA
<213>   Human

<400>   32
atgccgcgtg gctgggccgc ccccttgctc ctgctgctgc tccagggagg ctggggctgc     60
cccgacctcg tctgctacac cgattacctc cagacggtca tctgcatcct ggaaatgtgg    120
aacctccacc ccagcacgct caccccttacc tggcaagacc agtatgaaga gctgaaggac    180
gaggccacct cctgcagcct ccacaggtcg gcccacaatg ccacgcatgc cacctacacc    240
tgccacatgg atgtattcca cttcatggcc gacgacattt tcagtgtcaa catcacagac    300
cagtctggca actactccca ggagtgtggc agctttctcc tggctgagag catcaagccg    360
gctcccccctt tcaacgtgac tgtgaccttc tcaggacagt ataatatctc ctggcgctca    420
gattacgaag accctgcctt ctacatgctg aagggcaagc ttcagtatga gctgcagtac    480
aggaaccggg agacccctg ggctgtgagt ccgaggagaa agctgatctc agtggactca    540
agaagtgtct ccctcctccc cctggagttc cgcaaagact cgagctatga gctgcaggtg    600
cgggcagggc ccatgcctgg ctcctcctac caggggacct ggagtgaatg gagtgacccg    660
gtcatctttc agacccagtc agaggagtta aggaaggct ggaacgatga cgatgacaag    720
ggctccggcg acaaaactca cacatgccca ccgtgcccag cacctgaagc cctgggggca    780
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggaccccct    840
gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg    900
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac    960
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag   1020
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc   1080
aaagccaaag gcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggaggag   1140
atgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc   1200
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg   1260
```

```
ctggactccg acggctcctt cttcctctat agcaagctca ccgtggacaa gagcaggtgg   1320
cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg   1380

cagaagagcc tctccctgtc cccgggtaaa tga                                 1413
```

<210> 33
<211> 470
<212> PRT
<213> Human

<400> 33

```
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly
1               5                   10                  15

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
            20                  25                  30

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
            35                  40                  45

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
    50                  55                  60

Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
65                  70                  75                  80

Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
                85                  90                  95

Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
            100                 105                 110

Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
            115                 120                 125

Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
    130                 135                 140

Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145                 150                 155                 160

Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
                165                 170                 175

Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
            180                 185                 190

Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
            195                 200                 205

Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
    210                 215                 220

Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Asp Asp Asp Lys
225                 230                 235                 240

Gly Ser Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
                245                 250                 255

Ala Leu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
                260                 265                 270

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
    275                 280                 285

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
    290                 295                 300
```

```
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305             310             315             320

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
            325             330             335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
            340             345             350
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
            355             360             365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
    370             375             380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385             390             395             400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
            405             410             415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
            420             425             430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
            435             440             445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
    450             455             460

Ser Leu Ser Pro Gly Lys
465             470
```

```
<210>   34
<211>   1754
<212>   DNA
<213>   Mouse

<400>   34
atgccccggg gcccagtggc tgccttactc ctgctgattc tccatggagc ttggagctgc     60
ctggacctca cttgctacac tgactacctc tggaccatca cctgtgtcct ggagacacgg    120
agccccaacc ccagcatact cagtctcacc tggcaagatg aatatgagga acttcaggac    180
caagagacct tctgcagcct acacaggtct ggccacaaca ccacacatat atggtacacg    240
tgccatatgc gcttgtctca attcctgtcc gatgaagttt tcattgtcaa tgtgacggac    300
cagtctggca caactccca agagtgtggc agctttgtcc tggctgagag catcaaacca    360
gctccccct tgaacgtgac tgtggccttc tcaggacgct atgatatctc ctgggactca    420
gcttatgacg aaccctccaa ctacgtgctg aggggcaagc tacaatatga gctgcagtat    480
cggaacctca gagacccta tgctgtgagg ccggtgacca agctgatctc agtggactca    540
agaaacgtct ctcttctccc tgaagagttc acaaagatt ctagctacca gctgcaggtg    600
cgggcagcgc ctcagccagg cacttcattc aggggggacct ggagtgagtg gagtgacccc    660
gtcatctttc agacccaggc tggggagccc gaggcaggct gggacggctc cggctctaga    720
gagccccgcg accgacaat caagccctgt cctccatgca aatgcccagg taagtcacta    780
gaccagagct ccactcccgg gagaatggta agtgctataa acatccctgc actagaggat    840
aagccatgta cagatccatt tccatctctc ctcatcagca cctaacctcg agggtggacc    900
```

```
atccgtcttc atcttccctc caaagatcaa ggatgtactc atgatctccc tgagccccat    960

agtcacatgt gtggtggtgg atgtgagcga ggatgaccca gatgtccaga tcagctggtt   1020

tgtgaacaac gtggaagtac acacagctca gacacaaacc catagagagg attacaacag   1080

tactctccgg gtggtcagtg ccctccccat ccagcaccag gactggatga gtggcaaggc   1140

tttcgcatgc gccgtcaaca caaagacct cccagcgccc atcgagagaa ccatctcaaa   1200

acccaaaggt gagagctgca gcctgactgc atgggggctg ggatgggcat aaggataaag   1260

gtctgtgtgg acagccttct gcttcagcca tgacctttgt gtatgtttct accctcacag   1320

ggtcagtaag agctccacag gtatatgtct tgcctccacc agaagaagag atgactaaga   1380

aacaggtcac tctgacctgc atggtcacag acttcatgcc tgaagacatt tacgtggagt   1440

ggaccaacaa cgggaaaaca gagctaaact acaagaacac tgaaccagtc ctggactctg   1500

atggttctta cttcatgtac agcaagctga gagtggaaaa gaagaactgg gtggaaagaa   1560

atagctactc ctgttcagtg gtccacgagg gtctgcacaa tcaccacacg actaagagct   1620

tctcccggac tccgggtaaa tgagctcagc acccacaaaa ctctcaggtc caaagagaca   1680

cccacactca tctccatgct tcccttgtat aaataaagca cccagcaatg cctgggacca   1740

tgtaatagga attc                                                     1754
```

```
<210>   35
<211>   240
<212>   PRT
<213>   Mouse

<400>   35

Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Leu Ile Leu His Gly
1               5                   10                  15

Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr
            20                  25                  30

Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser
        35                  40                  45

Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe
    50                  55                  60

Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr
65                  70                  75                  80

Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val
                85                  90                  95

Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe
            100                 105                 110

Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Leu Asn Val Thr Val
        115                 120                 125

Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu
    130                 135                 140

Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145                 150                 155                 160
```

```
Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile
                165             170             175

Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys
            180             185             190

Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr
            195             200             205

Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
    210             215             220

Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Gly Ser Gly Ser Arg
225                 230             235             240
```

<210> 36
<211> 795
<212> DNA
<213> Mouse

<400> 36

```
ctgcaggtcg acaccaccat gccccggggc ccagtggctg ccttactcct gctgattctc      60

catggagctt ggagctgcct ggacctcact tgctacactg actacctctg gaccatcacc     120

tgtgtcctgg agacacggag ccccaacccc agcatactca gtctcacctg gcaagatgaa     180

tatgaggaac ttcaggacca agagaccttc tgcagcctac acaggtctgg ccacaacacc     240

acacatatat ggtacacgtg ccatatgcgc ttgtctcaat tcctgtccga tgaagttttc     300

attgtcaatg tgacggacca gtctggcaac aactcccaag agtgtggcag ctttgtcctg     360

gctgagagca tcaaaccagc tccccccttg aacgtgactg tggccttctc aggacgctat     420

gatatctcct gggactcagc ttatgacgaa ccctccaact acgtgctgag gggcaagcta     480

caatatgagc tgcagtatcg gaacctcaga gacccctatg ctgtgaggcc ggtgaccaag     540

ctgatctcag tggactcaag aaacgtctct cttctccctg aagagttcca caaagattct     600

agctaccagc tgcaggtgcg ggcagcgcct cagccaggca cttcattcag ggggacctgg     660

agtgagtgga gtgaccccgt catctttcag acccaggctg gggagcccga ggcaggctgg     720

gacggcagcg gacaccacca tcatcaccac ggtagcggcg actataaaga cgatgacgat     780

aagtagtgag aattc                                                       795
```

<210> 37
<211> 255
<212> PRT
<213> Mouse

<400> 37

```
Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Leu Ile Leu His Gly
1               5               10              15

Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr
            20              25              30

Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser
        35              40              45

Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe
    50              55              60
```

```
Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr
65               70              75              80

Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val
                85              90              95

Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe
            100             105             110

Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val
        115             120             125

Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu
    130             135             140

Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145             150             155             160

Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile
            165             170             175

Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys
            180             185             190

Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr
        195             200             205

Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
    210             215             220

Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Gly Ser Gly His His
225             230             235             240

His His His His Gly Ser Gly Asp Tyr Lys Asp Asp Asp Asp Lys
            245             250             255
```

```
<210>   38
<211>   792
<212>   DNA
<213>   Mouse

<400>   38

atgaaattct tagtcaacgt tgcccttgtt tttatggtcg tgtacatttc ttacatctat      60

gccggcagcg gacaccacca tcatcaccac ggtagcggcg actataaaga cgatgacgat     120

aagggttccg gatgcctgga cctcacttgc tacactgact acctctggac catcacctgt     180

gtcctggaga cacggagccc caaccccagc atactcagtc tcacctggca agatgaatat     240

gaggaacttc aggaccaaga gaccttctgc agcctacaca ggtctggcca acaccaca      300

catatatggt acacgtgcca tatgcgcttg tctcaattcc tgtccgatga agttttcatt     360

gtcaatgtga cggaccagtc tggcaacaac tcccaagagt gtggcagctt tgtcctggct     420

gagagcatca aaccagctcc cccccttgaac gtgactgtgg ccttctcagg acgctatgat     480

atctcctggg actcagctta tgacgaaccc tccaactacg tgctgagggg caagctacaa     540

tatgagctgc agtatcggaa cctcagagac ccctatgctg tgaggccggt gaccaagctg     600

atctcagtgg actcaagaaa cgtctctctt ctccctgaag agttccacaa agattctagc     660

taccagctgc aggtgcgggc agcgcctcag ccaggcactt cattcagggg gacctggagt     720

gagtggagtg accccgtcat ctttcagacc caggctgggg agcccgaggc aggctgggac     780
```

tagtgagaat tc   792

```
<210>   39
<211>   260
<212>   PRT
<213>   Mouse
```

```
<400>   39
```

Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
1   5   10   15

Ser Tyr Ile Tyr Ala Gly Ser Gly His His His His His Gly Ser
            20   25   30

Gly Asp Tyr Lys Asp Asp Asp Lys Gly Ser Gly Cys Leu Asp Leu
        35   40   45

Thr Cys Tyr Thr Asp Tyr Leu Trp Thr Ile Thr Cys Val Leu Glu Thr
    50   55   60

Arg Ser Pro Asn Pro Ser Ile Leu Ser Leu Thr Trp Gln Asp Glu Tyr
65   70   75   80

Glu Glu Leu Gln Asp Gln Glu Thr Phe Cys Ser Leu His Arg Ser Gly
                85   90   95

His Asn Thr Thr His Ile Trp Tyr Thr Cys His Met Arg Leu Ser Gln
            100   105   110

Phe Leu Ser Asp Glu Val Phe Ile Val Asn Val Thr Asp Gln Ser Gly
        115   120   125

Asn Asn Ser Gln Glu Cys Gly Ser Phe Val Leu Ala Glu Ser Ile Lys
    130   135   140

Pro Ala Pro Pro Leu Asn Val Thr Val Ala Phe Ser Gly Arg Tyr Asp
145   150   155   160

Ile Ser Trp Asp Ser Ala Tyr Asp Glu Pro Ser Asn Tyr Val Leu Arg
                165   170   175

Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Leu Arg Asp Pro Tyr
        180   185   190

Ala Val Arg Pro Val Thr Lys Leu Ile Ser Val Asp Ser Arg Asn Val
        195   200   205

Ser Leu Leu Pro Glu Glu Phe His Lys Asp Ser Ser Tyr Gln Leu Gln
    210   215   220

Val Arg Ala Ala Pro Gln Pro Gly Thr Ser Phe Arg Gly Thr Trp Ser
225   230   235   240

Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ala Gly Glu Pro Glu
                245   250   255

Ala Gly Trp Asp
            260

27/28

```
<210>   40
<211>   9
<212>   PRT
<213>   Mouse

<400>   40

Ser Val Tyr Asp Phe Phe Val Trp Leu
1               5

<210>   41
<211>   8
<212>   PRT
<213>   Mouse

<400>   41

Ser Ile Ile Asn Phe Glu Lys Leu
1               5


<210>   42
<211>   21
<212>   DNA
<213>   Artificial Sequence

<220>
<223>   Description of Artificial Sequence: 5' PCR Primer

<400>   42
gccttctcag gacgctatga t                                                 21


<210>   43
<211>   20
<212>   DNA
<213>   Artificial Sequence

<220>
<223>   Description of Artificial Sequence: 5' PCR Primer

<400>   43
ccctacagca cgtagttgga                                                   20


<210>   44
<211>   26
<212>   DNA
<213>   Artificial Sequence

<220>
<223>   Description of Artificial Sequence: PCR Probe

<400>   44
tcctgggact cagcttatga cgaacc                                            26
```